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"Le mystère est la plus belle chose de la vie; c’est la source de tout art et de toute science." 
Albert Einstein 
 
“Ce sont rarement les réponses qui apportent la vérité, mais l’enchaînement des questions” 
        Daniel Pennac 

Abstract 
 
The purpose of this thesis was to explore different approaches for the synthesis of advanced 
precursors of rhazinilam analogues. The intramolecular Michael Addition was envisaged in 
order to obtain the pyrrole or pyrrolinone based analogues. The aim of the first project was to 
develop a flexible, efficient synthesis towards model systems. N-acylation and N-alkylation of 
the corresponding substrates were intensively studied. 
 
 
Oxydizing the pyrrole ring to pyrrolinone and blocking the C-5 position on the pyrrolinone 
ring seem to be a promising way to increase the chemical stability of rhazinilam analogues 
and avoid its enzymatic deactivation in target cells. The second project focused on the 
preparation of highly substituted 2-pyrrolidinones by a key Mukaiyama aldol reaction – 
Staudinger type reductive cyclisation sequence. 
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Chapter one 
 
 
 
R-(−)-RHAZINILAM AND 
ITS ANALOGUES: 
BIOLOGICAL ACTIVITY 
AND SYNTHESES 

3 
 
1.1 R-(−)-Rhazinilam: occurrence, biosynthetic origins, semi-
synthesis and structural elucidation 
 
1.1.1 Isolation and structure determination of rhazinilam and its structural 
analogues 
 
(R)-(−)-Rhazinilam (1) was first isolated by Linde from Melodinus australis in 1965.1 The 
isolation from Rhazya stricta (1970)2,3 some years later lead to the trivial name used today. 
The natural product has been found in other South-east Asian members of the family 
Apocynaceae.4-12 The alkaloid 1 has also been obtained from somatic hybrid intragenic cell 
cultures.13 More recently, (R)-(−)-rhazinilam (1) was isolated from the plant species Kopsia 
arborea (2007).14,15  
The structure of (R)-(−)-rhazinilam (1) was established in 1972 through spectroscopic 
analysis, chemical degradation studies3 and finally confirmed by X-ray crystallographic 
techniques5 (Figure 1). The complete infra-red, mass spectra and 1H and 13C NMR analysis of 
compound 1 was reported later.16 The four rings are identified as rings A to D. The quaternary 
carbon center at C20 and a phenyl-pyrrole chirality axis are the two stereogenic elements of 
(R)-(−)-rhazinilam (1). The dihedral angle between rings A and C is almost 90°. The lactam 
bond is in the s-cisoid conformation. The nine-membered ring adopts a boat-chair 
conformation imposed by the two aromatic bonds and the lactam bond contained in the 
medium sized ring rigidifying the ring. It was not possible to determine the absolute 
configuration (R, aR) by X-ray. The absolute configuration was deduced via semi-synthesis 
from an aspidosperma alkaloid, namely (+)-1,2-didehydroaspidospermidine (15).17  
 
 
Figure 1.1. (R)-(−)-Rhazinilam (1).   
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Other alkaloids with the same tetracyclic array as (R)-(−)-rhazinilam (1) have been isolated 
from different members of the family Apocynaceae: 5,21-dihydrorhazinilam N-oxide (2),18 
rhazinicine (3),19-22 3-oxo-14,15-dehydrorhazinilam (4),23 nor-rhazinicine (5),18 (−)-
leuconolam (6),8,10,22,24,25 N-methylleuconolam (7),26 (+)-epi-leuconolam (8),8,10 3,14-
dehydroleuconolam (9),18 (R)-(−)-rhazinal (10),22,27 Kopsiyunnanines C1 (11), C2 (12), C3 
(13)15 (Figure 2). The formation of all these alkaloids is postulated to occur via oxidative 
pathways from 5,21-dihydrorhazinilam (5), which is co-isolated with 1.8-10,14,28  
 
 
Figure 1.2. Naturally occurring analogues of (R)-rhazinilam (1):  
 
1.1.2 Postulated formation of (R)-(−)-rhazinilam from indole alkaloids 
 
(R)-(−)-Rhazinilam (1) is now considered to be an artefact of the extraction procedure. The 
unstable 1,2 dihydrorhazinilam (16)3 aromatises spontaneously on exposure to air.8,9 The 
dihydro-derivative 16 is believed to be the immediate natural precursor of (R)-(−)-rhazinilam 
(1). More significantly the natural product 1 can also be synthesized starting from (+)-
vincadifformine (14) (Scheme 1.1). The mechanism of the stepwise conversion was proposed 
by Smith17 and later experimentally confirmed by Guenard.29,30 The sequence starts from (+)-
vincadifformine (14) and comprises an acid-catalysed ester hydrolysis and decarboxylation 
followed by an oxidation-reduction-oxidation sequence. The key step in this sequence is the 
MCPBA-promoted oxidative cleavage of the C2-C3 indoline bond in (+)-1,2-
didehydroaspidospermidine (15) producing the 5,21-dihydrorhazinilam N-oxide (2). This step 
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produces the characteristic structural array of (R)-(−)-rhazinilam (1). The N-oxide 2 could be 
reduced with Fe(II) to give a 9:1 mixture of (R)-(−)-rhazinilam (1) and 5,21-
dihydrorhazinilam (16). This conversion (R)-5,21-dihydrorhazinilam (16) → (R)-(−)-
rhazinilam (1) was slow. This observation suggests that the formation of rhazinilam from the 
5,21-dihydrorhazinilam N-oxide (2) occurred via a Polonovsky-type reaction.30,31 (+)-1,2-
Didehydroaspidospermidine (15) has never been detected in vivo together with 5,21-
dihydrorhazinilam (16) or (R)-(−)-rhazinilam (1). If (+)-1,2-didehydroaspidospermidine (15) 
is the precursor of (R)-(−)-rhazinilam (1) remains an open question. 
 
 
 
Scheme 1.1. Semi-synthesis of (R)-rhazinilam (1) from (+)-vincadifformine (14).   
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1.2 Biological activity of rhazinilam and its analogues 
(R)-(−)-Rhazinilam 1 and some of its congeners have a unique activity on the tubulin-
microtubules equilibrium involved in the formation of mitotic spindle.9,32-34 They induce both 
the abnormal spiralisation of tubulin and formation of extensively bundled, short microtubules 
in interphase (vinblastine effect) and block mitotic cells in aster-like structure inhibiting the 
cold-induced disassembly of microtubules (paclitaxel (TaxolTM) effect) (Figure 1.3 and Figure 
1.4). 
Figure 1.3. Schematic illustration of the cell cycle and its regulatory mechanisms that are 
relevant for the inhibitory effect imposed by Vionblastine and Paclitaxel (TaxolTM).  
As a consequence, (R)-(−)-rhazinilam, shows appreciable cytotoxicity toward both drug-
sensitive and vincristine-resistant KB cell lines, with IC50 values in the range of 0.5-1.16 
µM.22,32 In the absence of a crystallographic structure of the rhazinilam binding site in tubulin, 
a number of structure-activity relationship (SAR) studies have been conducted to gain greater 
understanding of the mode of interaction of these compounds with the protein and to solve the 
problem of in vivo inactivity. Despite huge synthetic efforts, none has succeeded thus far in 
producing a more cytotoxic analogue than (R)-(−)-rhazinilam.33,35,36  
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Figure 1.4. Vinblastine and TaxolTM structures and the cancers they are used to treat.  
 Figure 1.5. Some semi-synthetic analogues of (R)-rhazinilam (1). 
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However, the great structural diversity of the rhazinilam analogues30,32,35-45 and the 
considerable number of assays carried out on them allow defining the minimum structural 
requirements necessary for their biological activity (Figure 1.5 and Table 1.1). Notably, the 
introduction of substituents on rings A, B, and D decreases the tubulin activity, suggesting a 
narrow tubulin binding pocket surrounding the phenyl-pyrrolic subunit annulated to an 
adjacent piperidine ring (compounds 17a-17c). Increasing steric bulk on the A ring or 
replacement of the C-ring with heterocyclics such as pyridine (17fand 17i) lead to reduction 
or loss of biological activity.44,46 However, it was established that the D-ring conferring an 
additional structural rigidity to the natural product is not necessary for its binding activity 
(17g).39,47,48 In contrast, the analogues devoid of the lactam B-ring were found to be inactive 
(17h).37 It was shown that the conservation of the boat–chair conformation of B-ring, imposed 
by the cis-amide group and the quaternary C-20 carbon are essential for preserving the 
affinity for tubulin. The best substituents at C-20 seem to be ethyl group36 or diethyl 
substituent in the absence of D-ring42,45 (17i-17l) suggesting a direct interaction of the alkyl 
groups with tubulin. The replacement of lactam group with urethane resulted in the increase 
of the anti-tubulin activity (17m).43 Another important point is he A-C dihedral angle which is 
closely related to the size of B-ring. According to X-ray data, the aromatic rings of (−)-
rhazinilam are orthogonal with the A-C dihedral angle close to 95° and the amide bond 
possesses a s-cisoid conformation.5 However, the recent SAR studies suggest that there are 
certain degrees of freedom available for rhazinilam-type analogues while preserving the 
tubulin-binding affinity.41,45 Thus, the rac-B-norrhazinal (17n) with a more constrained 8-
membered lactam was found to display comparable tubulin-binding properties and similar 
cytotoxicity to that of (−)-rhazinilam.41 The X-ray analysis revealed, that the amide unit 
adopts an s-cisoid conformation and that the biaryl dihedral angle is ca. 56°.40 A curious 
observation was made with the D-ring seco-analogue, containing more constrained 7-
membered lactam (17o).45 It was found to be inactive on the disassembly of microtubules, 
while it acts as an inhibitor of tubulin assembly and displays a significant toxicity towards 
tumour KB cell lines, indicating a different mode of action towards tubulin in comparison to 
(−)-rhazinilam. This confirms that the size of the lactam ring, and consequently the dihedral 
angle of the biaryl moiety, play an essential role in the inhibition of cold microtubules 
disassembly. Despite the interesting biological properties and the significant progress in the 
understanding of the drug-tubulin interactions of the rhazinilam-type compounds, transferring 
the knowledge from in vitro studies to in vivo experiments has proved to be quasi impossible.  
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Table 1.1. Cytotoxic and anti-mitotic properties of some natural and semi-synthetic analogues 
of (R)-rhazinilam (1). 
Compound IC50/[IC50 (R)-1] in a cold-induced inhibition 
of microtubule disassembly assay 
IC50 (µM) cytotoxicity 
towards KB cells 
(−)-1 1 0.5 
3 10 3 
6 inactive inactive 
5 − 40 
10 6 − 
11 − − [a] 
12 − − [a] 
13 − − [a] 
17a inactive inactive 
17b inactive 44 
17c 80 inactive 
17d 80 inactive 
17e 5 4 
17f 9.5 − 
17g 2 − 
17h inactive inactive 
17i inactive − 
17j 8 5.5 
17k 20 − 
17l inactive − 
17m 0.5 0.5 
17n similar − [b] 
17o inactive[c] 7 
[a] Active against lung and colon adenocarcinoma cell lines: 11 (IC50 5 µM), 12 (IC50 6-7 
µM), 13 (IC50 8-9 µM).15 
[b] Active against CA46 Burkilt lymphoma cells (IC50 3 µM).41 
[c] Inhibits tubulin assembly (IC50 27 µM).45  
10 
 
1.3 Previous total syntheses of rhazinilam 
 
1.3.1 Total syntheses of rac-rhazinilam  
 
Six total syntheses of racemic (±)-rhazinilam have been reported. The main motivation for 
these studies was the unusual structure of (±)-rhazinilam. Over the almost forty years different 
strategies were applied to create the challenging elements contained in (±)-rhazinilam: the 
direct A-C biaryl link, the nine-membered lactam B ring, and the quaternary-carbon at C-20. 
 
First total synthesis of rac-rhazinilam by Smith 
 
The first total synthesis of the racemic (±)-rhazinilam (1) was reported by Smith and co-
workers in 1973.17 A convergent retrosynthetic plan was adopted by Smith. The natural 
product was cut into two pieces: the biaryl substructure containing the aromatic A ring 
directly linked to the pyrrolic C ring: intermediate 28. The other intermediate contained all the 
missing aliphatic carbon atoms: intermediate 22. Reacting ethyl magnesium bromide with 
diethyl 4-ketopimelate (18) gave after hydrolysis the lactone 19 in good yield (Scheme 1.2). 
Acyl chloride 20 was then reduced in a two-step sequence: Rosenmund reduction49 first 
followed by NaBH4 reduction. Tosylation of 21 with tosyl chloride in pyridine provided the 
desired tosyl derivative of γ-lactone 22 in 22% over six steps from commercially available 18.  
 
 
 
Scheme 1.2. Synthesis of intermediate 22.   
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Scheme 1.3. Smith’s total synthesis of rac-rhazinilam (1). 
 
The pyrrole 25 was prepared via Knorr-type condensation (Scheme 1.3). Vilsmeier 
formylation of compound 25 followed by silver oxidation and subsequent esterification with 
diazomethane generated the pyrrole 28 in 11% yield over four steps from 23.  
The crucial combination of the two intermediates was achieved by the N-alkylation of the 
sodium salt of the pyrrole 28 with the tosyl derivative of the lactone 22. The intramolecular 
Friedel-Crafts cyclisation of the pyrrole 29 gave the tetrahydroindolizine derivative 30 in 50% 
yield. The intermediate 30 contained all the carbons present in the target molecule. Catalytic 
reduction of the nitro group followed by lactamisation afforded compound 32. A two-step 
sequence had to be applied to produce rac-rhazinilam (1) under harsh conditions but in good 
overall yield. The synthesis proceeds through ten steps starting from the commercially 
available acid 23 in a remarkable 3.6% overall yield.  
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Total synthesis of rac-rhazinilam by Sames 
 
In 2000 a very elegant total synthesis of rac-(±)-rhazinilam (rac-1) was reported by Sames 
and co-workers.50 The key intermediate 43 was synthesized in the efficient sequence depicted 
in Schema 1.4. The Grigg-type 1,5-electrocyclisation reaction51 of 38 catalysed by silver 
carbonate produced the achiral intermediate 40 in 70% yield. The sensitive pyrrole ring was 
then protected in two steps as methyl ester 41. Selective reduction of 41 provided the aniline 
42 in 25% over seven steps from nitrile aldehyde 36. The second key step was the 
transformation of one of the ethyl groups into ethenyl group. Six synthetic steps were 
necessary to achieve the transformation from 43 to 49. The pivotal platinum complex 45 had 
to be synthesized, introducing a Schiff base first and treating the Schiff base 44 with the 
dimethyl platinum reagent [Me2Pt(µ-SMe2)]252 providing 45 in 88% yield. Treating the 
intermediate 45 successively with triflic acid followed by  thermolysis in trifluoroethanol at 
70 °C and then by decomplexation with potassium cyanide and hydrolysis of the Schiff base 
48 provided the racemic alkene 49 in 60% yield over four steps. The total synthesis was then 
completed via a formal one-carbon extension of the vinyl group and the subsequent closure of 
the medium sized lactam ring in six synthetic steps. Lemieux-Johnson oxidation provided the 
aldehyde 50 followed by WHE olefination. Selective reduction of the alkene 51, lactamisation 
and decarboxylation using Smith’s methodology17 afforded rac-1. The synthesis proceeds 
through twenty steps in 3.5% overall yield starting from nitrile aldehyde 36. The sequence is 
considerably longer than the Smith synthesis, but the overall yield is almost identical with the 
yield of the first synthesis. 
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Scheme 1.4. Sames’ total synthesis of rac-rhazinilam (1).  
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Total synthesis of rac-rhazinilam by Magnus 
 
In 2001 Magnus and co-workers published a straightforward and elegant synthesis of rac-
rhazinilam (rac-1)53 (Scheme 1.5).  
 
 
 
Scheme 1.5. Magnus’ convergent total synthesis of rac-rhazinilam (rac-1).  
 
The retrosynthetic analysis is very similar to the one used by Sames, with the difference that 
the two chains on the α-position of the pyrrole ring are already differentiated right from the 
start of the synthesis. The elegant but lengthy modification of one of the two ethyl groups can 
thereby be avoided, which reduces the number of steps. Starting from commercially available 
2-piperidone 52 the ethyl and allyl group are sequentially introduced in a total of six synthetic 
operations. N-alkylation of this thiophenyl imino ether 54 with 2-nitrocinnamyl bromide 35 
gave the corresponding iminium intermediate 55. This intermediate underwent a Grigg-type 
1,5-electrocyclisation/thiophenol elimination reaction51 to provide compound 56 in 71% yield. 
The compound 56 was transformed into the natural product rac-1 in a sequence of six steps: 
hydroboration, Swern-type oxidation with pyridine/sulphur trioxide/dimethylsulfoxide,54 
exhaustive oxidation using silver nitrate under alkaline condition, Raney nickel reduction and 
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finally lactamisation. The reaction types used in the end game of the Sames and Magnus 
syntheses are very similar. It is therefore all the more surprising that the Magnus group did 
not need to introduce any protection on the pyrrole ring. The Magnus group could reduce 
considerably the number of steps. The synthesis proceeds through nine steps in an impressive 
7.6% overall yield.  
 
Total synthesis of rac-rhazinilam by Trauner 
 
The Trauner’s synthesis published in 2005 forms in the last step rac-(±)-rhazinilam (rac-1) 
using an intramolecular Heck-type reaction55 starting from an intermediate containing the A-
D-C rings and forming the aryl heteroaryl bond last (Scheme 1.6). The difference to the 
Sames and Magnus syntheses is the presence of the amide bond directly connecting the A and 
the D rings. The Trauner group starts with the 2-carbomethoxy pyrrole 61 which is N-
alkylated with the tosyl derivative of γ-lactone 22. The alkylation and the intramolecular 
Friedel-Crafts cyclisation are almost identical to the Smith procedure.17 At this point the 
Trauner synthesis diverges from the Smith synthesis. Amide coupling introduces all the atoms 
of the rhazinilam skeleton. For the Heck type coupling the amide had to be protected with the 
with methoxymethyl (MOM) protecting group transforming compound 66 with 10 mol % of 
Buchwald’s “DavePhos” ligand 6756 and Pd(OAc)2 in the presence of potassium carbonate as 
base to give the strained nine-membered ring 68 in 47% yield. Removing first the MOM 
protecting group17,50,57 followed by saponification and acid-catalysed decarboxylation 
produced rac-1. Only seven steps are needed starting from commercially available pyrrole 61 
and an impressive 7.9% overall yield could be obtained. Starting from the commercially 
available diester 18 (rac)-rhazinilam (rac-1) can be obtained in thirteen steps and in 1.7% 
overall yield.  
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Scheme 1.6. Trauner’s total synthesis of rac-rhazinilam (rac-1).  
 
Total synthesis of rac-rhazinilam by Gaunt 
 
The synthesis of rac-rhazinilam reported by Gaunt and co-workers in 201258 adopts the 
synthetic strategy developed earlier for the synthesis of rac-rhazinicine.59 The key steps of 
this convergent synthesis use modern organometallic reactions to connect the rings A and C 
first and then to form the D-ring. The B-ring is formed via a lactamisation. The connection 
between the phenyl ring and the pyrrole is achieved by the one-pot IrI-catalyzed C-H bond 
borylation60,61 directly followed by subsequent Suzuki coupling reaction.62 The oxidative PdII-
catalysed pyrrole C-H bond cyclisation leads to the formation of the D-ring. The synthesis 
started with the preparation of the alkene monoester intermediate 73 (Scheme 1.7). The 
commercially available diethyl-4-oxo-pimelate (18) underwent the Wittig ethenylation 
followed by functional group manipulation (hydrolysis, esterification, acyl chlorination, 
reduction, and iodination) to obtain the intermediate 73 containing all the carbons for the rings 
B and D.  
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Scheme 1.7. Synthesis of iodide intermediate 73. 
 
The 3-arylated pyrrole 76 was obtained from pyrrole 74 and o-iodonitrobenzene (75) by the 
one-pot IrI-catalysed borylation/Suzuki coupling. Subsequent removal of Boc-protecting 
group under heating afforded in 63% overall yield the pyrrole 28 containing the A-C rings of 
rhazinilam (Scheme 1.8). 
 
Reacting the sodium anion of 28 with iodide intermediate 73 the N-alkylated pyrrole 77 was 
obtained in 85% yield. The intermediate 77 contains all the carbons present in the target 
molecule. Treating 77 with Pd(OAc)2 catalyst and NaOtBu in the presence of pivalic acid and 
oxygen resulted in the formation of the tetrahydroindolizine 78 in 60% yield. Simultaneous 
reduction of the nitro and alkene group of compound 78 followed by AlCl3-mediated removal 
of the 2-trimethylsilylethyl protecting group gave the carboxylic acid 31. Lactamisation of 
this compound under Mukaiyama conditions produced the methyl ester 32 in 73% yield. 
Removal of the methyl ester group of the pyrrole by saponification and subsequent 
decarboxylation afforded rac-1 in 68% yield. The synthesis proceeds through eight steps 
starting from pyrrole 74 in considerable 15.9% overall yield (through twelve steps starting 
from diester 18 in 8.4% overall yield). 
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Scheme 1.8. Gaunt’s total synthesis of rac-rhazinilam (rac-1). 
 
Total synthesis of rac-rhazinilam by Yao 
 
A new synthesis of rac-rhazinilam was reported by Yao and co-workers in 2014.63 The 
synthetic strategy is similar to that used by Zakarian group64 and involves an alkenylation 
using Pd(OAc)2 catalysed Heck reaction as a key step. The difference to Zakarian syntheses is 
a solvent-controlled regioselectivity based on the solvent effect. The pyrrole ring was 
synthesized first from phenyl acrylate 80 and toluenesulfonylmethyl isocyanide (TosMIC) 
(81) via a van Leusen procedure65 (Scheme 1.9). Alkylation of the sodium salt of 82 with 
iodoolefin 14064 (Scheme 1.15) provided the key intermediate 83 in 70% yield. The 
palladation of 83 occurs at the more electron-rich C5 position due to the fact that the strong 
coordinating solvent as DMSO overweighs the chelation effect of the carboxylate group. The 
alkenyllated product 86 was obtained in 56% yield (C5/C2 = 12:1) as a mixture of separable 
stereoisomers 86a and 86b.  
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Scheme 1.9. Yao’s total synthesis of rac-rhazinilam (rac-1). 
 
The total synthesis of rac-1 was completed via hydrogenation of 86a with Wilkinson’s 
catalyst66, decarboxylation, hydrogenation, and macrolactamization. The stereoisomer 86b 
was also transformed to rac-1 through the same sequence as 86a, since the biaryl axis can 
rotate after decarboxylation. The synthesis proceeds through seven steps starting from the 
commercially available phenyl acrylate 80 in a remarkable 23% overall yield.  
 
1.3.2 Total syntheses of R-(−)-rhazinilam 
 
Besides the six syntheses of racemic (±)-rhazinilam, six of the naturally occurring (−)-
enantiomer have been reported. The chirality of the A-C biaryl axis is determined by the 
absolute configuration of the quaternary-carbon at C-20. The challenge is therefore to obtain 
this quaternary center in enantiomerically pure form.  
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Sames’ second enantioselective total synthesis of (R)-(−)-rhazinilam  
 
The Sames group adapted their synthesis of (rac)-rhazinilam so that they could obtain the (R)-
(−)-rhazinilam.57 Sames choose to introduce a chiral auxiliary 92, so as to functionalize 
diastereoselectively the intermediate 93 to the product 97 (see scheme 1.11). Before removing 
the chiral auxiliary a preparative HPLC separation of the diastereomers was used to obtain the 
product 49 in high enantiomeric excess. The chiral auxiliary phenyl-(5R)-cyclohexyl-2-
oxazolinone 92 was prepared in three steps from commercially available mandelonitrile 88 in 
32 % overall yield (Scheme 1.10). 
 
 
Scheme 1.10. Synthesis of chiral oxazolyl ligand 92. 
 
 
Scheme 1.11. Sames’ total synthesis of (R)-(−)-rhazinilam (R)-1. 
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The desymmetrisation of the two enantiotopic ethyl groups in compound 42 was achieved by 
metal-induced C(sp3)-H activation via the six steps sequence leading to the alkene 49 (96% 
ee) (Scheme 1.11). After decomplexation of the platinum with potassium cyanide a mixture of 
the diastereomers of 97 were obtained with a de of 63-77%. In this sequence the 
diastereomers were separated by preparative HPLC to give after removal of the ligand the 
alkene 49. The palladium-catalysed carbonylation of the alkene 49 gave directly in 58% yield 
the required nine-membered ring lactam 32 which had been reported17,50 previously in its 
racemic form. This metal catalysed transformation replaced favourably the five step sequence 
used in the synthesis of the racemate. The enantiomerically pure (R)-(−)-rhazinilam (1) was 
finally obtained in 90% yield and 96% ee following the procedure described by Smith17. The 
synthesis proceeds through fifteen steps starting from nitrile aldehyde 36 in 1.6% overall 
yield. The synthesis of the racemate was twenty steps long, but the overall yield was much 
better 3.6%. The diastereoselectivity (de = 63-77%) of the metal-induced C(sp3)-H activation 
is the reason for this drop in the overall yield.  
 
Total synthesis of (R)-(−)-rhazinilam by Nelson 
 
In 2006 Nelson and co-workers report an elegant, enantioselective total synthesis of (R)-(-)-
rhazinilam (1) (Scheme 1.12).67 The enantioselective synthesis of the almost enantiopure β-
lactone 99 via a cyclocondensation68-70 using a quinine derived asymmetric catalyst installed 
the two chiral centers71 with high selectivity. From the β-lactone 99 the enantioenriched 
allene 102 was obtained by ring opening using the Grignard reagent 100 via an SN2’-type 
reaction followed by a methylation with trimethylsilyldiazomethane. The intramolecular 
asymmetric Au(I)-catalysed pyrrole addition to the allene installed the quaternary carbon 
stereocenter with good control and formed the ring D of rhazinilam. To make the pyrrole ring 
C resistant to the following reaction steps a methyl ester group was introduced first giving 
104. In a four step sequence the functionalized side chain was first degraded and then 
reconstructed to obtain 108. Electrophilic iodination41 followed by Suzuki-Miyaura cross-
coupling72 of compound 109 with the commercially available 2-(N-Boc-amino)phenylboronic 
acid pinacol ester (110) using Buchwald’s SPhos ligand73 afforded the 3-aryl pyrrole 111 
containing rings A, C and D of rhazinilam. Chemoselective ester saponification and TFA-
mediated aniline N-deprotection resulted in the formation of the previously reported17 amino 
acid 31, the precursor for the formation of the B ring. Lactamisation of this compound was 
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carried out with the HATU coupling reagent to produce the previously described17,50,57,55 ester 
32 in 74% yield. Removal of the methyl ester group in pyrrole 32, as previously reported by 
Smith,17 furnished (R)-(−)-rhazinilam (1) in 96% yield and 94% ee. Thus, the synthesis 
proceeds through fifteen steps starting from commercially available acyl aldehyde 98 in an 
impressive 19.8% overall yield.  
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Scheme 1.12. Nelson’s total synthesis of (R)-(−)-rhazinilam (R)-1. 
23 
 
Total synthesis of (R)-(−)-rhazinilam by Banwell 
 
Banwell and co-workers reported a synthesis of rac-(±)-rhazinal (rac-10)41 (Scheme 1.13) and 
based on this chemistry an enantioselective total synthesis of (R)-(−)-rhazinilam ((R)-1)74 
(Scheme 1.14). The key step of the enantioselective synthesis is a MacMillan’s chiral 
organocatalyst75 promoted intramolecular Michael addition reaction closing the D ring and 
creating the quaternary center in 74% enantiomeric excess. 
 
 
Scheme 1.13. Banwell’s total synthesis of (rac)-rhazinal rac-10.  
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The synthetic route to the pivotal intermediate 131 started with the N-alkylation of pyrrole 
with γ-butyrolactone 114 under conditions defined by Li and Snyder.76 Conversion into the 
corresponding Weinreb amide 116 using modified Mukaiyama conditions77 and subsequent 
treatment with ethyl magnesium bromide furnished the ketone 117. Wadsworth-Horner-
Emmons (WHE) olefination provided the β,β-disubstituted methyl acrylate 108 followed by 
reduction with excess DIBAL-H to give the corresponding alcohol 130. The alcohol 130 was 
oxidized with barium manganate78 to the aldehyde 131 obtained in 76% as a roughly 1:1 
mixture of E- and Z- isomers.  
Scheme 1.14. Banwell’s total synthesis of (R)-rhazinal, (R)-rhazinilam, (R,S) (−)-leuconolam 
and (R,R) (+)-epi-leuconolam. 
 
The pivotal intramolecular Michael addition reaction involved exposure of this mixture of 
aldehydes to (5S)-2,2,3-trimethyl-5-phenylmethyl-4-imidazolidinone monotrifluoroacetate 
(132) (MacMillan’s first generation organocatalyst) resulting in formation of the unstable 
indolizine aldehyde 133 in 81% yield. Subsequent reduction of compound 133 using sodium 
borohydride afforded the stable alcohol 120 in 84% yield in 74% ee. The completion of the 
synthesis of (R)-(−)-rhazinilam (1) involved the one-carbon homologation via SN2 reaction 
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using nitrile as one carbon nucleophile and the installation of the aniline moiety via by 
Suzuki-Miyaura cross-coupling.72  
During this sequence a Vilsmeier-Haack formylation had to be inserted the pyrrole aldehyde 
125. The aldehyde is at the same time a protecting group for the sensitive pyrrole ring and it 
dictates the regioselectivity of the following electrophilic iodination to give the iodo-pyrrole 
126 in quantitative yield. The final steps were the saponification of the ester followed by 
lactamisation delivering synthetic (R)-(-)-rhazinal (10). Conversion of (R)-10 into (R)-(-)-
rhazinilam (1) was achieved by heating of ((R)-10) with stoichiometric quantities of 
Wilkinsons “catalyst” in refluxing 1,4-dioxane. The synthesis proceeds through eighteen steps 
starting from pyrrole 113 and in 4.4% overall yield. Treatment of (R)-(-)-rhazinilam (1) with 
an excess of pyridinium chlorochromate (PCC) resulted in the conversion of this substrate 
into a chromatographically separable mixture of (-)-leuconolam (6) (28%) and (+)-epi-
leuconolam (8) (46%). 
 
Total synthesis of (R)-(-)-rhazinilam by Zakarian 
 
In 2010, Zakarian and co-workers reported a higly enantiospecific total synthesis of 
rhazinilam based on a Pd-catalyzed transannular cyclisation.64 In difference to Trauner 
synthesis using the intramolecular Heck-type reaction to connect the A and C rings, Zakarian 
choose to exploit an axial chirality of a halogenated 13-membered lactam 149, as so to create 
the quaternary chiral stereogenic center in target molecule and to form the B and D rings in a 
single bond-forming event. The synthesis of the aliphatic part proceeded through the 
iodoolefin 140 which was prepared from the commercially available tert-butyl acrylate (134) 
(Scheme 1.15). The Michael addition reaction of 2,4-pentanedione (135) to 134, followed by 
a cascade condensation-fragmentation process79 using aqueous formaldehyde afforded the 
enone 137. Luche redaction80 and acetylation of this intermediate, followed by Ireland-
Claisen rearrangement81 produced the acid 139. Selective reduction and iododehydroxylation 
of 139, gave the desired iodide 140 in 35% yield over seven steps. The precursor 144 
containing A-C rings was synthesized via known Pd-catalysed cross-coupling reaction82 of 
borylated TIPS-protected pyrrole 143 and 2-iodoaniline (64) (Scheme 1.16). After removal of 
TIPS-protecting group under basic conditions, the biaryl intermediate 145 was obtained in 
92% yield. A regioselective halogenation of 145 was required preceding the macrolactam 
formation. N-alkylation of potassium anion of 146 with iodide 140 gave the intermediate 147. 
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The synthesis of pivotal macrolactam 149 was achieved in three steps sequence by iodination, 
saponification of the ester 148 and subsequent macrocyclisation under Mukaiyama 
conditions.83  
 
 
Scheme 1.15. Synthesis of intermediate 140. 
 
Scheme 1.16. Zakarian’s total synthesis of (R)-(−)-rhazinilam (R)-1.  
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The resulting macrolactam presents axial chirality and the enantiomers were separated by 
preparative chiral HPLC to give enantioenriched (Ra)-149 and (Sa)-149 in high enantiomeric 
purity. The Pd-catalysed transannular cyclisation of key intermediate (Ra)-149 using Pd[PPh3] 
in the presence of Et3N gave after hydrogenation (R)-(−)-rhazinilam (1) in 60% yield and 99% 
ee. The synthesis proceeds through eleven steps starting from commercially available TIPS-
protected pyrrole 141 in 6.2% overall yield (through fourteen steps starting from tert-butyl 
acrylate 134 in 4.5% overall yield). 
 
Total synthesis of (R)-(−)-rhazinilam by Tokuyama 
 
In 2013, a protecting-group-free total synthesis of (R)-rhazinilam 1 was reported by 
Tokuyama and co-workers.84 The key step of this elegant synthesis is a gold-catalysed 
cascade cyclisation of linear intermediate 167 resulting in the one-pot formation of C and D 
rings (Scheme 1.18). The use of the sterically demanding acetal substrate is crucial in this step 
to avoid the undesired side reactions. For this purpose, the dimethylacetal 153 was 
transformed into the diisopropyl acetal 155 in three steps in 52% overall yield (Scheme 1.17).  
 
Scheme 1.17. Synthesis of intermediate 155. 
 
The synthesis of the fully functionalized ynamide 167 started with the construction of the 
quaternary stereocenter using the diastereoselective Michael addition reaction.85 For this 
reason, the commercially available 2-ethylcyclohexanone (156) was functionalized with (S)-
1-phenylethylamine (157) to provide a chiral enamine 158 which was engaged into the 
Michael addition reaction. Subsequent 2-step oxidation of ketoester 159 and epoxidation of 
the resulting cyclohexenone 160 afforded the epoxyketone 161. The synthesis of key 
intermediate 167 was achieved in five steps sequence by Eschenmoser-Tanabe-type 
fragmentation of semicarbazone 162 under Warkentin conditions,86 Pinnick oxidation87 of the 
aldehyde 163, condensation of the acid 164 with the diisopropyl acetal 155 and Sonogashira 
coupling of 165 with 2-bromoiodobenzene (166). The ynamide 167 contains all the carbons 
present in the natural product. The intramolecular nucleophilic addition of a nitrogen atom to 
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the alkyne bond activated by [Au(PPh3)]NTf2 resulted in formation of enamide 170 which 
underwent the subsequent aromatisation to produce the indolizinone 171 in 65% yield. 
Reduction of N-acyl pyrrole functionality was achieved in two steps using Luche conditions 
followed by hydroboration in acidic media.  
 
Scheme 1.18. Tokuyama’s total synthesis of (R)-(−)-rhazinilam (R)-1. 
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The compound 172 was transformed into the (R)-(−)-rhazinilam (1) in a sequence of tree 
steps: one-pot copper-mediated amination, saponification and finally lactamisation. The two 
last reactions of Tokuyama and Banwell syntheses are very similar despite of the Tokuyama 
group could slightly increase the yield. The synthesis proceeds through sixteen steps starting 
from 2-ethylcyclohexanone (156) in a good 6.3% overall yield and 98% ee.  
 
Total synthesis of (R)-(−)-rhazinilam by Zhu 
 
In 2014, Zhu and co-workers reported a concise enantioselective synthesis of (R)-rhazinilam 
1.88 In contrast to other reported methods for the synthesis of rhazinilam, the synthetic route 
started with a preparation of D ring bearing a chiral quaternary carbon (Scheme 1.19). The 
key step is an imidodiphosphoric acid catalysed desymmetrization of bicyclic bislactone 178. 
This intermediate was prepared from the butanal (173) by three-step procedure. Reacting the 
in situ generated enamine 175 with methyl acrylate (176) afforded the Kuehne’s aldehyde 
177.89 Hydrolysis and subsequent reaction of diacid with acetic anhydride produced the key 
intermediate 178 in 48% overall yield. A dessymetrization of 178 using MeOH as nucleophile 
in presence of the chiral phosphoric acid 17990 gave the enantiomerically enriched monoacid 
180 in 95% yield and 92:8 enanatiomeric ratio. Protection of aldehyde, chemoselective 
reduction of the ester and subsequent esterification of carboxylic acid afforded the alcohol 
183. Transformation of primary alcohol into the azide 184 followed by deprotection of 
dithiolan using o-iodoxybenzoic acid (IBX)91 gave the azido aldehyde 185. The azide 185 was 
converted into the cyclic imine 186 by Staudinger reduction and subsequent aza-Witig 
reaction.  
The total synthesis was then completed via a formal [3+2] cycloaddition between the allyl 
bromide 35 and intermediate 186, followed by reduction of 188 and macrolactamisation 
sequence. The synthesis proceeds through fifteen steps starting from butanal (173) in 9.8% 
overall yield. 
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Scheme 1.19. Zhu’s total synthesis of (R)-(−)-rhazinilam (R)-1. 
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1.4 Previous total syntheses of analogues of rhazinilam 
 
Several publications describe efforts dedicated to the total syntheses of analogues of 
rhazinilam. Some publications report the total syntheses of analogues obtained as “side 
products” of the efforts dedicated to the total synthesis of rhazinilam. Four different analogues 
isolated from nature have been synthesized so far: rhazinal in its racemic (two synthesis) and 
in its enantioenriched form (one synthesis, see Scheme 1.14), rhazinicine as racemate (one 
synthesis) and finally leuconolam and epi-leuconolam in enantioenriched form (one synthesis 
leading to the mixture of the two natural products, see Scheme 1.14).  
 
1.4.1 Total syntheses of rhazinal 
 
Total synthesis of rac-rhazinal and of (R)-(−)-rhazinal by Banwell 
 
Both syntheses use an intramolecular Michael addition as key step to form the C-D ring unit 
(Scheme 1.13 and 1.14). In 2003 Banwell and co-workers reported the first total synthesis of 
racemic rac-(±)-rhazinal (rac-10)41 achieved in fifteen steps with 6.6% overall yield. In 2006 
the Banwell group achieved the synthesis of the natural (R)-(−)-rhazinal ((R)-10)74 in 
seventeen steps with 5.0% overall yield.  
 
Total synthesis of rac-rhazinal of Trauner 
 
Trauner and co-workers reported92 a concise synthesis of rac-(±)-rhazinal (10) using Pd-
catalysed coupling reactions to form the ring D (cyclisation of 196 or alternatively of 199) and 
the ring B (cyclisation of 203) (Scheme 1.20). The synthesis of the aliphatic part proceeded 
through the E-trisubstituted ester 194 which was constructed from the known93 aldehyde 189. 
The α-methylation followed by treatment with methyllithium afforded the allylic alcohol 191. 
The Claisen rearrangement of the allylic alcohol produced the ester 192 in 94% yield. 
Deprotection of with tetra-n-butylammonium fluoride and subsequent tosylation of 193 
afforded the desired intermediate 194. Reaction of 194 with the potassium salt of pyrrole 198 
gave the N-alkylated pyrrole 199 in 67% yield.  
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Scheme 1.20. Trauner’s total synthesis of rac-rhazinal (10).  
 
The oxidative cyclisation of compound 199 using Pd(OAc)2 in the presence of t-BuOOH 
resulted in the formation of tetrahydroindolizine 200 in 69% yield. The C-D precursor was 
then protected as aldehyde 197 by subsequent Vilsmeier-Haack formylation (41% over three 
steps from compound 194). The intermediate 197 was prepared in parallel by a very similar 
sequence, where the formyl group was introduced on the pyrrole ring right from the beginning 
and where a direct Heck coupling involving the iodopyrrole 195 formed the D-ring.  
The selective reduction of the double bond using Crabtree’s catalyst followed by hydrolysis of 
the ester yielded the corresponding acid 202 in excellent yield. Coupling of the acid 202 with 
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2-iodoaniline (64) under Mukaiyama’s conditions provided the amide 203,55 which was 
protected as the methoxymethyl (MOM) key intermediate 204 in 75% yield. The B-ring was 
formed using 10 mol % of Buchwald’s “DavePhos” ligand 6756 and Pd(OAc)2 in the presence 
of potassium carbonate to produce the N-MOM rhazinal 205 in 43% yield. After removal of 
the MOM protecting group with a large excess of boron trichloride racemic rac-(±)-rhazinal 
(10) was obtained in 45% yield. The synthesis proceeds through thirteen steps in 1.3% overall 
yield (Method A) or through fourteen steps in 0.8% overall yield (Method B). We have 
calculated the yield starting from aldehyde 189 which is not commercial. The method used for 
the preparation of this aldehyde is not indicated. 
 
1.4.2 Total syntheses of rhazinicine 
 
Total synthesis of rac-rhazinicine by Gaunt 
 
The first total synthesis of the rac-rhazinicine (3) was reported by Gaunt and co-workers in 
2008.59 The synthetic approach and pathway are similar to the synthesis of rac-rhazinilam 
described above. The A, C and D rings are constructed via metal-catalysed C-H bond 
functionalization. The synthesis started from a different pyrrole 206 (Scheme 1.21). For the 
preparation of the biaryl intermediate 209 containing the A-C rings Boc and TMS protecting 
groups had to be introduced to obtain the doubly protected precursor 207. The one-pot IrI-
catalysed borylation/Suzuki coupling60-62 formed the 3-arylated pyrrole 208 in 78% yield. 
Removal of Boc-protecting group under heating afforded the pyrrole 209 containing the A-C 
rings of rhazinicine. Reacting the lithium anion of 209 with acid chloride of intermediate 72 
the N-acylated pyrrole 210 was obtained in 76% yield (Scheme 1.14). The intermediate 210 
contains all the carbons present in the target molecule. Treating 210 with Pd(TFA)2 catalyst 
and t-butylperoxybenzoate resulted in the formation of cyclisation product 211 in 53% yield. 
The synthesis was achieved in a three steps sequence: simultaneous reduction of the nitro and 
alkene groups, AlCl3-mediated removal of the silyl protecting groups and lactamisation under 
Mukaiyama conditions. The rac-rhazinicine (3) was obtained in eight steps starting from 
pyrrole 206 in 1.9% overall yield (in nine steps starting from diester 18 in 1.3% overall yield). 
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Scheme 1.21. Total synthesis of rac-rhazinicine (3) by Gaunt.  
 
Total synthesis of (R)-(−)-rhazinicine by Tokuyama 
 
The first total synthesis of the (R)-(−)-rhazinicine (3) was reported by and co-workers in 
2013.84 This protecting group free synthesis involved as a key step a gold-catalysed cascade 
cyclisation and follows the path depicted in Scheme 1.18 for the synthesis of (R)-(−)-
rhazinilam (1) until the final stages. The divergence occurs after the preparation of 
indolizinone 171 (Scheme 1.22). The N-acyl pyrrole functionality was preserved. In contrast 
to (R)-(−)-rhazinilam (1), the synthesis of (R)-(−)-rhazinicine (3) was achieved in three steps 
sequence by the smooth conversion of methyl ester 171 into amide 212 and subsequent 
macrolactamisation carried out via a copper-mediated intramolecular amidation. The 
synthesis proceeds through fourteen steps starting from 2-ethylcyclohexanone (156) in good 
7.7% overall yield and 98% ee. 
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Scheme 1.22. Total synthesis of (R)-(−)-rhazinicine (3) by Tokuyama.  
 
1.4.3 Total synthesis of leuconolam and epi-leuconolam by Banwell 
 
Banwell and co-workers reported the first total syntheses of (−)-leuconolam (6) achieved in 
nineteen steps with 1.2% overall yield, and (+)-epi-leuconolam (8)74 achieved in nineteen 
steps with 2.0% overall yield. Both syntheses involved as a key step an intramolecular 
Michael addition reaction. They were described in Scheme 1.14.  
 
1.4.4 Total synthesis of rac-kopsiyunnanine C3 by Gaunt  
 
The first total synthesis of the rac-kopsiyunnanine (13) was reported by Gaunt and co-
workers in 2012.58 The synthetic route follows the steps outlined previously for the synthesis 
of rac-rhazinilam in Scheme 1.8. The presence of ester group in intermediate 32 allowed 
applying the divergent endgame strategy and obtaining the rac-kopsiyunnanine C3 instead of 
rac-razhinilam by DIBAL-H reduction (Scheme 1.23). The synthesis proceeds through eight 
steps starting from pyrrole 74 in considerable 16.1% overall yield (through twelve steps 
starting from diester 18 in 8.7% overall yield). 
 
Scheme 1.23. Total synthesis of rac-kopsiyunnanine (13) C3 by Gaunt.  
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1.5 Comparison of the published rhazinilam syntheses  
 
General remarks 
 
The synthesis of rhazinilam has been studied for now almost 40 years. Twelve different 
syntheses have been reported so far: six of rac-rhazinilam and six of (R)-rhazinilam. Five 
analogues of rhazinilam have been synthesized by four different groups using four different 
approaches: rac-rhazinal, (R)-rhazinal, rac-rhazinicine, (R)-rhazinicine, (R)-leuconolam, (R)-
epi-leuconolam and rac-kopsiyunnanine C3. The methods to construct the rhazinilam skeleton 
have changed over the years; however the retrosynthetic cuts for all these synthesis have 
stayed rather similar. The major difference between the different syntheses is the sequence of 
the synthetic steps forming the tetracyclic structure and the methods used to create the 
different rings of rhazinilam. Most of the recent studies reported the synthesis of the 
enantiomerically enriched natural product (ee between 74% and 99%). The research leading 
to the very first synthesis had clearly been started before the structure of (R)-rhazinilam had 
been ascertained by the structure determination of the crystal by X-ray diffraction. This initial 
synthesis project follows therefore the logic of structure determination by total synthesis. For 
almost 30 years no new academic synthesis was reported. The recent synthesis reported since 
2000 have been designed around one or several key steps. The goal of these syntheses is to 
showcase the efficiency of these key steps applying them to a “real” synthetic goal. The use of 
transition metals for the forming of C-C and more recently of C-N bonds is illustrated in 
several of the recent total synthesis. Another important feature illustrating the latest 
development in organic synthesis is the application of organocatalysis for the asymmetric 
synthesis of a key intermediate. 
 
Comparison of the number of synthetic steps and the overall yield 
 
The development of synthetic methodologies since 1973 has been spectacular and it seems 
almost unfair to compare the first synthesis published in 1973 with the most recent synthesis 
published in 2014. If one wants to compare the overall yields and the number of synthetic 
steps from commercially available starting material for all ten syntheses we had in some cases 
to go back to the literature reports cited by the authors to identify the commercial starting 
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materials. In these cases we assumed that the authors have used the reported procedure and 
that the authors had obtained the yields of the cited procedures.  
 
Scheme 1.24. Comparison of the twelve total syntheses of rhazinilam reported during the last 
40 years. Six syntheses yielded rac-(±)-rhazinilam and six syntheses gave (R)-(−)-rhazinilam.  
 
The number of steps from commercial starting material varies from 9 to 20 steps (Scheme 
1.24). The lowest overall yield is 1.6% and the best 23%. The average yield per step is more 
than 70% for all the synthesis reported. The highest yielding synthesis reports an impressive 
average yield of 90% over 15 steps. The short syntheses tend to be more efficient, but it is 
interesting to emphasize that six of the ten syntheses have an overall yield between 1.6 and 
4.5%, despite the fact that the shortest of these syntheses needs only 10 steps whereas the 
longest needs 20 steps, twice as many compared with the shortest synthesis. 
Looking at these syntheses from the standpoint of overall yield the first synthesis is 
surprisingly efficient. In comparing the five syntheses of rac-rhazinilam the shortest synthesis 
with only 9 steps has been reported by Magnus. In the Magnus synthesis no protecting group 
on the pyrrole ring was introduced, which shortens the synthetic pathway by at least two 
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steps. The six enantioselective syntheses are all considerably longer, 14 to 18 steps. In two 
cases (Sames’ and Tokuyama’s syntheses) a chiral auxiliary had to be introduced and to be 
cleaved. The interesting strategy exploiting the axial chirality of the macrolactam ring had 
been applied in Zakarian’s synthesis to create the quaternary chiral center. Perhaps, despite 
the absence of protecting group on the pyrrole ring, the number of steps and yield are 
comparable to other syntheses. In the enantioselective syntheses by Nelson and by Banwell an 
enantioselective catalytic process is applied. The overall length of these two syntheses is 15 
respectively 18 steps. Based on the overall yield the synthesis reported by the Nelson group 
stands out with an overall yield, which is two time higher than the Gaunt synthesis and at least 
a factor of five better than most of the other syntheses.  
 
Comparison of the retrosynthetic analysis used 
 
The summary of the retrosynthetic analysis used in the different total syntheses leads to some 
interesting conclusions (Scheme 1.25). In most of the syntheses the B-ring is formed last. Due 
to this common retrosynthetic analysis the end game of all syntheses is quite similar. In ten of 
the twelve syntheses the lactam formation is the last step finishing the construction of the 
skeleton of rhazinilam. In Trauner’s and Zakarian’s syntheses the B-ring is closed via a Heck 
type C-C coupling. One has however to mention that the Trauner synthesis is an inversion of 
the sequence used by Nelson and Banwell. In Trauner’s synthesis the amide bond of the B-
ring is formed first and the ring closure is achieved via the Heck type coupling second. In the 
syntheses of Nelson and Banwell the sequence is inverted. The particularity of the Zakarian 
synthesis is the simultaneous formation of B and D rings.  
The other six syntheses propose the D-ring formation just before closing the lactam ring (ring 
B). In the two syntheses by Sames and the synthesis reported by Magnus the D-ring is part of 
the starting material and stays intact during the whole synthetic sequence. In Tokuyama 
synthesis the D ring is constructed together with the pyrrole ring in the one-pot reaction. In 
Zhu synthesis the D ring is prepared first bearing a chiral quaternary center.  
In the recent syntheses the aromatic A ring is introduced by Suzuki coupling reaction 
(Banwell, Nelson, Trauner, Gaunt, Zakarian syntheses) or Sonogashira coupling reaction 
(Tokuyama synthesis).  
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Scheme 1.25. Summary of the retrosynthetic analysis of the twelve total syntheses of 
rhazinilam reported during the last 40 years.  
 
Five of the twelve syntheses use a commercial precursor containing the intact pyrrole ring 
(Banwell, Nelson, Trauner, Gaunt, Zakarian syntheses). The groups of Smith, Sames, Magnus 
and more recently of Tokuyama, Zhu and Yao have applied synthetic schemes, where the 
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pyrrole ring is constructed during the preparation of rhazinilam. Smith uses a variant of a 
Knorr-type pyrrole synthesis whereas Sames, Magnus and Zhu use a Grigg-type 1,5-
electrocyclization. In Tokuyama synthesis the pyrrole ring construction proceeded through an 
intramolecular gold catalysed cyclisation process whereas Yao group adopted a Barton-Zard-
type pyrrole synthesis. 
Another observation concerns the use of “protecting” or stabilizing group on the pyrrole ring 
(Scheme 1.26). With five exceptions, all syntheses have to introduce or to carry on an electron 
attracting substituent on the pyrrole ring. Most of the syntheses use an ester group in the α-
position. The Banwell synthesis employs an aldehyde function as protecting group of the 
pyrrole. Very often two steps are needed to introduce the protecting group and one to two 
steps are again needed for the deprotection. The protecting group is in most of the syntheses 
carried along a good part of the synthetic sequence. In the Sames synthesis the ester 
protecting group is present during 14 steps. These substituents have to be removed towards 
the end of the synthesis. Even if it is not formally stated in most of the publications, their 
function is clearly to make the intermediates stable enough, that they can be manipulated. The 
exceptions are the more recent Magnus, Zakarian, Tokuyama, Zhu and Yao syntheses. 
Despite the fact that the Magnus’ group uses an intermediate, which is identical with the one 
reported in the first synthesis of Sames, the Magnus group was able to avoid the use of 
electron attracting group on the pyrrole ring. Such a comment can be made about Zakarian 
synthesis, the first steps and starting materials of which are similar to the synthesis of Gaunt. 
Curiously, despite the absence of protecting group, the Zakarian synthesis is longer than 
synthesis of Gaunt, 11 steps and 8 steps respectively starting from the corresponding pyrroles. 
Regarding the Tokuyama synthesis, one can note that the pyrrole ring is formed at latest stage 
and the protecting group is not needed for the end-game sequence. 
In summary the synthesis of rhazinilam is still a challenging synthetic problem. The syntheses 
reported are attractive and incorporate different interesting key steps. Despite the spectacular 
developments of organic synthesis even the very first reported synthesis is still a valid 
approach to this fascinating natural product. 
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Scheme 1.26. Protecting the α-position of the pyrrole C-ring introducing an electron 
attracting protecting group during the syntheses of rhazinilam. 
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Chapter two 
 
 
 
PREPARATION OF 
ADVANCED INTERMEDIATES 
FOR PYRROLINONE AND 
PYRROLE BASED 
RHAZINILAM ANALOGUES 
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2.1 Introduction 
 
As previously discussed, (R)-(–)-rhazinilam 1 and some of its congeners have unique 
antimitotic properties and were identified as promising targets for developing of a new 
generation of anticancer agents. The scientific challenge of this relatively simple natural 
product is to understand and to explain in structural terms its activity. Transferring the 
knowledge from in vitro studies to in vivo experiments has proved to be quasi impossible.94 
The combination of the findings on the chemical reactivity, with the well-known sensitivity of 
rhazinilam towards oxidative metabolic transformations95 was used as a guideline for 
proposing and designing novel rhazinilam analogues. The retrosynthetic approach chosen is 
conceived so as to avoid the notorious sensitivity of non-stabilized pyrroles towards oxidation 
and/or acid conditions avoiding protecting groups as much as possible.  
Our group has developed a convergent synthesis of the phenyl-pyrrolic core of rhazinilam 
involving a tandem Mukaiyama aldol-type condensation − Staudinger cyclisation sequence96-
101 (Scheme 2.1).  
 
Scheme 2.1. Retrosynthetic analysis involving Mukaiyama – Staudinger tandem sequence.  
 
The chosen convergent strategy allows the short and efficient synthesis of many derivatives. 
The new approach complements the classical Knorr pyrrole synthesis.102 The key intermediate 
is the 3-pyrrolin-2-one 235 serving two goals: facilitating the introduction of the substituents 
needed for the construction of rings B and D and reducing the sensitivity the pyrrole ring 
precursor (ring C). 
Having this key intermediate 218 in hand, the important challenges are to find good and 
efficient methodologies to introduce the B-ring and the D-ring.  
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2.2. Previous studies 
 
The first advanced studies were pursuing the goal to introduce the side chain needed for the 
creation of the B-ring (Schema 2.2). The realisation of this goal would be the preparation of 
analogue 1a of the general form depicted in the Scheme 2. Earlier structure activity studies 
had clearly indicated the importance of the B-ring,29,95 whereas the D-ring seemed to influence 
the in vitro activity only slightly.38,39,48 
 
 
Scheme 2.2. Synthetic pathway to the formation of lactam B-ring.100,103 
 
The synthetic pathway exploited the protocols established for the preparation of 3-pyrrolin-2-
one 218a involving the Mukaiyama crossed aldol condensation – Staudinger cyclisation 
sequence as a key reaction.  
The synthesis started with the commercially available 2-nitroacetophenone (213a) which is 
subsequently substituted with bromine and sodium azide to give the 2-azido-1-(2-
nitrophenyl)-ethanone (214a). The key step has proved to be sensitive to temperature and 
quantity of Lewis acid. Indeed, at temperatures above –10 °C the starting materials and 
products were unstable. As a result, the reduction of the yield was observed. On the other 
hand, the use of large amount of the strong Lewis acid such as TiCl4 which is needed to be 
neutralized during the work-up diminished the yield dramatically. Gratifyingly, treating the 
compound 214a with 3 equiv. of ketene acetal 215 and 0.5 equiv. of TiCl4 under the 
temperature keeping between –30 °C and –15 °C, the desired aldol product 216a was obtained 
in very good 76% yield. The Staudinger cyclisation using 1.5 equiv. of triphenylphosphine 
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proceeded smoothly to afford the pyrrolidinone 217a in 80% yield. The subsequent 
elimination of the tertiary alcohol was achieved under treatment of pyrrolidinone 7 with 2.1 
equiv. of Boc2O in the presence of catalytic amount of DMAP and resulted in the formation of 
Boc-protected 3-pyrrolin-2-one 218a in excellent yield. The side-chain was introduced into 
the compound 219 at C-5 position of 3-pyrrolin-2-one ring in a sequence of tree steps: 
silylation of 218a, second Mukaiyma type aldol condensation of silylpyrrole 219 with 
aldehyde 220 and finally Swern oxidation of the resulting aldol product. The resulting 
compound 221 contains all the carbons required to form the nine-membered lactam ring B.  
However, this intermediate has proved to be very sensitive to pH changes due to the acidic 
proton at C-5 of 3-pyrrolin-2-one ring. This proton can easily be deprotonated due to the keto-
enol equilibrium between the pyrrolinone and the aromatic hydroxyl-pyrrole tautomeric form 
(Figure 2.1).  
 
Figure 2.1. Keto-enol equilibrium in 3-pyrrolin-2-ones. 
 
The ease of tautomerisation makes this position particularly sensitive to unwanted side 
reactions. As a result, all efforts to saponify or to reduce these intermediates and thereby to 
increase their stability have been non-conclusive or have failed.  
Thus, alternative strategies avoiding or reducing the problem of stability of substituted 3-
pyrrolin-2-one were necessary to develop. Inverting the proposed sequence by constructing 
the D ring the first might bring a solution to the observed problem. This matter is addressed in 
the following sections. 
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2.3. N-Alkylation vs N-Acylation 
 
A strategy introducing a side chain containing all the carbon atoms of ring D and the 
appropriate functionality for the ring closure and the introduction of ring B on the 3-pyrrolin-
2-one ring was chosen. The attractivity of this strategy was the fact that the intramolecular 
Michael addition reaction has been successfully applied74 in former syntheses of rhazinilam. 
The activation of the pyrrole through the O-silyl group in the 2-position should facilitate the 
ring closing process (Scheme 2.3). 
 
Scheme 2.3. Synthetic pathway to the formation of D-ring via intramolecular Michael 
addition reaction. 
 
To realize this strategy the corresponding iodo acrylate 227 or the pentafluorophenylester 229 
had to be prepared. 
 
Scheme 2.4. Synthesis of acrylate 227 and 229. 
 
The synthesis of these acrylates started with commercially available γ-butyrolactone 114 
which were converted into the Weinreb amide 222 according to the procedure described by 
Fukuda et al.104,105 in 90% yield over the two steps (Scheme 2.4). Reaction of amide 222 with 
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ethylmagnesium bromide afforded the alkynone 223106 in nearly quantitative yield. 
Compound 223 underwent a Wadswoth-Horner-Emmons (WHE)74,107 olefination to give the 
unsaturated ester 224 as a 60:40 mixture of E/Z-isomers in excellent yield. After desilylation 
of 224 with TBAF, treatment of the resulting alcohol 225 with tosyl chloride produced the 
tosyl acrylate 22692 in 78% yield over the two steps. Finally 226 was converted into the 
desired iodo acrylate 227108 in excellent 67% overall yield over seven steps starting from the 
commercial lactone 114.  
The structure of 225 was determined by spectral analyses, and the stereochemistry was 
confirmed by NOE experiment (Figure 2.2). 
 
Figure 2.2. NOE experiments of (E)-225 and (Z)-225. 
 
In parallel, the alcohol 225 was oxidized with Jones' reagent109,110 (1.9 M, acetone/H2O, 0 °C) 
to provide the acid 228 in 81% yield. Activation of acid 228 using pentafluorophenol and 
N,N'-dicyclohexylcarbodiimide provided the pentafluorophenylester 229111 in moderate yield. 
However, the activated acrylate 229 could be obtained from the commercially available γ-
butyrolactone 114 in seven-steps and in 31% overall yield. 
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2.3.1. N-alkylation of 4-(2-nitrophenyl)-1H-pyrrol-2(5H)-one (235) 
 
In literature only few examples of N-alkylation of tetramates have been reported.112,113  
Thus, Jones and Bates112 accomplished the alkylation of NH-3-pyrrolin-2-one by two 
procedures. N-methylated 4-O-tetramate 231a was obtained from 3-pyrrolin-2-one 230a using 
a strong base such as n-BuLi under low temperature (Scheme 2.5).  
 
Scheme 2.5. Reported N-alkylation of O-methyl tetramate 230a using n-BuLi.112  
 
However, the most effective, reported N-alkylation procedure used phase-transfer conditions 
(PTC) for promoting N-1 deprotonation and alkyl iodides or benzyl bromides as electrophiles 
(Table 2.1, entry 2,5,7). Under these conditions double alkylation products 25 were often co-
isolated in minor amounts.  
 
A more recent systematic study of the reaction of 4-O-methyl tetramate was reported by Jones 
and Patience.113 The amount of N-1, C-5 or multiple alkylations could be influenced by the 
stoichiometry of the reagents (Table 1, entry 3,6,8-10). Di- and trialkyl derivatives were 
obtained using 10 mol equivalents of base and alkyl halide. In many cases increasing large 
excess of these reagents and/or longer reaction times led to extensive decomposition of 3-
pyrrolin-2-one. In some cases even O-alkylated by-products were isolated. However, the 
normal sequence of deprotonation of tetramates was brought to light (Figure 2.3). 
 
 
 
Figure 2.3. Sequence of deprotonation of 4-O-tetramate.  
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Table 2.1. Reported examples of N-alkylation of 4-O-methyl tetramates.112,113  
 
Entry Compound 
Alkyl 
halide 
Conditions 
Product 
(yield) 
1112 
230a   
(R1=H) 
MeI n-BuLi, 0°C 231a 
2112 
230a   
(R1=H) 
MeI KOH, Bu4NHSO4, THF, 25 °C 
231a (55%) + 
232a 
3113 
230a   
(R1=H) 
EtI 
(3 equiv.) 
KOH (1.4 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
231b (48%) 
4113 
230a   
(R1=H) 
EtI 
(10 equiv.) 
KOH (10 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
232b (69%) 
5112 
230a   
(R1=H) 
Octyl-I KOH, Bu4NHSO4, THF, reflux 
231c (43%) + 
232c 
6113 
230a   
(R1=H) 
BnBr 
(3 equiv.) 
KOH (1.4 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
231d (55%) 
7112 
230a   
(R1=H) 
BnBr KOH, Bu4NHSO4, THF, 25 °C 
231d (60%) + 
232d 
8113, [a] 
230b 
(R1=Me) 
MeI 
(10 equiv.) 
KOH (10 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
232a + 232e 
9113 
230b 
(R1=Bn) 
MeI 
(3 equiv.) 
KOH (1.4 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
231e (88%) 
10113 
230b 
(R1=Bn) 
BnBr 
(10 equiv.) 
KOH (10 equiv.), Bu4NHSO4, 
THF, 25 °C, 20 h 
232f (67%) 
 
[a] Some O-alkylated materials were obtained as by-product   
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As an alternative the authors investigated the alkylation at C-5 of the N-unsubstituted 
tetramates using at least two equivalents of a strong base under low temperature conditions 
(Scheme 2.6). The resulting dianion of 4-O-methyl tetramate 233 underwent preferential C-
alkylation in moderate to good yields using benzyl bromide or alkyl iodides as electrophiles.  
 
Scheme 2.6. Reported C-5-alkylation of the N-unsubstituted O-methyl tetramates via the 
intermediate dianion 233.113 
 
Based on the encouraging results reported in the literature, the further investigation was 
focused on the N-alkylation with alkyl iodide 227 of 3-pyrrolin-2-one 235 quantitatively 
prepared from compound 218 by deprotection using TFA. Disappointingly, despite numerous 
efforts varying the approach and the reaction parameters such as base, number of equivalents, 
temperature, reaction time, the N-alkylation of 3-pyrrolin-2-one 235 using olefin 227 could 
not be achieved (Table 2.2).  
Often starting material could be re-isolated or degradation of 3-pyrrolin-2-one was observed 
as evidenced by the poor mass-balance after work-up and purification. Using n-BuLi as a 
strong base at low temperatures and then warming the solution to room temperature led to 
recovery of the iodide 227 whereas the 3-pyrrolin-2-one 235 was degraded (Entry 1). Using 
the different variants of the phase transfer alkylation did not lead to product formation either. 
Under these milder conditions both starting materials could be partially recovered (Entry 2 – 
4). Using strong bases like potassium hexamethylsilazane (KHMDS) of sodium hydride in 
THF or in DMF did not allow detecting product formation (Entry 5 and 6 for KHMDS and 7 
to 9 for NaH).  
It seems that the nucleophilicity of the 3-pyrrolin-2-one substrate is not high enough for an 
optimal further transformation via N-alkylation. Obviously, such a proposal requires 
additional studies which are summarized in the following sections. 
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Table 2.2. Attempts to N-alkylate the 3-pyrrolin-2-one 235. 
 
Entry 
Electrophil
e (equiv.) 
Base 
(equiv.) 
PTS[a] 
(equiv.) 
Solvent T, °C 
t, 
h 
Product [b] 
1100,112 227 (1.13) 
n-BuLi 
(1.12) 
− THF 0−20 3.5 
227+ 235 
decomposed 
2112,114 227 (1.25) 
KOH 
(6.00)/ 
K2CO3 
(1.25) 
Bu4NHSO4 
(0.10) 
MePh 60 5 
227 + 235 
decomposed 
3113 227 (3.00) 
KOH 
(1.40) 
Bu4NHSO4 
(0.10) 
THF 0−20 18 
227 + 235 
decomposed 
4113 ,[c] BnBr (3.00) 
KOH 
(1.40) 
Bu4NHSO4 
(0.10) 
THF 0−20 18 BnBr + 235 
5115 226 (1.1) 
KHMDS 
(1.1) 
− THF 70 2 
226 + 235 
decomposed 
6115 227 (1.1) 
KHMDS 
(1.1) 
− THF 70 3 
227 + 235 
decomposed 
7116 226 (1.10) 
NaH 
(1.10) 
TBAI  
(0.22) 
THF 
DMF 
20 27 
226 + 235 
decomposed 
855 227 (1.10) 
NaH 
(1.10) 
− DMF 20 24 
227 + 235 
decomposed 
955 227 (1.10) 
NaH 
(1.10) 
− DMF 0−20 24 
227 + 235 
decomposed 
[a] Phase transfer catalyst was added. [b] According to NMR and/or GC. [c] Benzyl bromide 
was used as electrophile.    
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2.3.2. N-alkylation of substituted pyrrole 28 
 
Having this hypothesis in mind, the use of more nucleophilic aryl-pyrrole 28 was envisaged 
(Scheme 2.7). 
 
Scheme 2.7. Synthesis of biaryl 28. 
 
The synthesis started with a pyrrole 61 containing a temporary blocking group at C2 position. 
In most of the reported rhazinilam syntheses117,118 a carboxymethyl group at the C2 position 
of the pyrrole ring had to be used as temporary protecting group. This protection probably 
prevents competing oxidative pyrrole dimerization reactions.  
The key structural elements of 28 could be directly installed from a simple pyrrole nucleus by 
a metal-catalysed C-H bond arylation to produce the heterobiaryl framework.  
Thus, the IrI-catalysed C-H borylation, developed by the groups of Smith–Malezcka and 
Hartwig–Miyaura, 60,61,119 was adopted to furnish the desired pyrrole nucleus and then 
performed a Suzuki coupling. The tert-butylcarboxy (Boc) group is known120 to be a protector 
and director for Ir-catalysed borylations. The pyrrole 61 was converted into N-Boc-pyrrole 74 
in excellent yield. Compound 74 underwent an Ir-catalysed borylation under Smith–Malezcka 
conditions120 to yield a 4-borylated pyrrole 237 in 72% yield with complete regioselectivity at 
C-4. A Pd-catalysed Suzuki cross-coupling reaction of 237 with 2-bromo-nitrobenzene (238) 
was achieved quantitatively following the procedure described by Morrison and co-wokers.82 
Alternatively, the biaryl 76 could be obtained in 96% yield by one-pot IrI-catalysed C-H 
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borylation and Suzuki coupling on 74 (see experimental part). Removal of the Boc group 
under thermal conditions59,120,121 delivered quantitatively 28. 
Having sufficient quantities of the required aryl-pyrrole 28 available, we tested the alkylation 
reaction with the corresponding olefin (Table 2.3).  
 
Table 2.3. N-alkylation of the pyrrole 28. 
 
Entry Electrophile 
(equiv.) 
Base 
(equiv.) 
Solvent Temperature 
[°C]  
Time 
[h] 
Yield  
[%] 
1115 226 (1.1) KHMDS (1.1) THF 85  20 –[a] 
255 226 (1.1) NaH (1.1) DMF 0 – 20 20 63[b] 
355 227 (1.1) NaH (1.1) DMF 0 – 20 6 Quant. 
[a] Only starting materials were recovered. [b] According to NMR data.  
 
A nucleophilic substitution of the tosyl group by the potassium salt of pyrrole 28 was 
unsuccessful. The N-alkylated pyrrole 239 was isolated in moderated yield using the sodium 
salt of pyrrole precursor. Gratifyingly, N-alkylation of pyrrole 28 preceded smoothly and 
quantitatively using iodo-alkyl 227 as electrophile and NaH as a base.  
2.3.3. N-acylation of 3-pyrrolin-2-one 240 
 
Given the poor nucleophilic nature of 3-pyrrolin-2-one substrate, it was decided to investigate 
the N-acylation instead of the N-alkylation on the model series involving sterically less 
demanding substrates (Schema 2.8). Two retrosynthetic pathways were envisaged and 
experimentally tested. 
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Scheme 2.8. Retrosynthetic pathways for synthesis of 246 via N-acylation of pyrrolinone 235. 
 
N-Acylation of sterically hindered chiral cyclic amides has previously been described; 
especially the oxazolidinones have attracted much interest due to their use as chiral 
auxiliaries.122,123 Similar 3-pyrrolin-2-ones have been N-acylated using an n-BuLi protocol 
with electrophiles such as acid chlorides124 and pentafluorophenyl (Pfp) esters (Scheme 
2.9).125-127  
 
Scheme 2.9. N-acylation of 3-pyrrolin-2-one 240. 
 
The first attempt to perform the N-acylation using the 1H-pyrrol-2(5H)-one 240101 and the 
active ester 243 derived from the levulinic acid (242) (Scheme 2.10) was successful. Thus, 
activation of the carboxylic functionality of 242 as its pentafluorophenol ester 243, followed 
by condensation with the lithium salt of 240 afforded 244 in moderate 30% yield. 
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Scheme 2.10. N-acylation of 3-pyrrolin-2-one 240 with levulinic acid pentafluoroester 243. 
 
Unfortunately, all attempts to achieve WHE olefination of 244 using NaH (4 equiv.) and 
methyl diethylphosphonoacetate (3.52 equiv.) in dry THF were unsuccessful. Only starting 
materials and the products of hydrolysis of 3-pyrrolin-2-one 244, levulinic acid 242 and 1H-
pyrrole-2(5H)-one 240, were recovered.  
Given the failure to direct WHE olefination of 244, it was deemed necessary to synthesize 
first a α,β-unsaturated carbonyl chain. Thus, the pentafluorophenol ester 243 was subjected to 
WHE olefination using the conditions described above. Under such conditions, the activated 
ester 243 underwent WHE olefination to afford in 24% yield the acrylate 245 as a 75:15 
mixture of E- and Z-isomers (Scheme 2.11).  
 
Scheme 2.11. Olefination of levulinic acid pentafluorophenylester 243. 
 
The low yield should be due to a partial hydrolysis of ester 243. Nevertheless, the foregoing 
results demonstrated that the activated acrylate 245 could be obtained from the commercially 
available levulinic acid by two-step procedure and in 23% overall yield.  
This was a very positive outcome as it provided an easy access to a broad range of 
intramolecular Michael addition substrates.  
In light of these encouraging results, the N-acylation of more complex aryl-3-pyrrolin-2-one 
235 was investigated (Scheme 2.12).  
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Scheme 2.12. N-Acylation of 3-pyrrolin-2-one 235.  
 
The first attempt to perform the N-acylation on the 3-pyrrolin-2-one 235 using the activated 
acrylate 229 and n-BuLi at low temperature was successful. Such a result enabled to better 
understand the reactivity of this compound and to obtain the coupling product 246.  
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2.4. Preliminary investigation on the intramolecular Michael 
addition reaction of 239 and 246 to N-Tethered Acrylates 
 
After a number of synthetic efforts, the compounds 239 and 246 have been obtained and 
considered as promising advanced intermediates for obtaining the different derivatives of 
rhazinilam (Scheme 2.13).  
 
Scheme 2.13. Retrosynthetic pathway to formation of D-ring via intramolecular Michael 
addition reaction. 
 
With the requisite functional handle in place, the stage was now set for the implementation of 
the key intramolecular Michael addition reaction. Smith,17 Trauner55 and Banwel41 used the 
aluminium trichloride and the substituted pyrroles to achieve the itramolecular cyclisation 
(Scheme 2.14). 
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Scheme 2.14. Intramolecular cyclisations using AlCl3 as a Lewis acid activator: A) via an 
intramolecular Michael addition reaction;41 B) via an intramolecular Friedel-Crafts 
alkylation.17,55  
 
Unfortunately, all attempts to obtain the cyclic adduct 252 from acrylate 239 using aluminium 
chloride in diethyl ether or nitromethane are failed (Scheme 2.15).  
 
Scheme 2.15. Attempt to cyclicise the acrylate 239 into the tetrahydroindolizine 252. 
 
The presence of both methyl ester substituent on the pyrrole ring and 2-nitro group on the 
phenyl rings deactivates the pyrrole ring sufficiently preventing Michael addition reaction. 
The synthesis of the more nucleophilic pyrrole 254 was a logic solution overcoming this 
problem (Scheme 2.16). 
 
Scheme 2.16. Synthesis of biaryl 254. 
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The synthetic pathway started with the commercially available triisopropylsilyl-3-
bromopyrrole 141 which was easily converted into the pinacolboronate ester 143 via Pd-
catalysed carbon-boron bond formation using the procedure of Billingsley and Buchwald.128 
Pd-catalysed Suzuki-Miyaura cross-coupling of 143 and 2-bromo-nitrobenzene (238) was 
achieved quantitatively following the procedure described by Morrison and co-wokers.82 
Fluoro-desilylation of resulting biaryl 253 proceeded smoothly to yield the 3-(2-nitrophenyl)-
1H-pyrrole 254 in excellent yield.  
The next logical step was the N-alkylation of “more activated nucleophile” such us aryl 
pyrrole 254 using the procedure described above. The installation of a temporary blocking 
group for the C5 position59 of 255 should provide a handle for controlling the regioselectivity 
of the Michael addition reaction (Scheme 2.17).  
 
Scheme 2.17. Presumptive synthesis of precursor 256. 
 
Unfortunately, during the preparation of these intermediates, a total enantiospecific concise 
synthesis of rhazinilam was published by Professor Zakarian research group.64 The synthetic 
pathway required very similar steps for the construction of a target biaryl core. Thus we 
decided not to pursue this approach. 
Thereby, it was reasonable to turn the attention back to the studies of 3-pyrrolin-2-one 
chemistry. Thus, the activation of 3-pyrrolin-2-one 246 with tert-butyldimethylsilyl triflate 
could be easily performed and afforded the silyloxypyrrole 257 in good 69% yield (Scheme 
2.18).   
 
Scheme 2.18. Presumptive synthesis of precursor 258 via silyloxypyrrole 257. 
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However, the first trail to perform the intramolecular Michael addition using a Lewis acid 
such as BF3.Et2O at −90 °C failed. Only the desilylated product 246 was recovered. The 
screening of the reaction conditions needed for the formation of the desired Michael product 
258 has not been achieved yet.  
 
2.5. Summery. 
 
In summary, this project achieved the aims proposed at the outset. The N-alkylation and N-
acylation of 3-pyrrolin-2-one derivatives were investigated. This process was attractive 
because the products could contain all the atoms and the functionality needed for the 
formation of the D-ring via Michael addition. In this process the substituent for the 
elaboration of ring B could be introduced simultaneously. This building block, acrylates 227 
and 229, was prepared in remarkable yields.  
The introduction of a side chain by nucleophilic N-alkylation on 3-pyrrolin-2-one derivative 
could not be achieved whilst the reaction with a more nucleophilic pyrrole afforded in good 
yield the intermediate 239 for the further synthesis of pyrrole based rhazinilam analogues. 
Alternatively, the N-acylation on 3-pyrrolin-2-one derivatives was successfully performed. 
The advanced intermediates 246 and 257 contain all essential elements needed for the 
construction of pyrrolinone based rhazinilam analogues via a simple homologation step.  
Unfortunately, due to time constraints, it was not possible to continue the investigation of the 
intramolecular Michael addition reaction on the activated pyrrole 257. This compound is still 
to be a suitable substrate for further investigations. 
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Chapter three 
 
 
 
 
MUKAIYAMA CROSSED 
ALDOL REACTION 
METHODOLOGY 
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3.1 Introduction 
 
The recent metabolism studies were conducted in order to investigate the reasons for the in 
vivo lack of activity of (−)-rhazinilam.129 They revealed that rhazinilam is easily oxidized at 
positions 3 and 5 by human liver microsomes leading to the formation of metabolites, 
including leuconolam, which are much less active than rhazinilam or inactive in vitro and 
probably more rapidly eliminated. The isolated metabolites are mostly pyrrolinone containing 
derivatives of rhazinilam such as leuconolam. Our previous studies have shown that these 
products are also quite unstable.103,130 The introduction of a blocking group at the C-5 should 
overcome the problem of further oxidation.  
This observation led us to propose a new synthetic route to the phenyl-pyrrolidinone core of 
pyrrolinone-based analogues of rhazinilam. The process involves a tandem Mukaiyama aldol-
type condensation - Staudinger cyclisation sequence96-101 (Scheme 3.1). The chosen 
convergent strategy allows the short and efficient synthesis of more sterically hindered 
derivatives.  
 
 
Scheme 3.1. Retrosynthetic analysis involving Mukaiyama – Staudinger tandem sequence.  
 
3.2 Results and discussion 
3.2.1. Preparation of 1-(2-nitrophenyl) alkyl ketones.  
 
To synthesize the o-nitro-substituted phenyl pyrrolidinones using the approach reported 
above, it was essential to develop a flexible and efficient method for the preparation of the 
nitro-substituted alkyl phenyl ketone substrates.  
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Indeed, the formation of such a substrate is not trivial. A literature review of relevant studies 
shows that there are only a few synthetic routes to the ortho-nitro substituted alkyl phenyl 
ketones which can be divided into three major strategies.  
The most common approach is the nitration of the corresponding aryl ketones.131,132 Since 
Mitscherlich133,134 reported the first nitration of benzene with fuming nitric acid in 1834, the 
nitrating agent-involved electrophilic aromatic substitution has long been the most common 
approach for the preparation of nitroarenes.135,136 However, the traditional electrophilic 
nitration processes are usually associated with several persistent disadvantages including poor 
regioselectivity,137,138 poor chemoselectivity arising from overnitration, imperfect functional 
group and/or substrate compatibility under acidic conditions, nitration sites significantly 
depending on the directing effect of the different functional groups, and the use of 
environmentally harmful acid reagents.  
In the last decades, a more attractive method for the regiospecific synthesis of nitroarenes has 
been developed via the transition-metal-catalysed (Cu or Pd) ipso-nitration.139,140 Despite 
several characteristic advantages of these methods including improved regiospecificity for the 
ortho-substitution independent of the orientation rules, mononitration selectivity, broad 
functional group and substrate tolerance under neutral conditions, they suffer from the 
necessity to use  prefunctionalized starting materials such as aryl halides, pseudohalides, 
triflates, nonaflates or aryl boronic acids141-145 or they require the introduction of directing 
groups (Scheme 3.2).146  
 
Scheme 3.2. The site regiospecific nitration free from the effect of orientation rules involving 
the directing group (DG) installation.146  
 
An alternative strategy to ortho-nitro substituted alkyl phenyl ketones 261 was demonstrated 
by Kamath and co-workers.147 In this approach, nitro substituted alkyl phenyl ketones have 
been synthesized by reacting nitro substituted benzoyl chlorides (262) with morpholine 
enamines of aliphatic aldehydes 263. The resulting acylated enamines on hydrolysis afforded 
the desired products. However, 2-nitro and 2,4-dinitro substituted enamines on hydrolysis 
furnish the β-keto aldehydes which can be converted into the corresponding ketones by 
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additional treatment with aqueous sodium bicarbonate (Scheme 3.3). Nevertheless, this 
approach was found to be sensitive and afforded the desired product in unsatisfactory yield. 
 
Scheme 3.3. Synthesis of ortho-nitro substituted alkyl phenyl ketones via morpholine 
enamines formation, hydrolysis and deformylation.147  
 
The development of organometallic chemistry has seen major advances in the past half 
century. The nucleophilic addition of organometallic reagents to carbonyl compounds is a 
well-known reaction, which represents a powerful tool for the construction of carbon-carbon 
bonds.148 However, literature survey has revealed only few examples of the synthesis of 
ortho-nitro substituted alkyl phenyl ketones 261 via nucleophilic addition of organometallic 
reagents followed by oxidation of resulted alcohol. These approaches available for achieving 
the nucleophilic addition can be divided into one of two categories depicted in Scheme 3.4. 
Y
O
NO2
R
O
NO2
X
NO2
R-M(R'z) or
RMgX
O R
Y
electrophile
nucleophile
nucleophile
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M = Ti, Ga or Zn
261
 
Scheme 3.4. Synthesis of ortho-nitro substituted alkyl phenyl ketones 261 via nucleophilic 
addition of organometallic reagents.148  
 
Since the first reports on the alkyl groups transfer from organotitanium compounds to 
aromatic aldehydes,149,150 new methodologies using organozinc151-153 and organogallium154,155 
substrates have been developed in last 5 years (Scheme 3.5).  
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Scheme 3.5. Synthesis of ortho-nitro substituted phenyl alkyl alcohols using organozinc, 
gallium and titanium compounds.149-155 
 
Despite the attractiveness of these methods including the good yields, these organometallic 
compounds are expensive and sometimes difficult to handle due to their air- and moisture-
sensitivity. These facts limit their accessibility and, ultimately, the diversity of compounds 
that will be crucial for further investigation in this project.  
Reports on direct addition of Grignard reagents such as EtMgBr or MeMgBr to o-
nitrobenzoylchloride156 or o-nitrobenzaldehyde respectively157 are extremely rare and give the 
unsatisfactory yield.  
The replacement of alkyl by less nucleophilic vinyl magnesium bromide or chloride is most 
common way to deal with this issue.158-161 
Recently, Bouziane and co-workers proposed an interesting approach to the preparation of 
various aromatic ketones from the corresponding allylic alcohols by Ru-catalysed redox 
isomerization.162 However, the yield of ortho-nitro substituted phenyl ketone 261 was poor. 
The coordination of the nitro group to the ruthenium catalyst was invoked to explain the 
decreased reactivity (Scheme 3.6). 
 
 
Scheme 3.6. Synthesis of ortho-nitro substituted alkyl phenyl ketones via Grignard reaction 
followed by Ru-catalysed redox isomerization.162 
 
One of the possible reasons of inefficiency of Grignard reaction could be a well-known 
propensity of reactive Grignard and organolithium reagents to overadd to the substrate in the 
carboxylic acid oxidation state, producing a tertiary alcohol. Among the methods to solve this 
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problem, the use of Weinreb amide is especially convenient and attractive.163 Normally, no 
over-addition occurs due to formation of a very stable tetrahedral chelate 268 involving the –
OMe group of the substrate amide with the metal cation which prevents further reaction with 
the organometallic reagent (Scheme 3.7). This intermediate could be converted into the 
desired carbonyl compounds by treatment with acid.163-165 
 
Scheme 3.7. Formation of carbonyl compounds using Weinreb amide.163 
 
Indeed, a review of the literature shows that diverse aryl substituted N-methoxy-N-
methylamides (Weinreb amides) have been successfully converted into their corresponding 
ketones via modified Grignard reaction.166-171 Encouraged by these examples, our first attempt 
was focused on trying to employ the originally described conditions,168 involving addition of 
EtMgBr to the known172-174 Weinreb amide 270 (Scheme 3.8). Thus, N-methoxy-N-methyl-2-
nitrobenzamide 270 was prepared in 86% yield from ortho-nitrobenzoic acide(269) and N,O-
dimethylhydroxylamine hydrochloride using N-methylmorpholine (NMM) and 2-chloro-4,6-
dimethoxy-[1,3,5]triazine (CDMT) as a coupling agent under conditions defined by de 
Luca.173  
 
 
Scheme 3.8. Attempted synthesis of 1-(2-nitrophenyl)propan-1-one (261a) via Weinreb 
amide.  
 
However, the subsequent addition of 2 equiv. of EtMgBr at 0 °C resulted in decomposition of 
the starting material. It has been suggested that 1,2-and/or 1,6- conjugate addition175 to the 
phenyl ring activated by nitro-group may take place rather than substitution of N-methoxy-N-
methylamide functionality. This hypothesis is in accordance with studies conducted by 
several groups on the mechanism of reaction between Grignard reagents and nitroarenes.175-179 
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It was demonstrated that the reaction between nitroarenes and Grignard reagents may proceed 
through two different pathways (Figure 3.1), i.e. conjugate addition (path A) and reductive 
1,2-addition (path B). The nature of the carbanionic moiety is crucial: alkyl Grignard reagents 
yielded ring-alkylated products almost exclusively while PhMgX follow path B.  
 
Figure 3.1. Mechanism of the reaction between nitroarenes and Grignard reagents.175  
 
Even if nucleophilic substitution of the amine functionality of 270 were to occur, the role of 
methoxyamine segment in the post-reaction mixture seems to be not fully explored. Recent 
publications180,181 reported the substitution of Weinreb amide 270 with vinylmagnesium 
bromide followed by Michael addition reaction of the extruded N-methoxy-N-methylamine to 
form β-aminoketone 271 (Figure 3.2). 
 
Figure 3.2. Sequential nucleophilic substitution/Michael reaction of Weinreb amide 
270.180,181 
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The above experimental results and literature review suggested that the addition of Grignard 
reagents to nitro-substituted aryl carbonyl derivatives was not the optimal approach towards 
ortho-nitro substituted alkyl phenyl ketones. A change of strategy was then proposed, where 
the nitro-substituted aryl derivative may act as a nucleophile towards aliphatic aldehydes. 
Although reports on nucleophilic substitution reactions involving nitro-substituted aryl 
organometallic species are extremely rare, an interesting approach was proposed by Knochel 
group.182 In this approach, the aryl Grignard reagents with an ortho-nitro substituent have 
been prepared from 2-iodonitroaryl compounds through an I-Mg exchange reaction with 
PhMgCl (Figure 3.3).  
 
Figure 3.3. Preparation of o-nirtomagnesium halides through I-Mg exchange.182  
 
Interestingly, two observations were made: the use of more reactive Grignard reagents led to 
complex reaction mixtures suggesting the reaction of organometallic reagents with the nitro 
group, and the inductive and chelation effect of nitro group should favour the ortho-iodine–
magnesium exchange. Whilst the electrophiles in the original paper were cyclohexyl and 
phenyl aldehyde, it was decided to extend183 these conditions to aliphatic aldehydes. 
Fortunately, all aldehydes react smoothly with nitro-substituted Grignard reagent generated in 
situ from 2-iodonitrobenzene (75) to afford the corresponding alcohols 266a−b. After 
extraction of the reaction mixture and 1H NMR analysis of the product, it was found that the 
crude material was sufficiently clean to use without further purification. Thus, crude alcohols 
were oxidized to the corresponding ketones 261a−b using Jones reagent109,110 (1.9 M, 
acetone/H2O, 0 °C) (Scheme 3.9).  
 
Scheme 3.9. Synthesis of ortho-nitro substituted phenyl alkyl ketones 261a−b. 
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3.2.2. Preparation of α-bromoketones and α-azidoketones. 
The strategy of employing the Mukaiyama aldol reaction previously developed in our group 
required the α-azidoketone substrates. They were prepared by addition of bromine to the 
phenyl alkyl ketones followed by substitution of bromine with sodium azide. Some of the α-
bromoketones such as 2-bromoacetophenone 272b, 2-bromopropiophenone 272c, 2-
bromoisobutyrophenone 272f and 2-bromo-1-(4-nitrophenyl)ethanone 272g were 
commercially available. 2-Brom-2'-nitroacetophenone 272a was synthesized as described in 
previous work of our group (Scheme 3.10).100,101  
Scheme 3.10. Synthesis of 2-brom-2'-nitroacetophenone (272a) 
The procedure for the preparation of other α-bromoketones was slightly modified aiming to 
improve the reaction time and yields of bromination reaction.100,101 Thus, the reaction was 
completed within 0.5 h and afforded the brominated products in near quantitative yields using 
carbon tetrachloride184,185 instead of diethyl ether in absence of Lewis acid (Scheme 3.11).  
Scheme 3.11. Synthesis of α-bromoketones 272d−e and 272h−i 
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Substitution of α-bromoketones 272a−b with sodium azide was previously performed by our 
group. Whilst yields of these products were good, the reaction time was long, 48 h and 15 h 
respectively (Scheme 3.12, Method A: NaN3, MeOH/H2O, 15 h or 48 h, 4 °C). Fortunately, 
the change of the solvent system from protic MeOH/H2O to aprotic, polar DMSO decreased 
considerably the reaction time (from 15 h to 20 min) and the reaction could be performed at 
room temperature (Method B: NaN3, DMSO, 20 min, r.t.).186  
 
Scheme 3.12. Synthesis of α-azidoketones 214a−i. Reaction conditions: Method A: NaN3, 
MeOH/H2O, 15 h or 48 h, 4 °C; Method B: NaN3, DMSO, 20 min, r.t.; Method C: NaN3, 
Acetone, 18 h, r.t. 
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Although the phenyl substituted α-azidoketones 214c−f were obtained in high yields under 
these conditions, the application of this protocol to ortho-nitro substituted α-bromoketones 
272h−i led to decomposition of the substrate and/or the products. Interestingly, the para-
nirtophenacyl bromide 272g reacted smoothly with sodium azide to give the para-
nirtophenacyl azide 214g in 78% yield. This result was in accordance with data reported by 
Gong and co-workers for synthesis of para-and meta-nirtophenacyl azides.187 A successful 
alternative was found in conditions described by Zhao, employing acetone as aprotic solvent 
(Method C: NaN3, Acetone, 18 h, r.t.).188 Reaction of ortho-nitro substituted α-bromoketones 
272h−i with sodium azide under these conditions at room temperature afforded the desired α-
azidoketones 214h−i in good yields. This method is more suitable for the preparation of 
ortho-nitro substituted α-azidoketones than previous group procedure (Method A) for two 
reasons: shorter reaction time (18 h instead of 48 h) and optimal temperature (no practical 
complications of maintaining the reaction at 4 °C for extended periods). 
 
3.2.3. Synthesis of Pyrrolidinones via the Tandem Mukaiyama cross 
Aldol-Staudinger-type reductive cyclisation process. 
 
Subsequent to the formation of the α-azidoketones is the Mukaiyama crossed aldol reaction. 
This is a key step in the synthesis, as it involves the C-C bond formation between the phenyl 
and pyrrolidinone rings of the final compounds. The Mukaiyama crossed-aldol reaction 
typically involves the addition of silyl enol ether189-192 or more nucleophilic silyl ketene 
acetal193,194 (nucleophile) to an aldehyde or ketone (electrophile) in the presence of a Lewis 
acid catalyst such as TiCl4. (Figure 3.4).195 
 
 
Figure 3.4. Mukaiyama crossed aldol reaction.195 
 
The reaction mechanism has not been completely elucidated yet.196,197 The known facts are 
that a) Lewis acid enolates are not involved in this reaction:198 no transmetalation 
occurs;199,200 b) the Lewis acids coordinate with the carbonyl function leading to its 
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activation,201-205 and c) the Si-O bond is cleaved by the nucleophilic attack of the anionic 
species, generally halide, on silicon.196 Two possible mechanisms were proposed involving 
the stabilization of the aldol adducts by their intramolecular chelation with a titanium center 
277195,206 (Figure 3.5) or by their conversion into silyl ethers 281195,207,208 (Figure 3.6). 
Figure 3.5. Proposed mechanism of Mukaiyama aldol reaction via intramolecular chelation 
with titanium center.195,206 
 
Both mechanisms started with the coordination of the carbonyl's oxygen of 273 to titanium 
leading to the activation of the carbonyl for attack while also releasing a chloride ion. 
Accordingly to the first mechanism (Figure 3.5), the attack of the chloride on the silicon of 
the silyl ketene acetal 275 leads to the release of TMSCl followed by the addition of enolate 
to the activated carbonyl 274. The desilylated aldol adduct 276 could be stabilized by 
chelation with titanium 277.The subsequent aqueous work-up provides the final β-hydroxy 
ester 278.191,192 
An alternative mechanism suggests the formation of intermediate 279 followed by the 
chloride attack at the latest stages (Figure 3.6). The presumed product before hydrolysis is the 
silylated aldol adduct 281 which can be formed either by a quasi-concerted path, A, or by a 
nonconcerted process, B.208 Path A involves the intramolecular transfer of the silyl group 
from the ketonic oxygen atom to the bound alkoxide oxygen in chelated intermediate 280, 
resulting in the formation of the silylated aldol adduct 281 and the release of the catalyst. The 
nonconcerted path B leads to the formation of the aldolate intermediate 276 and TMSCl. For 
this pathway to occur the TMSCl is required to remove the titanium from intermediate 276 by 
an intermolecular process.  
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The combination of a strong Lewis acid, such as TiCl4, with the labile trimethylsilyl 
protecting group, which could be easily and reversibly coordinated to the oxygen atoms, 
opens up several pathways which may occur simultaneously. 
Figure 3.6. Proposed mechanism of Mukaiyama aldol reaction via transfer of silyl 
group.195,207,208  
 
Previous research in the group has focused on the development and optimization of the 
reaction conditions of the Mukaiyama aldol reaction between the acetophenone or its o-nitro-
substituted analogue and the silyl ketene acetal 215. It was found that the amount of reagent, 
the sequence of their addition and the temperature play a crucial role for the outcome. 
Optimized conditions employed silyl ketene acetal 215 (3 equiv.) and freshly distilled TiCl4 
(0.3 equiv.) to give compounds 216a and 216b in 76% and 74% yield respectively. The 
reaction was initiated at −30 °C and quenched at −15 °C However, under these conditions, the 
substituted β-hydroxy ester 216c could only be observed in a modest 40–60% yield after 7 h, 
as judged from the TLC and 1H NMR analyses. This might be due to the increased 
substitution of α-azido ketones 216c when compared to previous reactions. The tested ketones 
214c−i have greater steric hindrance at the α-position to the carbonyl group. This steric effect 
may lead to reduced reaction rates. In an attempt to accelerate the reaction, the use of 5 equiv. 
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of silyl ketene acetal 215 and 0.5 equiv. of TiCl4 was tested. The hypothesis being that an 
increased amount of silyl enolate and activated carbonyl present in the reaction would lead to 
greater conversion and shorter reaction times. Under these modified conditions, the reaction 
proceeded smoothly affording the desired substituted β-hydroxy ester 216c−i in good to 
excellent yields (Scheme 3.13).  
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Scheme 3.13. TiCl4-catalyzed Mukaiyama aldol reaction for aldol products 216a−i detailing the 
yields and diastereoselectivity.  
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Not surprisingly, the reaction of the more sterically hindered α-azido ketones such as 214e 
and 214f with silyl ketene acetal 215 led to reduced yields. With ketones bearing a substituent 
in α to carbonyl group this reaction proceeded in diastereoselective manner. The 
diastereomeric ratios were determined by by 1H NMR analysis of the crude reaction mixture, 
and confirmed by GC-MS analysis.  
 
The factors determining the diastereoselectivity of Mukaiyama aldol reaction have not been 
fully rationalized. Different types of transition-states were proposed.196,197,209 It was presumed 
that the stereoselectivity of Mukaiyama aldol reaction cannot be explained by classical 
“closed” six-membered transition-state models, such as Zimmermann-Traxler models,210 and 
the less organized open transition state models with no direct contact between the silyl enolate 
and the Lewis acid provides  a model in good agreement with the experimental results.211,212 
In our case, we have to deal with a pi-facial selectivity196,197 of azido ketones imposed by the 
presence of a chiral center in the α position to the carbonyl group. The stereochemical 
outcome and the problems arising from the 1,2-asymmetric induction has often be rationalized 
and predicted by the Felkin-Anh model.213-215 One of the first models used for the explanation 
of the observed selectivities is the Cram-model. Despite the fact, that the rationale behind the 
explanation is distinctly different between the Cram-model and the Felkin-Anh-model the 
terms are quite often used as synonyms for the description of the selectivity obtained by a 
diastereoselective addition to a carbonyl group. The main concept of the Felkin-Anh transition 
state model is that the substituent L exhibiting an electron-withdrawing effect (independently 
of its steric bulk) is placed orthogonal to the carbonyl group, allowing the nucleophile to 
attack anti to L following a Dunitz-Bürgi trajectory,216,217 thus most effectively avoiding steric 
repulsion.218 Following this model, the azido group should be aligned anti to the forming 
bond due to stereoelectronic reasons (Figure 3.7). A nucleophile would now preferentially 
attack from the side of the small substituent H, leading to the so-called Felkin-Anh product.  
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Figure 3.7. Felkin-Anh model for 1,2-assymetric induction applied to the synthesis of aldol 
product 214c.219 
 
The cases where the opposite selectivity is observed are called anit-Felkin-Anh selectivities or 
Cram chelate control. Our results are consistent with the Cram chelate control or the anti-
Felkin-Anh model. A high level of anti-Felkin-diastereoselectivity was observed for β-
hydroxy esters 216c and 216d. The relative configuration of the major diastereomer of 216c 
was confirmed by X-ray analysis (Figure 3.8). The major diastereomer (R/S) was obtained in 
a diastereomeric ratio 90:10. The enhanced diastereoselectivity as observed for compound 
216e can be rationalized by taking into account the increased bulk of the isopropyl 
substituent. Compounds 216h and 216i showed an even higher (almost perfect) level of 
diastereoselectivity may be due to the presence of the ortho nitro group increasing the steric 
bulk and thereby increasing the allylic strain.  
 
Figure 3.8. Anisotropic displacement ellipsoid plot of compound 216c showing the relative 
(S,R) configuration. 
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These results are in accordance with the Cram chelate rule.220-223 This model suggests the 
chelation between the carbonyl group and azido group facilitated by a Lewis acid. In this way, 
the substrate is locked into the chelated conformation (Figure 3.9). The remaining two 
substituents are placed on different sides of the carbonyl group. A nucleophile can attack the 
carbonyl group from the side of the small substituent H leading to the major product, which is 
generally called the Cram-chelate or anti-Felkin product. 
 
 
 
Figure 3.9. Cram chelate model for 1,2-assymetric induction applied to the synthesis of aldol 
product 214c.218,220 
 
Evidence of chelation might be accessible using specific NMR experiments. Complexing the 
α-azido ester with TiCl4 the postulated interaction between nitrogen and titanium should be 
observable by 14N NMR.  
 
The next step for investigation was to test the feasibility of the previously described 
Staudinger-type reductive cyclisation involving the more sterically hindered β-hydroxy esters.  
The transformation first reported by Staudinger and Meyer224 proceeds through a formation of 
iminophosphorane 282a with concomitant loss of nitrogen (Figure 3.10).225,226 This 
intermediate can undergo a number of reactions but in aqueous media it is hydrolysed to the 
amine and phosphane oxide.225,227 Vaultier and co-workers228,229 reported the synthesis of 
lactam from the azido esters which proceeds through a formation of the free amine 283 first 
followed by the nucleophilic attack on the carbonyl of the ester (Mechanism 1). However, 
iminophosphorane can react with the carbonyl electrophile to give intermediate 284, 
especially if the electrophilic attack proceeds in an intramolecular fashion.230-232 In this case 
the new amide bond is formed prior to hydrolysis (Mechanism 2).  
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Figure 3.10. Plausible mechanisms of Staudinger-type reductive cyclisation.229,232 
 
The preferred procedure used in our group this transformation involves a treatment of azido 
esters 216a−i with 1.5 equiv. of triphenylphosphine (PPh3) or tributylphosphine (P(nBu)3) in 
THF in presence of 1% water. The choice of the phosphine was determined by the efficiency 
of the work-up which followed the reaction. Whilst the nitro-phenyl substituted products 
precipitated during the reaction with PPh3 and could be purified by crystallization. Without 
the nitro group we could not purify the phenyl-substituted products by simple crystallization. 
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Purification had to be done by flash chromatography on silica gel. Triphenylphosphine oxide 
notoriously creates major problems in this type of separation and the product contaminated 
with the phosphine oxide was obtained. Changing PPh3 to P(nBu)3, the phenyl substituted 
products were obtained in good yields after chromatography due to the water solubility of the 
tributylphosphine oxide (Scheme 14).  
 
Scheme 3.14. Staudinger-type reductive cyclisation for pyrrolidinones 217a−i. 
  
85 
 
Table 3.1. Reaction conditions for Staudinger-type reductive cyclisation.  
 
Entry Azido ester Phosphine Time [days] Product Yield [%] 
1 216a P(Ph)33 3 217a 81 
2 216b P(nBu)3 3 217b 76 
3 216c P(nBu)3 3 217c 56 
4 216d P(nBu)3 3 217d 57 
5 216e P(nBu)3 6 217e 54 
6 216f P(nBu)3 4 217f 62 
7 216g P(Ph)3 7 217g 79 
8 216h P(Ph)3 6 217h 54 
9 216i P(Ph)3 7 217i 49 
 
We were able to obtain the X-ray structures of the new compounds 217c−h which confirmed 
the structure attribution. The major diastereomers have R/S relative configuration (see 
Appendix). 
 
While the reaction time was much longer than in the cases studied before, all products were 
obtained in good to satisfactory yields. The following observations can be made. The steric 
hindrance on the azido esters diminished the yields (Table 3.1, Entry 3-6 and 8-9). Monitoring 
by TLC showed a very slow progress of the reaction. The comparison between the yields of 
the products 217c and 217h or 217d and 217i (Entry 3, 8 and 4, 9) with similar steric bulk, led 
to the conclusion that extending reaction times would not be an effective solution to increase 
the yield. However, the given strategy allowed synthesizing a variety of highly substituted 
pyrrolidinones.  
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3.2.4. Synthesis of intermediate 290 
 
These results demonstrated that even the azido ketones with bulky substituents in α to 
carbonyl can be subjected to the tandem Mukaiyama cross-aldol – Staudinger cyclization 
sequences giving access to highly substituted pyrrolidinones. The next logical step was to 
obtain a cyclisation precursor containing all atoms necessary to the construction of 
pyrrolinone-based rhazinilam analogues (Scheme 3.15). The route previously described for 
the synthesis of ortho-nitro substituted phenyl ketones should be used to form the 
intermediate 289, followed by investigations of bromination in the α-position to the ketone, 
substitution of the bromine with azide and tandem Mukaiyama aldol reaction – Staudinger 
reductive cyclisation. This approach seemed attractive as the majority of the route was well 
developed, and the bromination and substitution with azide were expected to be standard 
transformation, allowing focusing the attention on the critical azido ester formation-
cyclisation step.  
 
Scheme 3.15. Retrosynthetic pathway for the synthesis of pyrrolinone-based analogue 4a. 
 
The route began with the preparation of 2-ethyl ε-caprolactone (286) by alkylation of ε-
caprolactone (285) with ethyl iodide using procedure defined by Nicolaou and co-workers233 
(Scheme 3.16). Subjecting the lactone 286 to DIBAL reduction followed by silylation 
afforded the aldehyde 288 in 78% overall yield. Treatment of aldehyde 288 with the Grignard 
reagent generated in situ from 2-iodonitrobenzene (75) by I-Mg exchange182 and subsequent 
oxidation with Jones’ reagent give the corresponding ketone 289 in 75% overall yield. 
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Bromination of 289 using aforementioned conditions produced the α-bromo ketone 290 in 
53% yield. The challenge, then, was to form the α-azido ketone 291. The previous approach 
using sodium azide in acetone was tried, but no reaction was observed under these conditions 
after 24 h and only the starting material was recovered. The reaction was repeated in DMF. 
After 2 h at room temperature, no conversion was detected by 1H NMR and the reaction 
mixture was allowed to stir at room temperature overnight. However, only the product of the 
unwanted bromo elimination 292a and 292b were recovered in 1:2 ratio and 86% overall 
yield. 
This result demonstrated that in DMF elimination is favoured. Other reaction conditions have 
to be tried (e.g. changing the solvent and the temperature) hopefully giving preference to the 
substitution. Due to time reasons the transformation of α-bromo ketone 290 into the 
corresponding α-azido ketone 291 was not investigated further. 
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Scheme 3.16. Attempted synthesis of azido ketone 291.  
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3.2.5. Dehydration of pyrrolidinone 217i 
 
An alternative approach to pyrrolinone-based analogue 4a was envisaged via the reaction of 
activated pyrrolinone 296 with the bromoester 294 by an alkylation followed by subsequent 
macrolactamisation (Scheme 3.17). Intermediate 296 should be obtained from 217i by 
hydroxy group elimination. 
  
Scheme 3.17. Retrosynthetic pathway for the synthesis of analogue 4a via intermediate 218i. 
 
The previous research demonstrated that pyrrolidinone 217a and 217b103 can be converted 
into 3-pyrrolin-2-one 218a and 218b at room temperature by hydroxy group elimination using 
2.1 equiv. of Boc2O and 0.4 equiv. of DMAP (Scheme 2.2). The reaction times were 2 h for 
nitrophenyl substituted pyrrolidinone and 24 h for its phenyl analogue. These conditions were 
applied to the pyrrolidinone 217i (Scheme 3.18). However, the major product which was 
recovered in 86% yield after 3 days was a di-boc substituted pyrrolidinones 295. Only a minor 
amount (5 % from 1H NMR analysis of the crude mixture) of hydroxyl-elimination product 
218i was recovered.  
 
Scheme 3.18. Synthesis of 3-pyrrolin-2-one 218i. 
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In an attempt to accelerate the elimination the temperature was increased. Heating the 
pyrrolidinone 295 under reflux in the presence of 0.5 equiv. of DMAP afforded 70% 
conversion to 3-pyrroline-2-one 218i after 48 hours. The separation by column 
chromatography of the product 218i from the unreacted compound 295 proved to be difficult. 
Product 295 was isolated and fully characterized whereas 218i was partially characterized 
using the best fractions from the column. 
 
The formation of compounds 295 and 218i could be explained by the mechanism of Boc-
protection and tertiary alcohol elimination (Scheme 3.19). DMAP plays a dual role in this 
process: generates the more reactive specie reacting with Boc2O and releases the tert-
butanoate allowing the deprotonation of amide and hydroxyl groups. This previous study100 
suggests that the first step is the N-bocylation followed by the O-bocylation. Ethyl substituent 
in α to hydroxy could make the O-bocylation more difficult due to the steric hindrance. 
However, this process takes place and the di-boc intermediate 295 is isolated in excellent 
yield. The elimination of carbonate should be a crucial step for formation of 3-pyrrolin2-one 
218i. The structure of di-boc protected pyrrolidinone 295 was confirmed by X-Ray analysis 
(Figure 3.11). 
Carbonate is not a good leaving group. Nevertheless, this process must be irreversible and 
thermodynamically favoured due to CO2 removal from the reaction mixture. Moreover, the 
tert-butyl carbonate group is bulky and induces an important steric hindrance on a quaternary 
carbon. The loss of carbonate results in the formation of stable carbocation. From these points 
of view the mechanism E1 should be favoured. However, without heating, the desired product 
was observed in insignificant yield. This is possibly due to the increased substitution of 
compound 217i when compared to previous alcohol intermediates 217a prepared in the group. 
The increased steric hindrance surrounding the hydroxyl group may lead to the observed 
lower reaction rates. 
90 
 
 
Scheme 3.19. Proposed mechanism of Boc-protection and elimination. 
 
Figure 3.11. Anisotropic displacement ellipsoid plot of compound 295.  
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3.3. Summery. 
 
In summary, this project achieved the aims proposed at the outset. Two key transformations 
were investigated using the sterically hindered starting materials. First, a TiCl4 promoted 
Mukaiyama crossed aldol addition of silyl ketene acetal to α-substituted azidoketones was 
employed to produce a library of aldol products with considerable diastereoselectivity. The 
modified reaction conditions afforded these products in improved yields. The bulky 
substituent in α to carbonyl seems to have a relatively small impact on the reaction outcome. 
Second, the Staudinger reductive cyclization was a critical step in the formation of the highly 
substituted lactam rings present in the target compounds. Bulkier substituents bearing the 
azido group have a slightly negative impact on this transformation.  
 
Unfortunately, due to time constraints, it was not possible to continue the investigation of the 
project beyond this point. The procedure for preparation of sterically hindered ketones 
possessing a fully substituted carbon in the α-position and tandem Mukaiyama aldol – 
Staudinger reaction sequences could be applied to the synthesis of advanced intermediates. 
The investigations of the elimination of the tertiary alcohol proofed the optimization of the 
reaction conditions are crucial. Optimization of the steps needed for the formation of the 
desired 3-pyrrolin-2-ones has not been achieved yet.  
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Chapter four 
 
 
 
 
 
CONCLUSIONS 
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Conclusions 
 
In summary, this research programme consisted of two distinct projects, which will be 
considered in turn below. 
 
The aim of the first project was a synthesis of advanced intermediates of rhazinilam 
analogues. The retrosynthetic approach focused on the synthesis of the heterobiarylic core, 
attaching the chains and functional groups needed for the formation of rings B and D in a later 
stage. Building on the known sensitivity of pyrrole rings lacking electronic or steric 
stabilization, the synthetic intermediates were designed to contain at least one stabilizing 
element: either the well-known methoxycarbonyl ester group or the novel pyrrolinone 
element. 
 
The N-alkylation and N-acylation of the 3-pyrrolin-2-ones derivatives, as discussed above, 
received a particular attention. Thus, the intramolecular Michael addition of activated 
pyrrolinone to N-tethered acrylate was envisaged in order to obtain the indolizine–type 
cyclisation product. Starting from the previously described Staudinger cyclisation product, N-
acylation and N-alkylation were applied towards the synthesis of a model system. Under the 
conditions reported in the literature and under the conditions tested in our laboratory, the 
introduction of a side chain on 3-pyrroline-2-one by nucleophilic N-alkylation could not be 
achieved. In contrast, the use of more nucleophilic aryl-pyrrole synthesized for this proposal 
from a simple pyrrole nucleus by a metal-catalysed C-H bond arylation afforded the desired 
N-alkylated biaryl intermediate.  
 
Given the poor nucleophilic nature of 3-pyrrolin-2-one substrate, the N-acylation was 
investigated instead of the N-alkylation on the model series involving sterically less 
demanding substrates. The optimized conditions were then successfully applied to the more 
complex aryl-3-pyrroline-2-one.  
 
Whilst this project achieved its primary aims and two advanced intermediates were obtained 
for the further synthesis of the pyrrole or pyrrolinone based rhazinilam analogues there are a 
number of avenues that could be investigated. The screening of the reaction conditions needed 
for the formation of the desired Michael products has not been achieved yet. 
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The aim of the second project was to expand the scope of the tandem Mukaiyama cross aldol 
− Staudinger reaction to the preparation of highly substituted phenyl-pyrrolinones having a 
blocking group at the C-5. The attractivity of this approach was the synthesis of chemically 
stable intermediates which not undergo the further oxidation process and undesirable side 
reactions.  
 
There are several attractive facets of the developed methodology. Two key transformations 
were investigated using the sterically hindered starting materials. Whilst, the bulky substituent 
in α to carbonyl seems to have a relatively small impact on the Mukaiyama reaction outcome, 
the Staudinger reductive cyclization was a critical step. Bulkier substituents bearing the azido 
group had a slightly negative impact on this transformation. However, an important library of 
highly substituted pyrrolidinones with considerable diastereoselectivity was prepared.  
 
In addition, an efficient methodology for the synthesis of ortho-nitro phenyl substituted 
ketones with long alkyl chain was developed. Moreover, the modified reaction conditions for 
bromination and subsequent substitution offers improved yields, fewer synthetic 
manipulations, and compared to previous work are advantageous in terms of time economy. 
 
Finally, the procedure for preparation of sterically hindered ketones possessing a fully 
substituted carbon in the α-position and tandem Mukaiyama aldol – Staudinger reaction 
sequences could be applied to the synthesis of advanced intermediates. The investigations of 
the elimination of the tertiary alcohol proofed the optimization of the reaction conditions are 
crucial. Optimization of the steps needed for the formation of the desired 3-pyrrolin-2-ones 
has not been achieved yet.  
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Chapter five 
 
 
 
 
 
EXPERIMENTAL SECTION 
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5.1. General Remarks 
 
Reactions employing air- and/or moisture-sensitive reagents and intermediates were carried 
out under an atmosphere of dry, oxygen-free nitrogen or argon. 
 
5.1.1. Chromatography 
 
Thin layer chromatography 
 
Thin layer chromatography (TLC) was conducted on glass-backed 0.2 mm thick silica-gel 
plates (Merck) and the chromatograms were visualised under a 254 nm UV lamp and/or by 
treatment with a potassium permanganate dip (2.5 g KMnO4, 2.5 g K2CO3, 250 mL water) or 
a Ehrlich reagent dip (2 g dimethylaminoacetaldehyde, 20 mL perchloric acid diluted to 50 
mL with acetic acid) followed by heating. All mixed solvent systems were reported as v/v 
solutions. The retardation factor (Rf) quoted is rounded to the nearest 0.1.  
 
Column chromatography 
 
Flash column chromatography was performed on silica gel silica gel (Silica 32-63, 60 Å; 
Chemie Brunschwig AG, Basel, Switzerland) as the stationary phase in conjunction with the 
analytical reagent (AR) grade solvents indicated. 
 
Gas chromatography 
 
Gas chromatography (GC) was performed on Agilent 6850 Series chromatograph using high 
resolution gas chromatography HP-5 column (30 m × 0.32 mm × 0.25 µm). Polymer nature: 
polysiloxane (crosslinked 5% Ph, Me siloxane), gas vecteur : He, 1.1 mL/min. Injection 
temperature : 245 °C, detector temperature (FID) : 300 °C. The two following temperature 
programs were employed: 1) IZ: 100 °C (3 min)/ 15 °C/min/ 280 °C/ 280 °C (4 min); 2) AG: 
220 °C (2 min)/ 5 °C/min/ 300 °C/ 300 °C (10 min). Spectra were treated by ChemStation 
program.  
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5.1.2. Infrared Spectroscopy (IR) 
 
Infrared spectra were obtained with a Perkin–Elmer Spectrum One version B FT-IR unit with 
the resolution of 2 cm-1. Software used: Spectrum version 5.0.1. The solid substances and 
thick oil like substances were analysed by KBr (Fluka puriss., p.a.) pressed films. Liquid 
samples were analysed using KBr plates. The absorption bands between 4000 and 400 cm-1 
were measured. Absorption maxima (υmax) are reported in wave numbers (cm-1). The intensity 
of spectrum was divided into five equal parts for the abbreviations vs (very strong – the 
maximum intensity), s (strong), m (medium), w (weak), vw (very weak) and br (broad). 
 
5.1.3. Nuclear Magnetic Spectroscopy (NMR) 
 
All reported NMR spectra were recorded on Bruker Avance-400 spectrometer at 400 (1H 
NMR), 376 (19F NMR) or 100 (13C NMR) at 298 K. The NMR solvents were purchased from 
Cambridge Isotope Laboratories. Chemical shifts are reported as δ values relative to TMS, 
defined as δ = 0.00 ppm (1H NMR) or δ = 0.0 ppm (13C NMR) and are referenced to the 
risidual protonated NMR solvent, defined as δ = 7.26 ppm (1H NMR) or δ = 77.00 ppm (13C 
NMR) for CHCl3, δ = 3.31 ppm (1H NMR) or δ = 49.00 ppm (13C NMR) for CH3OH, δ = 2.50 
ppm (1H NMR) or δ = 39.52 ppm (13C NMR) for DMSO-d6, δ = 2.05 ppm (1H NMR) or δ = 
29.84 and 206.26 ppm (13C NMR) for acetone-d6. The 13C spactra were measured by 
decoupling from 1H. 1H NMR data are recorded as follows: chemical shift (δ) [multiplicity, 
number of protons, coupling constant(s) J (Hz) and assignment (where possible)] where 
multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = quartet; quint = quintet; br = 
broad; m = multiplet or combinations of the above. The sign “≈” denotes for the average value 
of J varying from 0.2 to 0.4 Hz.  
 
5.1.4. Mass Sectrometry 
 
GC-MS analyses were performed by EI (electron impact) (70 eV) on a ThermoFinnigan 
PolarisQ instrument equipped with a Trace GC gas chromatograph and PolarisQ mass 
spectrometer. Software used : Xcalibur version 1.2. The following temperature program was 
employed: 60 °C (1min)/ 10 °C/min/ 250 °C/ 250 °C (60 min). The mass spectra for ESI 
(electro-spray ionisation) or APCI (atmospheric pressure chemical ionisation) were recorded 
on a ThermoFinnigan LCQ instrument (San Jose, California, USA). Software: Tune Plus 
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version 1.2. The values given are average mass of ion with precision of ±0.1. The nature of 
ion pattern is specified in parentheses with intensity. Only the mass corresponding to the 
highest abundant isotope is indicated. 
 
The high resolution mass spectrometry (HR-MS) was made at University of Fribourg 
(Switzerland) in the group of Professor Gossauer and recorded on a Brücker BioAPEX II 
Daltonics instrument by ESI unless otherwise specified.  
 
5.1.5. Glass Apparatus 
 
For reactions under inert atmosphere (Ar or N2), the glass apparatus were oven-dried at 150 
°C for at least 2 h. The apparatus were assembled and cooled to ambient temperature under Ar 
or N2 atmosphere. For reactions at low temperature, salt – ice bath (0 °C to –10 °C) and 
acetone/liquid nitrogen bath (down to –80 °C) were used. For extended periods of low 
temperature reactions (2 days), cryostat was used. For heating reactions, polyethylene glycol 
(PEG) bath was used. The reaction temperatures were measured in situ. 
 
5.1.6. Melting points 
 
Melting points were determined in open capillaries with a Gallenkamp melting point 
apparatus without correction. 
5.1.7. Elemental analysis 
 
The elemental analyses (CHN) were made at ETH Zurich (Switzerland) in the group of 
Professor Pretsch.  
5.1.8. Solvents 
 
Standard solvents 
 
For the purpose of chromatography and extractions, technical grade solvents were distilled 
over drying agent. 
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Solvent Abbreviation used Drying agent 
Chloroform CHCl3 CaCl2 
Cyclohexane Cyclohexane Molecular sieve 0.4nm 
Dichloromethane CH2Cl2 CaCl2 
Diethyl ether Et2O CaCl2 
Ethyl acetate AcOEt K2CO3 
Hexane Hexane CaCl2 
Methanol MeOH CaO 
Petrolium ether Petrolium ether CaCl2 
 
Solvents for reactions with distillation 
Solvent Abbreviation used Drying agent 
Carbon tetrachloride CCl4 P2O3 
Dichloromethane CH2Cl2 P2O5 
Diethyl ether Et2O LiAlH4 
Pentane Pentane P2O5 
Tetrahydrofuran THF Sodium (benzophenone) 
 
Solvents for reactions without distillation 
 
Solvent Abbreviation used Quality 
Acetic acid glacial AcOH Carlo Erba, for analysis 
Acetone Acetone Aldrich, CHROMASOLV ® 
Plus, for HPLC, ≥99.9% 
Acetonitrile ACN Aldrich, sealed-bottle over 
molecular sieve (H2O ≤0.01%), 
≥99.5% (GC). 
n-Butanol nBuOH Aldrich, anhydrous, 99.8%  
Chloroform CHCl3 Aldrich, anhydrous, contains 
amylenes as stabilizer, ≥99% 
Dichloromethane CH2Cl2 Acros, 99.8%, extra dry over 
molecular sieve 
1,2-Dimethoxyethane DME Aldrich, puriss., dried over 
molecular sieve (H2O ≤0.005%), 
≥99.5% (GC)  
Dimethyl formamide DMF Aldrich, puriss., absolute, over 
molecular sieve (H2O ≤0.005%), 
≥99.5% (GC)  
Dimethyl sulfoxyde DMSO Aldrich, puriss., absolute, over 
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molecular sieve (H2O ≤0.01%), 
≥99.5% (GC) 
Isopropanol iPrOH Aldrichanhydrous, 99.5% 
Methanol MeOH Fluka, puriss. abs., ≥99.5% over 
molecular sieve (H2O ≤0.01%) 
Pyridine Pyridine Fluka, puriss., ≥99.5% (with 
crown cap) 
Tetrahydrofuran THF Aldrich, sealed-bottle over 
molecular sieve (H2O ≤0.005%), 
contains ~0.025% 2,6-di-tert-
butyl-4- methylphenol as 
stabilizer, ≥99.5% (GC) 
Toluene Toluene Aldrich, absolute, over molecular 
sieve (H2O ≤0.005%), ≥99.7% 
(GC) 
5.1.9. Reagents and products 
Reagents 
 
Reagent Abbreviation used Quality 
Aluminium chloride AlCl3 Fluka, puriss. p.a.99% 
Ammonium carbonate (NH4)2CO3 Acros 
Ammonium chloride NH4Cl Fluka, purum p.a. 
Argon Ar Carbagas, tech. 
Bis(acetonitrile)
dichloropalladium(II) 
PdCl2(CH3CN)2 Aldrich, 99%  
Boron trifluoride diethyl etherate BF3·OEt2 Fluka, purum 
Bromine Br2 Acros p.a. 
2-Bromoacetophenone – Fluka, puriss >99.0% 
2-Bromoisobutyrophenone – Aldrich, 98%  
2-Bromo-2'-nitroacetophenone – Aldrich, 99% 
2-Bromo-4′-nitroacetophenone – Aldrich, 95%  
1-Bromo-2-nitrobenzene – Aldrich, 98%  
2-Bromopropiophenone – Aldrich, 97%  
3-Bromo-1(triisopropysilyl)pyrrole – Aldrich, 97%  
tert-Butyldimethylsilyl 
trifluoromethanesulfonate 
TBSOTf Acros, 98% 
tert-Butyldiphenylsilyl chloride TBDPS-Cl Aldrich, 98%  
n-Butyllithium solution nBuLi Aldrich, 2.0 M in cyclohexane  
Butyraldehyde – Aldrich, ≥99.0%, dry  
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γ-Butyrolactone – Aldrich, ≥99%  
Butyrophenone – Aldrich, ≥99%  
ε-Caprolactone – Aldrich, 97%  
Celite 535 – Fluka, 10-40mm 
Chlorotrimethylsilane TMSCl Fluka, puriss., ≥99.0% (GC) 
Chromium (VI) oxide  CrO3 Fluka, purum p.a., ≥99.0% (RT)  
1,5-
Cyclooctadiene(methoxy)iridium(I) 
dimer 
[Ir(OMe)(COD)]2  Aldrich 
N,N′-Dicyclohexylcarbodiimide DCC Fluka, puriss., ≥99.0% (GC)  
2-Dicyclohexylphosphino-2′,6′-
dimethoxybiphenyl 
SPhos Aldrich, 97%  
Diisobutylaluminum hydride 
solution 
DIBALH Acros, 1.0 M in hexane 
Dimethyl sulfoxyde DMSO Aldrich, anhydrous, ≥99.9 
Dimethylaluminum chloride Me2AlCl Aldrich, 1.0 M in hexanes  
4-(Dimethylamino)pyridine DMAP Fluka, purum >98% 
N,O-Dimethylhydroxylamine 
hydrochloride 
HN(OMe)·HCl Aldrich, 98%  
Di-tert-butyl dicarbonate Boc2O Acros, 99% 
4,4'-Di-tert-butyl-2,2'-dipyridine dtbpy Aldrich, 98%  
Ethylmagnesium bromide EtMgBr Aldrich, 1.0 M in THF  
Hexamethylphosphoramide HMPA Aldrich, absolute, over molecular 
sieve (H2O ≤0.01%), ≥98.0% 
Hydrochloric acid HCl Prochimie, 32% 
Imidazole ImH Fluka, puriss.., ≥99% 
Iodoethane EtI Aldrich, 99%  
1-Iodo-2-nitrobenzene – Aldrich, 97% 
Isovalerophenone – Aldrich, ≥98.0% (GC)  
Levulinic acid – Aldrich, 98%  
Lithium bis(trimethylsilyl)amide 
solution 
LHMDS Alldrich, 1.0 M in THF 
Lithium diisopropylamide LDA Aldrich, 2.0 M in THF 
2,6-Lutidine – Fluka, puriss p.a. >99.7 
Magnesium sulfate  MgSO4 Aldrich, puriss. p.a., drying 
agent, anhydrous, ≥98.0% (KT), 
powder (very fine)  
Methyl 2-pyrrolecarboxylate – Aldrich, 97% 
Methyl acetate – Fluka, puriss p.a. >99% 
Methyl diethylphosphonoacetate (EtO)2POCH2CO2Me Aldrich, 97%  
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Molecular sieve 4A – Fluka, powder 
2'-Nitroacetophenone – Aldrich, 95% 
Nitogen N2 Carbagas, tech. 
Nitric acid  HNO3 Fluka, fuming >99.5% 
Palladium(II) acetate Pd(OAc)2 Fluka, 98% 
Pentafluorophenol PfpOH Aldrich, ≥99%  
Phenylmagnesium chloride PhMgCl Aldrich, 2.0 M in THF  
Pinacolborane HBpin Aldrich, 97%  
Poly(4-vinylpyridine) – Fluka, purum 
Potassium K Fluka, purum 
Potassium carbonate K2CO3 Fluka, purum p.a., anhydrous, 
≥99.0% 
Potassium phosphate K3PO4 Aldrich, 97%  
Propionaldehyde – Aldrich, ≥97%  
p-Toluenesulfonyl chloride Ts-Cl Fluka, puriss. 
Sodium azide  NaN3 Fluka, purum  ≥ 99.0% 
Sodium carbonate NaCO3 Fluka 
Sodium chloride NaCl Prochimie 
Sodium dihydrogen phosphate  NaH2PO4 Fluka, purum, ≥99%   
Sodium hydride NaH Aldrich, dry, 95%  
Sodium hydrogen carbonate NaHCO3 Fluka, purum p.a., ≥99.0% 
Sodium hydroxyde  NaOH Fluka, puriss., p.a. 
Sodium iodide NaI Fluka, purum p.a., ≥99.0% 
Sodium sulfate Na2SO4 Fluka, anhydrous, powder 
Sodium thiosulfate Na2S2O3 Aldrich, purum p.a., anhydrous, 
≥98.0% (RT)  
Sulfuric acid  H2SO4 Prochimie, 96% 
Tetrabutylammonium floride  TBAF Fluka, 1.0 M in THF 
Titanium tetrachloride TiCl4 Fluka, purum, ≥98.0% and then 
distilled over poly vinyl pyridine 
Tributyl phosphine P(nBu)3 Fluka, techn. >99% 
Triethyl phosphonoacetate (EtO)2POCH2CO2Et Aldrich, 98%  
Triethylamine Et3N Fluka, puriss. p.a. ≥99.5% 
Trifluoroacetic acid TFA Fluka, puriss p.a. >99% 
Triphenylphosphine PPh3 Fluka, puriss. ≥98.5 % 
Zinc Zn Fluka, p.a. > 99.0% 
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Destruction of sodium azide  
 
All the aqueous phases coming from the extraction of azido products and containing NaN3 
were stored separately for treating the solution with freshly prepared nitrous acid and then 
were discarded.  
2 NaNO2 + H2SO4 → 2 HNO2 + Na2SO4 
2 NaN3 + 2 HNO2 → 3N2 + 2 NO + 2 NaOH 
Treatment: The treatment is performed in a hood due to the formation of nitric oxide. The 
aqueous solution containing NaN3 was put into a three-necked flask equiped a stirrer, a 
dropping funnel, and an outlet for gas. The sodium nitrite aqueous solution (7.5 g of NaNO2 
in 38 mL of water for 5 g of NaN3) was added dropwise under vigorous stirring, followed by a 
slow addition of 20% H2SO4 until the reaction mixture is acidic to pH paper. When the 
evolution of nitrogen oxides is over, the acidic solution was tested with starch-iodide paper. 
The color change from white to blue means that excess nitrite is present and decomposition is 
complete. The solution was neutralized with dilute NaOH solution to pH 6-9 prior to 
discharge and was washed down the drain. 
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5.2. Experimental procedures and characterization data 
associated with compounds described in Chapter Two 
5.2.1. 2-Bromo-1-(2-nitrophenyl)ethanone (272a) 
 
To a stirred mixture of 2′-nitroacetophenone (213a) (20 g, 121 mmol) and AlCl3 (500 mg, 
3.75 mmol) in dry ether (600 mL) at 0 °C and under argon was added dropwise bromine (6.2 
mL, 121 mmol) over 1 h. The reaction mixture was allowed to warm to room temperature and 
stirred for 3 h (reaction progress monitored by TLC). The organic layer was washed with 
water (3 x 200 mL), dried over MgSO4, filtered and evaporated. The residue was purified by 
column chromatography on silica gel (CH2Cl2/petroleum ether, 70:30) to afford 31.7 g of 272 
as a yellow solid. The product was crystallised from MeOH to give 26.1 g (73%) of pure 272 
as colourless micro-needles. 
 
Analytical Data for 272: 
 
TLC: Rf (CH2Cl2/petroleum ether, 70:30) = 0.37 
 
1H-NMR (400 MHz, CDCl3): δ 8.21 (dd, 3JH3’,H4’ = 8.1 Hz, 4JH3’,H5’ = 1.2 Hz, 1 H, H3’), 7.79 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.3 Hz,  1 H, H5’), 7.68 (ddd, 3JH4’,H3’ = 8.1 Hz, 
3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.6 Hz, 1 H, H4’), 7.50 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.6 Hz, 1 
H, H11), 4.30 (s, 2 H, H2) 
 
13C-NMR (100 MHz, CDCl3): δ 194.3 (C1), 145.4 (C2’), 134.9 (C1’), 134.8 (C5’), 131.3 (C4’), 
129.1 (C6’), 124.5 (C3’), 33.9 (C2)  
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5.2.2. 2-Azido-1-(2-nitrophenyl)ethanone (214a) 
To a mechanically stirred solution of sodium azide (3.68 g, 56.55 mmol) in water (55 mL) at 
6 °C was added a solution of 2-bromo-2′-nitroacetophenone (272) (9.20 g, 37.70 mmol) in 
MeOH (190 mL). The reaction mixture was stirred for 48 h at 6 °C and then extracted with 
Et2O (4 x 200 mL). The organic layer was washed with water (1 x 200 mL), dried over 
MgSO4, filtered and evaporated. The residue was purified by column chromatography on 
silica gel using CH2Cl2 as eluent to afford 6.17 g of 214a as a brown solid. The product was 
crystallised from Et2O/hexane to give 5.83 g (75%) of pure 214a as yellow-brown micro-
needles. 
Analytical Data for 214a: 
TLC: Rf (CH2Cl2, 100%) = 0.47 
1H-NMR (400 MHz, CDCl3): δ 8.23 (dd, 3JH3’,H4’ = 8.0 Hz, 4JH3’,H5’ = 1.5 Hz, 1 H, H3’), 7.80 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.4 Hz, 4JH5’,H3’ = 1.5 Hz,  1 H, H5’), 7.70 (ddd, 3JH4’,H3’ = 8.0 Hz, 
3JH4’,H5’ = 7.4 Hz, 4JH4’,H6’ = 1.6 Hz, 1 H, H4’), 7.43 (dd, 3JH6’,H5’ = 7.4 Hz, 4JH6’,H4’ = 1.6 Hz, 1 
H, H11), 4.32 (s, 2 H, H2) 
13C-NMR (100 MHz, CDCl3): δ 197.2 (C1), 145.9 (C2’), 135.2 (C1’), 135.0 (C5’), 131.5 (C4’), 
127.9 (C6’), 124.6 (C3’), 57.8 (C2) 
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5.2.3. ((1-Methoxyvinyl)oxy)trimethylsilane (215) 
To a stirred solution of LHMDS (1.0 M in THF, 100 mL, 100 mmol) in dry THF (30 mL) was 
added dropwise a solution of methyl acetate (S1) (6.17 g, 83.33 mmol) in dry THF (37 mL) at 
−78 °C and under argon. After 30 min at −78 °C, TMSCl (10.86 g, 100 mmol) was added 
dropwise over 20 min. The mixture was allowed to stir at −78 °C for 1.5 h. The solvent was 
removed in vacuo and the excess salts were precipitated by the addition of dry pentane (30 
mL). After filtration through a plug of Celite and evaporation of solvent, the residue was 
purified by distillation (P = 45 mmHg, T = 48-50 °C) to afford 11.68 g (96%) of S4 as a clear, 
colourless oil.  
Analytical Data for 215: 
TLC: Rf (CH2Cl2, 100%) = 0.35 
1H-NMR (400 MHz, CDCl3): δ 3.55 (s, 3 H, H1’), 3.22 and 3.11 (2 x d, AB system, 2JH2a,H2b 
= 2.6 Hz,  2 H, H2a and H2b), 0.25 (s, 9 H, H2’) 
13C-NMR (100 MHz, CDCl3): δ 162.1 (C1), 59.9 (C2), 55.1 (C1’), 2.5 (C2’) 
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5.2.4. Methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)butanoate (216a) 
2-Azido-1-(2-nitrophenyl)-ethanone (214a) (3.0 g, 14.55 mmol) was added portionwise to a 
stirred solution of ((1-methoxyvinyl)oxy)trimethylsilane 215 (6.39 g, 43.66 mmol, 3 equiv.) 
in dry CH2Cl2 (60 mL) at −30 °C and under argon. A solution of freshly distilled TiCl4 (0.84 
mL, 7.28 mmol) in dry CH2Cl2 (10 mL) was added dropwise over 15 min. The resulting 
mixture was stirred stirred at −30 °C for 15 min and then allowed to reach −15 °C over a 
period of 30 min. The dark red solution was quenched with NaOH (2.0 M, 15 mL) and 
extracted with CHCl3 (4 x 20 mL). The combined organic phases were washed with brine (30 
mL), dried over MgSO4, filtered and concentrated. The residue was purified by flash 
chromatography on silica gel using CH2Cl2 as eluent to afford 3.39 g of 216a as a clear, 
slightly yellowish oil which solidified on standing. The product was crystallised from 
Et2O/hexane to give 3.10 g (76%) of pure 216a as white solid. 
Analytical Data for 216a: 
TLC: Rf (CH2Cl2, 100%) = 0.30 
MP: 77 °C 
1H-NMR (400 MHz, CDCl3): δ 7.45-7.52 (m, 4 H, H3’, H4’, H5’ and H6’), 4.83 (s, 1 H, OH), 
3.66 (s, 3 H, H1’’), 3.80 and 3.59 (2 x d AB system, 2JH4a,H4b = 12.7 Hz, 2 H, H4a and H4b), 
3.17 and 3.06 (2 x d AB system, 2JH2a,H2b = 16.7 Hz, 2 H, H2a and H2b) 
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13C-NMR (100 MHz, CDCl3): δ 172.8 (C1), 150.4 (C2’), 134.6 (C1’), 131.1 (C5’), 129.4 (C4’), 
128.1 (C3’), 124.5 (C6’), 76.2 (C3), 59.2 (C4), 52.5 (C1’’), 41.0 (C2) 
5.2.5 4-Hydroxy-4-(2-nitrophenyl)pyrrolidin-2-one (217a) 
Methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)butanoate (216a) (8.42 g, 30.05 mmol) and 
triphenylphosphine (12.00 g, 45.07 mmol) were dissolved in THF (126 mL) at room 
temperature. After 30 min, deionized water (1%, 1.26 mL) was added. The resulting mixture 
was stirred at room temperature for 3 days and then the solvents were evaporated in vacuo. 
The crude product was crystallised from MeOH and washed with EtOAc to give 5.43 g (81%) 
of pure 217a as white solid.  
Analytical Data for 217a: 
MP: 223 °C 
1H-NMR (400 MHz, DMSO-d6): δ 7.77 (br s, 1 H, H1), 7.66 (dd, 3JH3’,H4’ = 7.8 Hz, 4JH3’,H5’ = 
1.4 Hz, 1 H, H3’), 7.65 (dd, 3JH6’,H5’ = 7.9 Hz, 4JH6’,H4’ = 1.4 Hz, 1 H, H6’), 7.59 (m (partially 
solved), 3JH5’,H6’ = 7.9 Hz, 3JH5’,H4’ = 7.3 Hz, 4JH5’,H3’ = 1.4 Hz, 1 H, H5’), 7.50 (m (partially 
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solved), 3JH4’,H3’ =7.8 Hz, 3JH4’,H5’ = 7.3 Hz, 4JH4’,H6’ = 1.4 Hz,  1 H, H4’), 6.06 (s, 1 H, OH), 
3.65 and 3.46 (2 x d AB system, 2JH5a,H5b = 10.6 Hz, 2 H, H5a and H5b), 2.96 and 2.42 (2 x d 
AB system, 2JH3a,H3b = 16.6 Hz, 2 H, H3a and H3b) 
 
13C-NMR (100 MHz, DMSO-d6): δ 173.8 (C2), 150.1 (C2’), 137.0 (C1’), 131.2 (C5’), 128.7 
(C4’), 127.4 (C6’), 123.9 (C3’), 76.3 (C4), 55.4 (C5), 45.7 (C3) 
 
MS-ESI: 245.2 (100, [M+Na]+) 
 
IR (KBr): ν = 3403 (s), 3227 (m), 1673 (vs), 1525 (s), 1481 (w), 1441 (w), 1405 (w), 1373 
(s), 1321 (w), 1243 (m), 1204 (w), 1104 (m), 1050 (w), 985 (w), 957 (vw), 931 (vw), 912 
(vw), 855 (w), 796 (vw), 781 (w), 751 (w), 725 (w), 681 (vw), 645 (m), 632 (s), 567 (w), 547 
(w), 508 (vw) cm–1 
 
5.2.6. tert-Butyl 4-(2-nitrophenyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate (218a) 
 
 
To a stirred suspension of pyrrolidinone 217a (1.0 g, 4.50 mmol) in dry THF (100 mL) at 
room temperature and under argon was added DMAP (222 mg, 1.80 mmol) followed by 
Boc2O (2.06 g, 9.45 mmol). The resulting solution was stirred at room temperature for 5 days, 
then was concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel (CH2Cl2/MeOH, 99:1) to afford 1.39 g (100%) of Boc-protected pyrrolinone 218a as a 
viscous, brownish red oil. The product was crystallised from Et2O/petroleum ether to give 
0.97 g (71%) of pure 218a as white solid. 
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Analytical Data for 218a: 
TLC: Rf (CH2Cl2/MeOH, 99:1= 0.16 
1H-NMR (400 MHz, CDCl3): δ 8.12 (dd, 3JH3’,H4’ = 8.1 Hz, 4JH3’,H5’ = 1.2 Hz, 1 H, H3’), 7.74 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.1 Hz,  1 H, H5’), 7.65 (td, 3JH4’,H3’ = 3JH4’,H5’ = 7.7 
Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 7.43 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.4 Hz, 1 H, H6’), 6.15 
(t, 4JH3,H5 = 1.5 Hz, 1 H, H3), 4.56 (d, 4JH5,H3 = 1.5 Hz, 2 H, H5), 1.58 (s, 9 H, H3’’) 
13C-NMR (400 MHz, CDCl3): δ 168.4 (C2), 155.7 (C1’’), 149.6 (C2’), 147.8 (C4), 134.0 (C5’), 
131.1 (C4’), 130.7 (C6’), 128.7 (C1’), 125.4 (C3’), 125.3 (C3), 83.7 (C2’’), 53.4 (C5), 28.5 (C3’’) 
MS-ESI: 326.9 (100, [M+Na]+) 
IR (KBr): ν = 3105 (vw), 2981 (w), 2924 (w), 1781 (vs), 1693 (m), 1604 (w), 1571 (w), 1520 
(vs), 1477 (w), 1448 (m), 1368 (s), 1357 (vs), 1339 (vs), 1322 (s), 1289 (vs), 1261 (m), 1225 
(w), 1204 (w), 1158 (s), 1072 (s), 877 (w), 863 (m), 847 (m), 796 (w), 774 (w), 761 (m), 748 
(w), 739 (m), 693 (w), 639 (vw), 579 (vw), 531 (vw), 490 (vw), 457 (vw) cm–1 
5.2.7. 4-(2-Nitrophenyl)-1H-pyrrol-2(5H)-one (235) 
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Trifluoroacetic acid (1.60 mL) was added dropwise to a solution of Boc-protected pyrrolinone 
218a (200 mg, 0.66 mmol) in dry CH2Cl2 (8.0 mL) at room temperature. The mixture was 
stirred at room temperature for 40 min (reaction progress monitored by TLC) and then 
quenched with a saturated aqueous NaHCO3 (30 mL). The organic and aqueous layers were 
separated and the organic layer was washed with brine (20 mL), dried over MgSO4, filtered 
and evaporated. 131 mg (98%) of deprotected pyrrolinone 235 were recovered as a yellow 
solid.  
 
Analytical Data for 235: 
 
 
TLC: Rf (EtOAc, 100%) = 0.29 
 
GC (method IZ): tR = 15.71 min 
 
1H-NMR (400 MHz, CD3OD): δ 8.03 (dd, 3JH3’,H4’ = 8.1 Hz, 4JH3’,H5’ = 1.3 Hz, 1 H, H3’), 7.76 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.3 Hz,  1 H, H5’), 7.66 (td, 3JH4’,H3’ = 3JH4’,H5’ = 7.5 
Hz, 4JH4’,H6’ = 1.3 Hz, 1 H, H4’), 7.59 (dd, 3JH6’,H5’ = 7.6 Hz, 4JH6’,H4’ = 1.5 Hz, 1 H, H6’), 6.12 
(t, 4JH3,H5 = 1.6 Hz, 1 H, H3), 4.35 (d, 4JH5,H3 = 1.6 Hz, 2 H, H5) 
 
13C-NMR (100 MHz, CD3OD): δ 176.0 (C2), 158.3 (C4), 149.6 (C2’), 134.4 (C5’), 131.6 (C4’), 
131.6 (C6’), 129.4 (C1’), 126.6 (C3’), 125.3 (C3), 51.6 (C5) 
 
MS-ESI: 227.2 (100, [M+Na]+) 
 
HR-MS (ESI): 227.04317 ([M+Na]+; C10H8N2O3Na+; calc. 227.04326) 
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5.2.8. 4-Hydroxy-N-methoxy-N-methylbutanamide (S2) and 4-(tert-
butyldiphenylsilyloxy)-N-methoxy-N-methylbutanamide (222)24 
 
 
 
N, O-dimethylhydroxylamine hydrochloride (1.03 g, 10.31 mmol) was dissolved in dry 
CH2Cl2 (50 mL) under argon. The solution was cooled to 0 °C and Me2AlCl (1.0 M solution 
in n-hexane, 10.3 mL, 10.31 mmol) was added dropwise. The resulting mixture was stirred at 
0 °C for 1 h. Neat γ–butyrolactone (0.72 mL, 93.8 mmol) was then added slowly and the 
resulting mixture was stirred at room temperature for 21 h. The reaction mixture was 
quenched with water (10 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 x 10 mL). Aqueous phase was diluted with a saturated Rochelle’s 
salt (10 mL) and extracted with CH2Cl2 (3 x 40 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated to afford 1.42 g of the crude alcohol S2 as a clear, 
colourless oil. Rf (CH2Cl2/MeOH, 95:5) = 0.23. GC (method IZ): tR = 6.67 min. 
 
Under argon, imidazole (728 mg, 10.69 mmol) was added to a solution of the crude alcohol 
S2 in dry CH2Cl2 (50 mL) and the solution was cooled to 0 °C. tert-Butyldiphenylchlorosilane 
(2.32 mL, 9.75 mmol) and 4-DMAP (58 mg, 0.47 mmol) were added and the resulting 
mixture was stirred at room temperature for 17 h. The reaction mixture was diluted with water 
(20 mL). The phases were separated and the aqueous phase was extracted with CH2Cl2 (3 x 40 
mL). The combined organic phases were dried over MgSO4, filtered and concentrated. The 
residue was purified by flash chromatography on silica gel (petroleum ether and then 
petroleum ether/EtOAc gradually to 70:30) to afford 3.25 g (90%) of 222 as a clear, 
colourless oil. 
 
 
 
 
116 
Analytical Data for 222: 
TLC: Rf (Petroleum ether/EtOAc, 50:50) = 0.58 
GC (method IZ): tR = 16.28 min 
1H-NMR (400 MHz, CDCl3): δ 7.66 (≈ td, 3JH6,H7 obs. = 6.1 Hz, 4JH6,H8 obs. = 4JH6,H6’ obs. = 1.5 
Hz, 4 H, H6, H6’), 7.44-7.35 (m, 6 H, H7, H7’, H8), 3.73 (t, 3JH4,H3 = 6.1 Hz, 2 H, H4), 3.67 (s, 3 
H, H12), 3.18 (s, 3 H, H11), 2.56 (t, 3JH2,H3 = 7.5 Hz, 2 H, H2), 1.89 (tt, 3JH3,H2 = 7.5 Hz, 3JH3,H4 
= 6.1 Hz, 2 H, H3), 1.05 (s, 9 H, H10) 
13C-NMR (100 MHz, CDCl3): δ 174.4 (C1) visible on HMBC spectrum, 135.5 (C6, C6’), 
133.9 (C5), 129.6 (C8), 127.6 (C7, C7’), 63.2 (C4), 61.2 (C12), 32.3 (C11), 28.4 (C3), 27.6 (C2), 
26.9 (C10), 19.2 (C9) 
MS-ESI: 408.5 (100, [M+Na]+) 
5.2.9. 6-(tert-Butyldiphenylsilyloxy)hexan-3-one (223)52 
Weinreb amide 222 (3.25 g, 8.41 mmol) was dissolved in dry THF (17 mL) under argon. The 
solution was cooled to 0 °C and ethyl magnesiumbromide (1.0 M solution in THF, 16.83 mL, 
16.83 mmol) was added dropwise. The resulting mixture was stirred at room temperature for 
117 
 
45 min and quenched with a saturated aqueous NH4Cl (40 mL). The mixture was poured into 
Et2O (60 mL) and the phases were separated. The aqueous phase was extracted with Et2O (3 x 
100 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated. 
The solvent was removed in vacuo to afford 2.98 g (100%) of a pure ketone 223 as a clear, 
colourless oil. The crude product was engaged in the next step without further purification. 
 
Analytical Data for 223: 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.62 
 
GC (method IZ): tR = 15.01 min 
 
1H-NMR (400 MHz, CDCl3): δ 7.65 (≈ td, 3JH8,H9 obs. = 6.1 Hz, 4JH8,H10 obs. = 4JH6,H8’ obs. = 1.5 
Hz, 4 H, H8, H8’), 7.45-7.35 (m, 6 H, H9, H9’, H10), 3.66 (t, 3JH6,H5 = 6.1 Hz, 2 H, H6), 2.52 (t, 
3JH4,H5 = 7.4 Hz, 2 H, H4), 2.41 (q, 3JH2,H1 = 7.3 Hz, 2 H, H2),  1.83 (tt, 3JH5,H4 = 7.4 Hz, 3JH5,H6 
= 6.1 Hz, 2 H, H5), 1.04 (t, 3JH1,H2 = 7.3 Hz, 3 H, H1), 1.04 (s, 9 H, H12) 
 
13C-NMR (100 MHz, CDCl3): δ 211.5 (C3), 135.5 (C8, C8’), 133.8 (C7), 129.6 (C10), 127.6 
(C9, C9’), 63.1 (C6), 38.7 (C4), 35.9 (C2), 26.9 (C12), 26.7 (C5), 19.2 (C11), 7.8 (C1) 
 
MS-ESI: 377.6 (100, [M+Na]+) 
  
  
118 
5.2.10. (E/Z)-Ethyl 6-(tert-butyldiphenylsilyloxy)-3-ethylhex-2-enoate 
(224)24 
A flame-dried 250 mL two-necked round bottom flask was charged with NaH (864 mg of 
95%, 34.21 mmol) and 100 mL of dry DME. Neat triethyl phosphonoacetate (7.62 mL, 37.25 
mmol) was then added slowly to the suspension at room temperature. After the addition was 
completed (~15 min), a solution of the ketone 223 (2.70 g, 7.60 mmol) in dry DME (25 mL) 
was added. The homogeneous mixture was refluxed overnight then cooled to room 
temperature. The reaction mixture was diluted with 70 mL of water and 100 mL of EtOAc. 
The phases were separated and the aqueous phase was extracted with EtOAc (3 x 100 mL). 
The combined organic phases were washed with brine (80 mL), dried over MgSO4, filtered 
and concentrated. The residue was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 99:1 to 96:4) to afford 3.13 g (97%) of E/Z mixture (60:40) of 224 as a clear, 
slightly yellowish oil. 
Analytical Data for 224: 
TLC: Rf (Petroleum ether/EtOAc, 95:5) = 0.24 
MS-ESI: 447.6 (100, [M+Na]+) 
HR-MS (ESI): 447.23192 ([M+Na]+; C26H36O3SiNa+; calc. 447.23259) 
IR (KBr, film): ν = 3072 (w), 3050 (w), 2959 (s), 2933 (vs), 2897 (s), 2859 (s), 1960 (vw), 
1890 (vw), 1741 (m), 1716 (vs), 1645 (s), 1590 (vw), 1473 (m), 1463 (m), 1428 (s), 1390 (m), 
1305 (w), 1272 (m), 1240 (m), 1207 (s), 1180 (s), 1147 (vs), 1111 (vs), 1041 (s), 1008 (w), 
998 (w), 974 (w), 940 (w), 868 (w), 824 (m), 741 (m), 702 (vs), 688 (m), 614 (m), 506 (s) cm–
1
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Analytical Data for (E)-224: 
 
1H-NMR (400 MHz, CDCl3): δ 7.66 (ddd, 3JH12,H13 = 7.7 Hz, 4JH12,H14 = 2.7 Hz, 4JH12,H12’ = 
1.5 Hz, 4 H, A2B2, H12, H12’), 7.35-7.446 (m, 6 H, A2B2, H13, H13’, H14 ), 5.61 (s, 1 H, H2), 
4.14 (q, 3JH9,H10 = 7.2 Hz, 2 H, H9), 3.67 (t, 3JH6,H5 = 6.2 Hz, 2 H, H6), 2.60 (q, 3JH7,H8 = 7.5 Hz, 
2 H, H7), 2.25 (≈t, 3JH4,H5 = 7.3 Hz, 2 H, H4), 1.72 (≈quint, 3JH5,H4 = 3JH5,H6 = 6.2 Hz, 2 H, H5), 
1.28 (t, 3JH10,H9 = 7.2 Hz, 3 H, H10), 1.06 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8), 1.05  (s, 9 H, H16) 
 
13C-NMR (100 MHz, CDCl3): δ 166.6 (C1), 165.7 (C3), 135.7 (C12, C12’), 134.0 (C11), 129.8 
(C14), 127.8 (C13, C13’), 115.0 (C2), 63.4 (C6), 59.6 (C9), 34.4 (C4), 30.8 (C5), 27.0 (C16), 25.4 
(C7), 19.4 (C15), 14.5 (C10), 13.1 (C8) 
 
GC (method IZ): tR = 17.33 min  
 
Analytical Data for (Z)-224: 
 
1H-NMR (400 MHz, CDCl3): δ 7.66 (ddd, 3JH12,H13 = 7.7 Hz, 4JH12,H14 = 2.7 Hz, 4JH12,H12’ = 
1.5 Hz, 4 H, A2B2, H12, H12’), 7.35-7.446 (m, 6 H, A2B2, H13, H13’, H14 ), 5.61 (s, 1 H, H2), 
4.11 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 3.71 (t, 3JH6,H5 = 6.4 Hz, 2 H, H6), 2.67 (≈t, 3JH4,H5 = 7.8 
Hz, 2 H, H4), 2.17 (dq, 3JH7,H8 = 7.4 Hz, 4JH7,H2 = 1.0 Hz, 2 H, H7), 1.70 (≈quint, 3JH5,H4 = 
3JH5,H6 = 6.2 Hz, 2 H, H5), 1.25 (t, 3JH10,H9 = 7.1 Hz, 3 H, H10), 1.05 (t, 3JH8,H7 = 7.3 Hz, 3 H, 
H8), 1.05  (s, 9 H, H16) 
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13C-NMR (100 MHz, CDCl3): δ 166.7 (C1), 165.6 (C3), 135.8 (C12, C12’), 134.2 (C11), 129.7 
(C14), 127.7 (C13, C13’), 114.6 (C2), 64.1 (C6), 59.6 (C9), 31.8 (C7), 31.4 (C5), 28.9 (C4), 27.0 
(C16), 19.4 (C15), 14.5 (C10), 12.2 (C8) 
 
GC (method IZ): tR = 17.06 min  
 
5.2.11. (E/Z)- Ethyl 3-ethyl-6-hydroxyhex-2-enoate (225)24  
 
 
 
At 0° C and under argon, TBAF (1.0 M solution in THF, 6.65 mL, 6.65 mmol) was added to a 
solution of acrylate 224 (2.57 g, 6.04 mmol) in 35 mL of dry THF. The resulting solution was 
stirred at room temperature for 3 h then concentrated. The residue was diluted with water (40 
mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were washed 
with brine (40 mL), dried over MgSO4, filtered and concentrated. The residue was purified by 
flash chromatography on silica gel (petroleum ether/EtOAc, 50:50) to afford 1.00 g (89%) of 
E/Z mixture (60:40) of 225 as a clear, slightly yellowish oil. The relative stereochemistry was 
determined by NOESY experiment. 
 
Analytical Data for 225: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 50:50) = 0.40 
 
MS-ESI: 209.3 (100, [M+Na]+) 
 
HR-MS (ESI): 209.11464 ([M+Na]+; C10H18O3Na+; calc. 209.11536) 
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IR (KBr, film): ν = 3415 (br s), 2938 (vs), 2876 (s), 1715 (vs), 1644 (s), 1463 (s), 1421 (m), 
1380 (s), 1304 (s), 1275 (s), 1209 (vs), 1148 (vs), 1097 (s), 1038 (vs), 920 (w), 870 (m), 809 
(vw), 736 (w), 628 (w) cm–1 
 
Analytical Data for (E)-225: 
 
1H-NMR (400 MHz, CDCl3): δ 5.63 (s, 1 H, H2), 4.14 (q, 3JH9,H10 = 7.0 Hz, 2 H, H9), 3.67 (t, 
3JH6,H5 = 6.4 Hz, 2 H, H6), 2.62 (q, 3JH7,H8 = 7.5 Hz, 2 H, H7),  2.24 (≈t, 3JH4,H5 = 7.2 Hz, 2 H, 
H4), 1.77-1.70 (m (partial solved), 3JH5,H4 = 7.2 Hz, 3JH5,H6 = 6.4 Hz, 2 H, H5), 1.27 (t, 3JH10,H9 = 
7.1 Hz, 3 H, H10), 1.08 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
 
1H, NOE diff: irrad H2 (5.63) → enh H4 (2.24) and H5 (1.77-1.70) 
 
13C-NMR (100 MHz, CDCl3): δ 166.4 (C1), 165.0 (C3), 115.1 (C2), 62.2 (C6), 59.5 (C9), 34.1 
(C4), 30.5 (C5), 25.3 (C7), 14.3 (C10), 13.0 (C8) 
 
GC-MS (EI, 70 eV): tR = 13.21 min; m/z (%) = 187.0 (1, [M+H]+), 157.1 (84, [M-29]+), 
125.1 (49, [M-61]+), 111.1 (100, [M-75]+), 109.1 (34, [M-77]+), 96.1 (41, [M-90]+), 95.1 (50, 
[M-91]+), 81.1 (72, [M-105]+), 79.1 (94, [M-107]+), 69.1 (75, [M-117]+), 67.1 (88, [M-119]+) 
 
Analytical Data for (Z)-225: 
 
1H-NMR (400 MHz, CDCl3): δ 5.74 (s, 1 H, H2), 4.15 (q, 3JH9,H10 = 7.0 Hz, 2 H, H9), 3.56 (t, 
3JH6,H5 = 5.6 Hz, 2 H, H6), 2.71 (t, 3JH4,H5 = 7.0 Hz, 2 H, H4), 2.18 (dq, 3JH7,H8 = 7.4 Hz, 4JH7,H2 
= 1.0 Hz, 2 H, H7), 1.77-1.70 (m (partial solved), 3JH5,H4 = 7.2 Hz, 3JH5,H6 = 5.7 Hz, 2 H, H5), 
1.28 (t, 3JH10,H9 = 7.1 Hz, 3 H, H10), 1.08 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
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1H, NOE diff: irrad H2 (5.74 ) → enh H7 (2.18) and H8 (1.08) 
13C-NMR (100 MHz, CDCl3): δ 166.4 (C1), 164.9 (C3), 115.5 (C2), 60.7 (C6), 60.0 (C9), 30.6 
(C7), 30.5 (C5), 27.7 (C4), 14.2 (C10), 12.1 (C8) 
GC-MS (EI, 70 eV): tR = 12.72 min; m/z (%) = 187.1 (1, [M+H]+), 157.1 (56, [M-29]+), 
125.1 (31, [M-61]+), 111.1 (100, [M-75]+), 109.2 (41, [M-77]+), 95.1 (50, [M-91]+), 81.1 (66, 
[M-105]+), 79.1 (75, [M-107]+), 69.1 (50, [M-117]+), 67.2 (62, [M-119]+) 
5.2.12. (E/Z)- Ethyl 3-ethyl-6-(tosyloxy)hex-2-enoate (226)53 
To a solution of alcohol 225 (1.00 g, 5.37 mmol) in dry CH2Cl2 (5 mL) at 0 °C and under 
argon was added p-toluene sulfonyl chloride (1.56 g, 8.16 mmol), followed by pyridine (0.93 
mL, 11.60 mmol). The reaction mixture was stirred at room temperature overnight then 
diluted with 50 mL of water and 50 mL of Et2O. The phases were separated and the aqueous 
phase was extracted with Et2O (2 x 50 mL). The combined organic phases were washed with 
1M HCl (50 mL), saturated aqueous NaHCO3 (50 mL), brine (50 mL), dried over MgSO4, 
filtered and concentrated. The residue was purified by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10 to 80:20) to afford 1.60 g (88%) of E/Z mixture (60:40) of 226 
as a clear, colourless oil. 
Analytical Data for 226: 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.32 
GC (method IZ): tR = 15.70 min 
MS-ESI: 363.3 (100, [M+Na]+) 
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HR-MS (ESI): 363.12288 ([M+Na]+; C17H24O5SNa+; calc. 363.12421) 
IR (KBr, film): ν = 2974 (m), 2934 (m), 1713 (vs), 1645 (m), 1599 (w), 1496 (vw), 1463 
(m), 1363 (vs), 1308 (w), 1274 (w), 1209 (s), 1189 (vs), 1177 (vs), 1149 (s), 1098 (m), 1037 
(m), 1009 (w), 967 (m), 929 (s), 870 (w), 836 (m), 816 (m), 785 (w), 738 (w), 706 (vw), 690 
(vw), 665 (s), 577 (w), 555 (s) cm–1 
Analytical Data for (E)-226: 
1H-NMR (400 MHz, CDCl3): δ 7.80 (d, 3JH12,H13 = 8.1 Hz, 2 H, A2B2, H12, H12’), 7.35  (d, 
3JH13,H12 = 8.1 Hz, 2 H, A2B2, H13, H13’), 5.51  (s, 1 H, H2), 4.13 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 
4.04 (t, 3JH6,H5 = 6.2 Hz, 2 H, H6), 2.54 (q, 3JH7,H8 = 7.5 Hz, 2 H, H7), 2.45  (s, 3 H, H15), 2.17 
(≈t, 3JH4,H5 = 7.3 Hz, 2 H, H4), 1.84 (≈quint, 3JH5,H4 = 3JH5,H6 = 6.2 Hz, 2 H, H5), 1.27 (t, 3JH10,H9 
= 7.1 Hz, 3 H, H10), 1.02 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
1H, NOE diff: irrad H2 (5.51) → enh H6 (4.04), H4 (2.17) and H5 (1.84) 
13C-NMR (100 MHz, CDCl3): δ 166.1 (C1), 163.2 (C3), 144.8 (C11), 133.1 (C14), 129.9 (C13), 
127.9 (C12), 115.7 (C2), 69.6 (C6), 59.6 (C9), 33.3 (C4), 26.9 (C5), 25.1 (C7), 21.6 (C15), 14.3 
(C10), 12.9 (C8) 
Analytical Data for (Z)-226: 
1H-NMR (400 MHz, CDCl3): δ 7.80 (d, 3JH12,H13 = 8.1 Hz, 2 H, A2B2, H12, H12’), 7.34 (d, 
3JH13,H12 = 8.1 Hz, 2 H, A2B2, H13, H13’), 5.63 (s, 1 H, H2), 4.11 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 
4.06 (t, 3JH6,H5 = 6.4 Hz, 2 H, H6), 2.58 (≈t, 3JH4,H5 = 7.8 Hz, 2 H, H4), 2.45  (s, 3 H, H15), 2.13 
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(dq, 3JH7,H8 = 7.4 Hz, 4JH7,H2 = 1.3 Hz, 2 H, H7), 1.80 (≈quint, 3JH5,H4 = 3JH5,H6 = 6.2 Hz, 2 H, 
H5), 1.25 (t, 3JH10,H9 = 7.1 Hz, 3 H, H10), 1.04 (t, 3JH8,H7 = 7.4 Hz, 3 H, H8)  
1H, NOE diff: irrad H2 (5.63) → enh H7 (2.13) and H8 (1.04) 
13C-NMR (100 MHz, CDCl3): δ 166.4 (C1), 163.7 (C3), 144.7 (C11), 133.2 (C14), 129.8 (C13), 
127.9 (C12), 115.3 (C2), 70.5 (C6), 59.6 (C9), 31.2 (C7), 28.4 (C4), 27.9 (C5), 21.6 (C15), 14.3 
(C10), 11.9 (C8) 
5.2.13. (E/Z)- Ethyl 3-ethyl-6-iodohex-2-enoate (227)54 
To a solution of tosylate 226 (700 mg, 2.06 mmol) in acetone (70 mL) was added sodium 
iodide (925 mg, 6.17 mmol), followed by K2CO3 (853 mg, 6.17 mmol). The reaction mixture 
was refluxed for 5 h then concentrated. The residue was purified by flash chromatography on 
silica gel (petroleum ether/EtOAc, 90:10) to afford 594 mg (98%) of E/Z mixture (60:40) of 
227 as a clear, colourless oil. 
Analytical Data for 227: 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.59 
MS-ESI: 353.4 (10, [M+K+H2O]+), 319.1 (100, [M+Na]+), 304.5 (33, [(M+Na)-15]+) 
HR-MS (ESI): 319.01666 ([M+Na]+; C10H17IO2Na+; calc. 319.01654) 
IR (KBr, film): ν = 2964 (s), 2929 (s), 2873 (m), 1715 (vs), 1645 (s), 1460 (m), 1379 (m), 
1314 (m), 1272 (m), 1205 (vs), 1151 (vs), 1096 (w), 1078 (w), 1037 (m), 948 (vw), 870 (w), 
810 (vw), 726 (vw), 594 (vw), 502 (vw) cm–1 
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Analytical Data for (E)-227: 
1H-NMR (400 MHz, CDCl3): δ 5.63 (s, 1 H, H2), 4.14 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 3.18 (t, 
3JH6,H5 = 6.9 Hz, 2 H, H6), 2.61 (q, 3JH7,H8 = 7.5 Hz, 2 H, H7), 2.27 (≈t, 3JH4,H5 = 6.9 Hz, 2 H, 
H4), 1.99 (≈quint, 3JH5,H4 = 3JH5,H6 = 6.9 Hz, 2 H, H5), 1.28 (t, 3JH10,H9 = 7.2 Hz, 3 H, H10), 1.08 
(t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
13C-NMR (100 MHz, CDCl3): δ 166.4 (C1), 163.4 (C3), 116.0 (C2), 59.8 (C9), 38.5 (C4), 31.3 
(C5), 25.3 (C7), 14.5 (C10), 13.1 (C8), 5.8 (C6) 
GC (method IZ): tR = 10.10 min 
Analytical Data for (Z)-227: 
1H-NMR (400 MHz, CDCl3): δ 5.67 (s, 1 H, H2), 4.14 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 3.22 (t, 
3JH6,H5 = 7.2 Hz, 2 H, H6), 2.68 (≈t, 3JH4,H5 = 7.7 Hz, 2 H, H4), 2.19 (dq, 3JH7,H8 = 7.4 Hz, 
4JH7,H2 = 1.2 Hz, 2 H, H7), 1.99 (≈quint, 3JH5,H4 = 3JH5,H6 = 6.9 Hz, 2 H, H5), 1.28 (t, 3JH10,H9 = 
7.1 Hz, 3 H, H10), 1.08 (t, 3JH8,H7 = 7.4 Hz, 3 H, H8) 
13C-NMR (100 MHz, CDCl3): δ 166.6 (C1), 163.6 (C3), 115.5 (C2), 59.8 (C9), 33.6 (C4), 32.8 
(C5), 31.5 (C7), 14.4 (C10), 12.1 (C8), 6.4 (C6) 
GC (method IZ): tR = 9.89 min 
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5.2.14. (E/Z)- 6-Ethoxy-4-ethyl-6-oxohex-4-enoic acid (228)51 
Preparation of Jones’ reagent 1.9 M CrO3 in 2.95 M H2SO4 (4 mL): Water (3.34 mL) was 
added dropwise to a solution of CrO3 (760 mg, 7.6 mmol) in 0.66 mL of 96% H2SO4 at 0 °C.  
To a stirred solution of alcohol 225 (200 mg, 1.07 mmol) in acetone (4.5 mL) at 0 °C was 
added dropwise a freshly prepared Jones’ reagent (1.9 M, ca. 2 mL). The addition of the 
oxidant was continued until the starting material was consumed as determined by TLC 
analysis (ca. 0.5 h). The resulting yellow-brown reaction mixture was stirred for an additional 
2 h at 0 °C, before it was quenched with iPrOH (2 mL) and warmed to room temperature for 
10 min. The crude reaction mixture was then filtered through a plug of Celite (eluting with 30 
mL of Et2O) and concentrated in vacuo. The organic residue was taken up in Et2O (100 mL) 
and washed with brine (40 mL), dried over Na2SO4, filtered and concentrated. The residue 
was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10 to 50:50) 
to afford 175 mg (81%) of E/Z mixture (60:40) of 228 as a clear, slightly yellowish oil.  
Analytical Data for 228: 
TLC: Rf (Petroleum ether/EtOAc, 50:50) = 0.20 
MS-ESI: 223.1 (100, [M+Na]+) 
HR-MS (ESI): 223.09407 ([M+Na]+; C10H16O4Na+; calc. 223.09463) 
IR (KBr, film): ν = 2976 (vs), 2934 (vs), 1715 (vs), 1646 (vs), 1447 (s), 1422 (s), 1381 (s), 
1276 (vs), 1209 (vs), 1148 (vs), 1096 (m), 1040 (s), 920 (m), 870 (s), 759 (w), 666 (w) cm–1 
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Analytical Data for (E)-228: 
 
 
1H-NMR (400 MHz, CDCl3): δ 5.61 (s, 1 H, H2), 4.15 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 2.63 (q, 
3JH7,H8 = 7.5 Hz, 2 H, H7), 2.58-2.48 (m, 2 H, H5), 2.53 (≈t, 3JH4,H5 = 6.7 Hz, 2 H, H4), 1.27 (t, 
3JH10,H9 = 7.1 Hz, 3 H, H10), 1.09 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
 
13C-NMR (100 MHz, CDCl3): δ 177.6 (C6), 166.2 (C1), 162.7 (C3), 115.4 (C2), 59.7 (C9), 
32.2 (C5), 31.7 (C4), 25.4 (C7), 14.3 (C10), 12.9 (C8) 
 
Analytical Data for (Z)-228: 
 
 
1H-NMR (400 MHz, CDCl3): δ 5.69 (s, 1 H, H2), 4.16 (q, 3JH9,H10 = 7.2 Hz, 2 H, H9), 2.88 
(≈t, 3JH4,H5 = 7.6 Hz, 2 H, H4), 2.58-2.48 (m, 2 H, H5), 2.21 (dq, 3JH7,H8 = 7.4 Hz, 4JH7,H2 = 1.3 
Hz, 2 H, H7), 1.28 (t, 3JH10,H9 = 7.2 Hz, 3 H, H10), 1.08 (t, 3JH8,H7 = 7.4 Hz, 3 H, H8)  
 
13C-NMR (100 MHz, CDCl3): δ 177.9 (C6), 166.4 (C1), 162.9 (C3), 115.7 (C2), 59.8 (C9), 
32.8 (C5), 31.4 (C7), 27.5 (C4), 14.1 (C10), 11.9 (C8) 
 
5.2.15. (E/Z)- 1-Ethyl 6-perfluorophenyl 3-ethylhex-2-enedioate (229)56 
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To a stirred solution of acid 228 (110 mg, 0.55 mmol) in dry CH2Cl2 (1.0 mL) at 0 °C and 
under argon was added pentafluorophenol (111 mg, 0.60 mmol) followed by N,N'-
dicyclohexylcarbodiimide (127 mg, 0.62 mmol). The reaction mixture was allowed to warm 
to room temperature and stirred for 3 days, then was filtered through a plug of Celite (eluting 
with 40 mL of CH2Cl2) and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 90:10) to afford 98 mg (49%) of E/Z 
mixture (60:40) of 229 as a clear, slightly yellowish oil.  
 
Analytical Data for 229: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.56 
 
MS-ESI: 389.1 (100, [M+Na]+) 
 
HR-MS (ESI): 389.07832 ([M+Na]+; C16H15F5O4Na+; calc. 389.07882) 
 
IR (KBr, film): ν = 2932 (s), 2857 (m), 2669 (vw), 2461 (vw), 2120 (m), 1791 (vs), 1717 
(vs), 1649 (s), 1521 (vs), 1466 (m), 1380 (m), 1314 (m), 1275 (m), 1207 (vs), 1150 (vs), 1100 
(vs), 1042 (s), 1004 (vs), 873 (m), 741 (m), 729 (vw), 618 (vw), 553 (vw) cm–1 
 
Analytical Data for (E)-229: 
 
 
1H-NMR (400 MHz, CDCl3): δ 5.67 (s, 1 H, H2), 4.16 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 2.86 
(≈t, 3JH4,H5 = 8.0 Hz, 2 H, H4), 2.67 (q, 3JH7,H8 = 7.5 Hz, 2 H, H7), 2.63 (t, 3JH5,H4 = 7.8 Hz, 2 H, 
H5), 1.28 (t, 3JH10,H9 = 7.1 Hz, 3 H, H10), 1.12 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8)  
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13C-NMR (100 MHz, CDCl3): δ 168.4 (C6), 165.9 (C1), 165.9 (2 x ar.), 161.5 (C3), 142.4 
(ar.), 139.8 (ar.), 138.9 (ar.), 125.0 (ar.), 116.0 (C2), 59.7 (C9), 32.1 (C5), 31.3 (C4), 25.3 (C7), 
14.2 (C10), 12.9 (C8) 
19F-NMR (376 MHz, CDCl3): δ -151.5 (d, 3JF12,F13 = 3JF12’,F13’ = 19.4 Hz, 2 F, A2B2, F12, F12’), 
-156.7 (≈t, 3JF14,F13 = 3JF14,F13’ = 19.1 Hz, 1 F, A2B2, F14), -161.1 (≈t, 3JF13,F14 = 3JF13,F12 = 
3JF13’,F14’ = 3JF13’,F12’ = 20.1 Hz, 2 F, A2B2, F13, F13’)  
 
Analytical Data for (Z)-229: 
 
 
1H-NMR (400 MHz, CDCl3): δ 5.75 (s, 1 H, H2), 4.17 (q, 3JH9,H10 = 7.1 Hz, 2 H, H9), 3.01 (t, 
3JH4,H5 = 8.0 Hz, 2 H, H4), 2.88 (≈t, 3JH5,H4 = 8.0 Hz, 2 H, H5), 2.26 (dq, 3JH7,H8 = 7.4 Hz, 4JH7,H2 
= 1.4 Hz, 2 H, H7), 1.29 (t, 3JH10,H9 = 7.1 Hz, 3 H, H10), 1.11 (t, 3JH8,H7 = 7.4 Hz, 3 H, H8)  
 
13C-NMR (100 MHz, CDCl3): δ 168.9 (C6), 166.2 (C1), 165.9 (2 x ar.), 161.8 (C3), 142.3 
(ar.), 139.8 (ar.), 138.9 (ar.), 125.0 (ar.), 116.3 (C2), 59.9 (C9), 32.1 (C5), 31.4 (C7), 27.5 (C4), 
14.2 (C10), 11.9 (C8) 
 
19F-NMR (376 MHz, CDCl3): δ -151.5 (d, 3JF12,F13 = 3JF12’,F13’ = 17.4 Hz, 2 F, A2B2, F12, F12’), 
-157.1 (≈t, 3JF14,F13 = 3JF14,F13’ = 19.0 Hz, 1 F, A2B2, F14), -161.4 (≈t, 3JF13,F14 = 3JF13,F12 = 
3JF13’,F14 = 3JF13’,F12’ = 20.7 Hz, 2 F, A2B2, F13, F13’)  
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5.2.16. 1-tert-Butyl 2-methyl 1H-pyrrole-1,2-dicarboxylate (74)55 
 
 
 
At room temperature and under argon, (Boc)2O (1.92 g, 8.79 mmol) was added to a solution 
of a pyrrole (61) (1.0 g, 8.00 mmol) and DMAP (49 mg, 0.40 mmol) in dry CH3CN (2.6 ml). 
The resulting mixture was stirred at room temperature for 1 h then diluted with 20 mL of 
water and 30 mL of EtOAc. The phases were separated and the aqueous phase was extracted 
with EtOAc (2 x 30 mL). The combined organic phases were washed with brine (20 mL), 
dried over Na2SO4, filtered and concentrated. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 90:10) to give 1.78 g (99%) of 74 as a 
clear, colourless oil. 
 
Analytical Data for 74: 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.46 
 
GC (method IZ): tR = 8.87 min 
 
1H-NMR (400 MHz, CDCl3): δ 7.32 (dd, 3JH5,H4 = 3.1 Hz, 4JH5,H3 = 1.7 Hz, 1 H, H5), 6.83 
(dd, 3JH3,H4 = 3.4 Hz, 4JH3,H5 = 1.7 Hz, 1 H, H3), 6.17 (t, 3JH4,H3 = 3JH4,H5 = 3.3 Hz, 1 H, H3), 
3.84 (s, 3 H, H2’), 1.58 (s, 9 H, H3’’) 
 
13C-NMR (100 MHz, CDCl3): δ 161.3 (C1’), 148.4 (C1’’), 126.7 (C5), 125.2 (C2), 120.8 (C3), 
110.1 (C4), 84.8 (C2’’), 51.9 (C2’), 27.7 (C3’’) 
 
MS-ESI: 473.0 (100, [2M+Na]+), 248.1 (88, [M+Na]+), 192.0 (46, [M-33]) 
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IR (KBr, film): ν = 3132 (vw), 2983 (m), 2953 (m), 1752 (vs), 1729 (vs), 1549 (w), 1451 
(vs), 1414 (s), 1396 (m), 1371 (vs), 1358 (s), 1319 (vs), 1272 (vs), 1216 (vs), 1196 (vs), 1159 
(vs), 1097 (vs), 1064 (s), 1021 (w), 949 (m), 887 (w), 848 (s), 797 (m), 775 (s), 759 (s), 746 
(s), 646 (vw), 600 (vw), 569 (vw), 494 (vw), 450 (vw), 417 (vw) cm–1 
 
5.2.17. 1-tert-Butyl 2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-1H-pyrrole-1,2-dicarboxylate (237)36 
 
 
A glass microwave tube was initially charged with [Ir(OMe)(COD)]2 (20 mg, 0.03 mmol, 3 
mol % Ir) and 4,4’-di-tert-butyl-2,2’-bipyridine (16 mg, 0.06 mmol, 3 mol %). The vial was 
sealed with a Teflon-coated screw cap, a needle was inserted through the cap and the vial was 
then evacuated and backfilled with argon. 3 mL of dry and degased hexane were added at 
room temperature. To a resulting mixture were added dropwise pinacolborane (0.35 mL, 2.40 
mmol) followed by pyrrole 74 (450 mg, 2.00 mmol). The resulting mixture were heated at 80 
°C for 6 h, and then stirred at room temperature overnight. The reaction solution was filtered 
through a thin pad of Celite (eluting with 50 mL of EtOAc), and the eluent was concentrated 
under reduced pressure. The crude material so obtained was purified by flash chromatography 
on silica gel (petroleum ether and then petroleum ether/EtOAc gradually to 50:50) to afford 
508 mg (72%) of 237 as a white solid. 
  
Analytical Data for 237: 
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TLC: Rf (Petroleum ether/EtOAc, 95:5) = 0.12 
 
GC (method IZ): tR = 11.70 min 
 
1H-NMR (400 MHz, CDCl3): δ 7.68 (d, 4JH5,H3 = 1.7 Hz, 1 H, H5), 7.12 (d, 4JH3,H5 = 1.7 Hz, 1 
H, H3), 3.82 (s, 3 H, H2’), 1.57 (s, 9 H, H3’’), 1.31 (s, 12 H, H2’’’) 
 
13C-NMR (100 MHz, CDCl3): δ 161.2 (C1’), 148.0 (C1’’), 134.8 (C5), 126.0 (C2), 125.7 (C3), 
110.9 (C4), 85.0 (C2’’), 83.6 (C1’’’), 51.8 (C2’), 27.7 (C3’’), 24.8 (C2’’’) 
 
MS-ESI: 374.2 (100, [M+Na]+) 
 
HR-MS (ESI): 374.17396 ([M+Na]+; C17H26BNO6Na+; calc. 374.17509) 
 
5.2.18. 1-tert-Butyl 2-methyl 4-(2-nitrophenyl)-1H-pyrrole-1,2-
dicarboxylate (76) 
 
Method A:37 
 
 
In an over-dried glass microwave flask, the solid starting materials were combined: N-
(Boc)pyrrole pinacol boronate 237 (450 mg, 1.28 mmol), 2-bromo-nitrobenzene (238) (216 
mg, 1.07 mmol), palladium acetate (12 mg, 0.05 mmol), 2-dicyclohexyl-phosphino-2′,6′-
dimethoxybiphenyl (44 mg, 0.11 mmol), and K3PO4 (453 mg, 2.14 mmol). The vial was 
sealed with a Teflon-coated screw cap, a needle was inserted through the cap and the vial was 
then evacuated and backfilled with argon. The solvent system (2.56 mL, 2.0 mL/mmol 2-
bromo-nitrobenzene), consisting of degassed n-butanol (1.83 mL) and degassed deionized 
water (0.73 mL) in the ratio of 2.5:1 was added. The resulting mixture was heated at 35 °C for 
16 h. The crude reaction mixture was then filtered through a plug of silica gel (eluting with 35 
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mL of EtOAc) and concentrated in vacuo. The crude material so obtained was purified by 
flash chromatography on silica gel (petroleum ether and then petroleum ether/EtOAc 
gradually to 90:10) to provide 380 mg (100%) of desired Boc-protected phenylpyrrole 76 as a 
yellow oil. 
 
Method B (one-pot synthesis): 
N
Boc
Bpin
CO2Me
N
Boc
CO2Me
NO2
N
Boc
CO2Me
[Ir(OMe)(COD)]2
HBpin, dtbpy
hexane
ArBr 238, Pd(OAc)2
SPhos,K3PO4
nBuOH/H2O
(96%)
74 237
76
C11H15NO4
225.24
C17H26BNO6
351.20
C17H18N2O6
346.33
 
A glass microwave flask was initially charged with [Ir(OMe)(COD)]2 (20 mg, 0.03 mmol, 3 
mol % Ir) and 4,4’-ditertbutyl-2,2’-bipyridine (16 mg, 0.06 mmol, 3 mol %). The vial was 
sealed with a Teflon-coated screw cap, a needle was inserted through the cap and the vial was 
then evacuated and backfilled with argon. 3 mL of dry and degased hexane were added at 
room temperature. To a resulting mixture were added dropwise pinacolborane (0.35 mL, 2.40 
mmol) followed by pyrrole 74 (450 mg, 2.00 mmol). The resulting mixture were heated at 80 
°C for 6 h, and then stirred at room temperature overnight. The screw cap was removed and 
the solid starting materials were added to a crude mixture: 2-bromo-nitrobenzene (238) (403 
mg, 2.00 mmol), palladium acetate (19 mg, 0.04 mmol), SPhos (68 mg, 0.08 mmol), and 
K3PO4 (706 mg, 1.66 mmol). The vial was sealed with a Teflon-coated screw cap, a needle 
was inserted through the cap and the vial was then evacuated and backfilled with argon. The 
solvent system (2.56 mL, 1.0 mL/mmol 2-bromo-nitrobenzene), consisting of degassed n-
butanol (1.83 mL) and degassed deionized water (0.73 mL) in the ratio of 2.5:1 was added. 
The resulting mixture was heated at 35 °C for 16 h. The crude reaction mixture was then 
filtered through a plug of silica gel (eluting with 30 mL of EtOAc) and concentrated in vacuo. 
The crude material so obtained was purified by flash chromatography on silica gel (petroleum 
ether and then petroleum ether/EtOAc gradually to 90:10) to give 661 mg (96% starting from 
pyrrole 74) of desired Boc-protected phenylpyrrole 76 as a yellow oil. 
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Analytical Data for 76: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.30 
 
1H-NMR (400 MHz, acetone-d6): δ 7.87 (dd, 3JH8,H9 = 8.1 Hz, 4JH8,H10 = 1.0 Hz, 1 H, H8), 
7.72  (ddd, 3JH10,H11 = 7.9 Hz, 3JH10,H9 = 6.9, 4JH10,H8 = 1.2 Hz, 1 H, H10), 7.68 (dd, 3JH11,H10 = 
7.7 Hz, 4JH11,H9 = 1.8 Hz, 1 H, H11), 7.60 (d, 4JH5,H3 = 1.9 Hz, 1 H, H5), 7.59  (ddd, 3JH9,H8 = 8.0 
Hz, 3JH9,H10 = 6.9 Hz, 4JH9,H11 = 1.9 Hz, 1 H, H9), 6.90 (d, 4JH3,H5 = 1.9 Hz, 1 H, H3), 3.84 (s, 3 
H, H2’), 1.60 (s, 9 H, H3’’) 
 
13C-NMR (100 MHz, acetone-d6): δ 161.4 (C1’), 150.1 (C1’’), 148.9 (C7), 133.2 (C9), 132.3 
(C11), 129.4 (C10), 128.0 (C6), 126.8 (C4), 125.2 (C5), 124.6 (C8), 121.8 (C2), 119.9 (C3), 86.3 
(C2’’), 52.4 (C2’), 27.7 (C3’’) 
 
MS-ESI: 369.3 (100, [M+Na]+), 269.2 (17, [M-77]) 
 
HR-MS (ESI): 369.10566 ([M+Na]+; C17H18N2O6Na+; calc. 369.10626) 
 
IR (KBr, film): ν = 3134 (w), 2983 (m), 2954 (m), 1732 (vs), 1613 (m), 1569 (m), 1529 (vs), 
1459 (s), 1436 (s), 1395 (vs), 1371 (vs), 1344 (vs), 1284 (vs), 1246 (m), 1155 (vs), 1078 (vs), 
1037 (w), 954 (m), 929 (w), 849 (vs), 802 (m), 776 (vs), 748 (vs), 704 (w), 648 (w), 634 (w), 
596 (vw), 527 (vw) cm–1 
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5.2.19. Methyl 4-(2-nitrophenyl)-1H-pyrrole-2-carboxylate (28)39  
 
 
Under argon, a solution of Boc-protected phenylpyrrole 76 (330 mg, 0.95 mmol) in dry DMF 
(3 mL) was heated at 120 °C for 3 h. The reaction mixture was cooled to room temperature 
and poured into water (100 mL). The aqueous layer was extracted with EtOAc (3 x 60 mL). 
Combined organic extracts were washed with water (2 x 50 mL), brine (60 mL), dried over 
MgSO4, filtered and evaporated. The residue was purified by flash chromatography on silica 
gel (petroleum ether/EtOAc, 90:10 to 70:30) to afford 243 mg (100%) of deprotected 
phenylpyrrole 28 as a yellow solid.  
 
Analytical Data for 28: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.15 
 
GC (method IZ): tR = 14.04 min 
 
1H-NMR (400 MHz, acetone-d6): δ 11.28 (br s, 1 H, NH), 7.75 (dd, 3JH8,H9 = 7.9 Hz, 4JH8,H10 
= 0.9 Hz, 1 H, H8), 7.68 (dd, 3JH11,H10 = 7.6 Hz, 4JH11,H9 = 1.8 Hz, 1 H, H11), 7.65 (ddd, 3JH10,H11 
= 7.8 Hz, 3JH10,H9 = 6.6, 4JH10,H8 = 1.2 Hz, 1 H, H10), 7.49 (ddd, 3JH9,H8 = 8.1 Hz, 3JH9,H10 = 6.8 
Hz, 4JH9,H11 = 1.9 Hz, 1 H, H9), 7.30 (dd, 3JH5,H1 = 3.0 Hz, 4JH5,H3 = 1.8 Hz, 1 H, H5), 6.93 (t, 
4JH3,H5 = 4JH3,H1 = 1.9 Hz, 1 H, H3), 3.81 (s, 3 H, H2’) 
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13C-NMR (100 MHz, acetone-d6): δ 161.5 (C1’), 150.3 (C7), 132.7 (C10), 131.7 (C11), 129.1 
(C6), 128.3 (C9), 124.5 (C2), 124.1 (C8), 123.1 (C5), 121.1 (C4), 114.6 (C3), 51.6 (C2’) 
 
MS-ESI: 245.3 (100, [M-H]-) 
 
HR-MS (ESI): 269.05355 ([M+Na]+; C12H10N2O4Na+; calc. 269.05383) 
 
IR (KBr): ν = 3282 (vs), 3128 (w), 2956 (m), 2925 (s), 2855 (m), 1967 (vw), 1926 (vw), 
1697 (vs), 1608 (s), 1568 (m), 1516 (vs), 1438 (s), 1393 (s), 1367 (s), 1309 (s), 1292 (s), 1251 
(m), 1217 (s), 1174 (m), 1151 (s), 1048 (w), 992 (m), 943 (w), 929 (w), 854 (m), 834 (s), 807 
(vw), 764 (vs), 741 (vs), 703 (m), 648 (m), 611 (w), 543 (w), 503 (w), 459 (vw), 438 (vw), 
419 (vw) cm–1 
 
5.2.20. (E/Z) - Methyl 1-(6-ethoxy-4-ethyl-6-oxohex-4-enyl)-4-(2-
nitrophenyl)-1H-pyrrole-2-carboxylate (239)  
NaH, DMF
0 °C to r.t.
(100%)
N
H
CO2Me
NO2
28
C12H10N2O4
246.22
O
I
O
227
C10H17IO3
296.15
+
239
C22H26N2O6
414.45
N CO2Me
NO2
O
O
 
To a solution of phenylpyrrole 28 (20 g, 0.08 mmol) in dry DMF (0.3 mL) at 0 °C was added 
95% NaH (2 mg, 0.09 mmol) under argon. After 10 min at 0 °C, the solution was stirred at 
room temperature for 1 h. The mixture was cooled to 0 °C, and a solution of iodo acrylate 227 
(26 mg, 0.09 mmol) in dry DMF (0.1 mL) was added dropwise. The flask containing 227 was 
rinsed with an additional 0.2 mL of dry DMF. The resulting solution was stirred at room 
temperature for 6 h, and then poured into water (20 mL) and extracted with EtOAc (3 x 10 
mL). The combined organic extracts were washed with water (2 x 10 mL), brine (15 mL), 
dried over MgSO4, filtered, and concentrated. The product was purified by column 
chromatography (petroleum ether and then petroleum ether/EtOAc, 90:10) to afford 36 mg 
(100%) of E/Z mixture (70:30) of 239 as a yellowish oil. 
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Analytical Data for 239: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.33 
 
MS-ESI: 437.5 (100, [M+Na]+), 453.3 (13, [M+K]+) 
 
HR-MS (ESI): 437.16802 ([M+Na]+; C22H26N2O6Na+; calc. 437.16886) 
 
IR (KBr, film): ν = 3065 (w), 2956 (s), 2874 (m), 1713 (vs), 1645 (s), 1609 (s), 1563 (s), 
1531 (vs), 1495 (s), 1476 (s), 1446 (vs), 1394 (vs), 1368 (vs), 1259 (vs), 1206 (vs), 1148 (vs), 
1105 (vs), 1038 (s), 959 (w), 933 (m), 853 (s), 812 (w), 779 (m), 749 (vs), 696 (m), 674 (vw), 
651 (w), 561 (vw), 509 (vw), 445 (vw) cm–1 
 
Analytical Data for (E)-239: 
N
NO2
O
O
O
O
1
2
34
5
2'1'
7
6
8
9
10
11
121314
1516
18
19
17
20
21
N CO2Me
NO2
O
O
1
2
34
5
7
6
8
9
10
11
1213
14
15
16
18
19
17
20
21
H
H
H
H HNOE
NOE
 
1H-NMR (400 MHz, acetone-d6): δ 7.75 (dd, 3JH8,H9 = 7.9 Hz, 4JH8,H10 = 2.4 Hz, 1 H, H8), 
7.68-7.62 (m, 2 H, H10, H11), 7.49 (ddd, 3JH9,H10 = 8.8 Hz, 3JH9,H8 = 8.1 Hz, 4JH9,H11 = 4.3 Hz, 1 
H, H9), 7.35 (d, 4JH5,H3 = 2.1 Hz, 1 H, H5), 6.99 (d, 4JH3,H5  = 2.1 Hz, 1 H, H3), 5.63 (s, 1 H, 
H16), 4.45 (t, 3JH12,H13 = 7.1 Hz, 2 H, H12), 4.08 (q, 3JH20,H21 = 7.1 Hz, 2 H, H20), 3.81 (s, 3 H, 
H2’), 2.64 (q, 3JH18,H19 = 7.5 Hz, 2 H, H18), 2.23 (≈t, 3JH14,H13 = 7.5 Hz, 2 H, H14), 2.00 (≈quint, 
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3JH13,H14 = 3JH13,H12 = 7.3 Hz, 2 H, H13), 1.21 (t, 3JH21,H20 = 7.1 Hz, 3 H, H21), 1.03 (t, 3JH19,H18 = 
7.5 Hz, 3 H, H19)  
1H, NOE diff: irrad H16 (5.63) → enh H14 (2.23) and H13 (2.00) 
 
13C-NMR (100 MHz, acetone-d6): δ 166.4 (C17), 165.1 (C15), 161.6 (C1’), 150.2 (C7), 132.7 
(C10), 131.6 (C11), 128.9 (C6), 128.6 (C5), 128.3 (C9), 124.2 (C8), 123.3 (C2), 119.0 (C4), 117.5 
(C3), 116.0 (C16), 59.8 (C20), 51.5 (C2’), 49.5 (C12), 35.2 (C14), 30.2 (C13), 25.3 (C18), 14.6 
(C21), 13.3 (C19) 
 
GC (method IZ): tR = 21.27 min  
 
Analytical Data for (Z)-239: 
 
 
1H-NMR (400 MHz, acetone-d6): δ 7.75 (dd, 3JH8,H9 = 7.9 Hz, 4JH8,H10 = 2.4 Hz, 1 H, H8), 
7.68-7.62 (m, 2 H, H10, H11), 7.49 (ddd, 3JH9,H10 = 8.8 Hz, 3JH9,H8 = 8.1 Hz, 4JH9,H11 = 4.3 Hz, 1 
H, H9), 7.37 (d, 4JH5,H3 = 2.1 Hz, 1 H, H5), 6.98 (d, 4JH3,H5 = 2.1 Hz, 1 H, H3), 5.66 (s, 1 H, 
H16), 4.44 (t, 3JH12,H13 = 7.2 Hz, 2 H, H12), 4.10 (q, 3JH20,H21 = 7.0 Hz, 2 H, H20), 3.80 (s, 3 H, 
H2’), 2.67 (≈t, 3JH14,H13 = 7.7 Hz, 2 H, H14), 2.22 (dq, 3JH18,H19 = 7.5 Hz, 4JH18,H16 = 1.2 Hz, 2 H, 
H18), 1.97 (≈quint, 3JH13,H14 = 3JH13,H12 = 7.4 Hz, 2 H, H13), 1.22 (t, 3JH21,H20 = 7.1 Hz, 3 H, 
H21), 1.05 (t, 3JH19,H18 = 7.4 Hz, 3 H, H19)  
 
13C-NMR (100 MHz, acetone-d6): δ 166.4 (C17), 164.9 (C15), 161.6 (C1’), 150.2 (C7), 132.7 
(C10), 131.6 (C11), 128.9 (C6), 128.6 (C5), 128.2 (C9), 124.2 (C8), 123.3 (C2), 118.9 (C4), 117.4 
(C3), 115.8 (C16), 60.0 (C20), 51.5 (C2’), 49.9 (C12), 31.5 (C18), 30.9 (C13), 29.6 (C14), 14.3 
(C21), 12.3 (C19) 
 
GC (method IZ): tR = 20.55 min  
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5.2.21. 1H-Pyrrole-2(5H)-one (240) 
 
 
To a solution of pyrrole S3 (5.00 g, 74.5 mmol) in water (450 mL) were added H2O2 (35%, 
6.18 mL, 74.5 mmol) and BaCO3 (1.50 g, 7.6 mmol). The resulting mixture was stirred at 
reflux for 4 h. The excess of oxidant was destroyed with small quantity of PbO2, the inorganic 
salts were filtered through Celite pad, and the filtrate was concentrated in vacuo. The residue 
was purified by bulb-to-bulb distillation (T=100-130 °C), P=0.5 mmHg) to give 1.8 g (29%) 
of 240 as a light yellow oil. 
 
Analytical Data for 240: 
 
1H-NMR (400 MHz, CDCl3): δ 6.91 (dq, 3JH3,H4 = 5.6 Hz, 4JH3,H5 = 4JH3,H1 = 1.7 Hz, 1 H, H3), 
5.85 (≈dq, 3JH4,H3 = 5.6 Hz, 3JH4,H5 = 4JH4,H1 ≈ 1.9 Hz, 1 H, H4), 3.78 (≈q, 3JH5,H1 ≈ 3JH5,H4 ≈ 
4JH5,H3 ≈ 1.8 Hz, 2 H, H5)  
 
13C-NMR (100 MHz, CDCl3): δ 175.9 (C2), 146.5 (C3), 127.6 (C4), 49.3 (C5) 
 
MS-ESI: 84.1 (100, [M+H]+) 
 
IR (KBr, film): ν = 3271 (m), 1672 (vs), 1583(w), 1449 (w), 1245 (w), 1101 (vw), 1055 
(vw), 943 (vw), 807 (m), 692 (w), 485 (vw) cm–1 
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5.2.22. Perfluorophenyl 4-oxopentanoate (243)56 
 
To a stirred solution of levulinic acid (242) (0.96 mL, 9.38 mmol) in dry CH2Cl2 (40 mL) at 0 
°C and under argon was added pentafluorophenol (1.90 g, 10.32 mmol) followed by N,N'-
dicyclohexylcarbodiimide (2.17 g, 10.51 mmol). The reaction mixture was allowed to warm 
to room temperature and stirred for 18 h, then was filtered through a plug of Celite (eluting 
with 40 mL of CH2Cl2) and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel using CH2Cl2 as eluent to afford 2.90 g (85%) of 243 as a 
colourless oil which solidifies upon cooling in a refrigerator overnight. 
 
Analytical Data for 243: 
 
TLC: Rf (CH2Cl2) = 0.43 
 
MS-ESI: 304.9 (100, [M+Na]+), 301.1 (86, [M+H2O+H]+) 
 
1H-NMR (400 MHz, CDCl3): δ 2.96-2.88 (m, 4 H, H2, H3), 2.23 (s, 3 H, H5)  
 
13C-NMR (100 MHz, CDCl3): δ 205.3 (C4), 168.9 (C1), 142.3 (ar.), 139.9 (ar.), 139.1 (ar.), 
138.2 (ar.), 136.6 (ar.), 125.0 (ar.), 37.7 (C3), 29.7 (C5), 27.2 (C2)  
 
19F-NMR (376 MHz, CDCl3): δ -153.5 (d, 3JF7,F8 = 3JF7’,H8’ = 18.2 Hz, 2 F, A2B2, F7, F7’), -
159.0 (t, 3JF9,F8 = 3JF9,F8’ = 21.7 Hz, 1 F, A2B2, F9), -163.4 (≈t, 3JF8,F7 = 3JF8,F9 = 3JF8’,F7’ = 3JF8’,F9 
= 19.9 Hz, 2 F, A2B2, F8, F8’)  
 
IR (KBr, film): ν = 3556 (vw), 3419 (vw), 2953 (m), 2669 (w), 2461 (w), 2141 (w), 2097 
(w), 1783 (vs), 1717 (vs), 1657 (m), 1521 (vs), 1470 (m), 1418 (vs), 1365 (s), 1346 (m), 1317 
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(vs), 1302 (vs), 1154 (vs), 1118 (vs), 1077 (vs), 1039 (s), 991 (vs), 913 (s), 839 (m), 753 (m), 
701 (vw), 622 (m), 580 (s), 488 (w), 428 (m) cm–1 
5.2.23. 1-(2-Oxo-2,5-dihydro-1H-pyrrol-1-yl)pentane-1,4-dione (244) 
 
 
To a solution of pyrrol-2-one 240 (0.5 g, 6.02 mmol) in dry THF (80 mL) was added 
dropwise BuLi (1.6 M in cyclohexane, 4.21 mL, 6.74 mmol) at 0 °C and under argon. After 
1.5 h at 0 °C, a solution of activated ester 243 (1.92 g, 6.80 mmol) in dry THF (30 mL) was 
added dropwise over 15 min. The mixture was allowed to stir for an additional 30 min at 0 °C, 
then 3 h at room temperature. The resulting mixture was quenched with a solution of saturated 
NH4Cl (20 mL) and extracted with CHCl3 (3 x 40 mL). The combined organic phases dried 
over Na2SO4, filtered and concentrated.   The product was purified by column 
chromatography on silica gel (CH2Cl2/MeOH, 9:1) to afford 332 mg (30%) of 244 as an 
orange oil.  
 
Analytical Data for 244: 
 
TLC: Rf (CH2Cl2/MeOH, 9:1) = 0.56 
 
1H-NMR (400 MHz, CDCl3): δ 7.31-7.30 (m, 1 H, H3), 6.19-6.18 (m, 1 H, H4), 4.40-4.39 (m, 
2 H, H5), 3.25-3.22 (m, 2 H, H7), 2.83-2.80.71 (m, 2 H, H8), 2.23 (s, 3 H, H10)  
 
13C-NMR (100 MHz, CDCl3): δ 207.2 (C9), 172.2 (C6), 170.2 (C2), 146.8 (C3), 127.8 (C4), 
50.7 (C5), 37.1 (C8), 30.8 (C7), 30.1 (C10) 
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5.2.24. (E/Z)- 1-Methyl 6-perfluorophenyl 3-methylhex-2-enedioate (245) 
 
 
 
A flame-dried 25 mL two-necked round bottom flask was charged with NaH (333 mg of 95%, 
13.88 mmol) and 10 mL of dry THF. Neat methyl diethylphosphonoacetate (2.24 mL, 12.20 
mmol) was then added slowly (in 5 min.) to the suspension at 0 °C. The resulting mixture was 
stirred at room temperature for 45 min and a solution of the ketone 243 (0.50 g, 1.77 mmol) in 
dry THF (5 mL) was added. The homogeneous mixture was stirred for 24 h at room 
temperature. The reaction mixture was diluted with brine (20 mL) and extracted with Et2O (3 
x 20 mL). The combined organic phases were dried over MgSO4, filtered and concentrated. 
The residue was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 
90:10) to afford 140 mg (24%) of E/Z mixture (70:30) of 245 as a clear, slightly yellowish oil. 
 
Analytical Data for 245: 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.51 
 
MS (EI, 70 eV): 395.2 (88, [M+K+H2O]+), 209.1 (100) 
 
Analytical Data for (E)-245: 
 
1H-NMR (400 MHz, CDCl3): δ 5.67 (≈q, 4JH2,H7 = 1.3 Hz, 1 H, H2), 3.69 (s, 3 H, H8), 2.50-
2.47 (m, 4 H, H4, H5), 2.16 (d, 4JH7,H2 = 1.3 Hz, 3 H, H7)  
 
1H, NOE diff: irrad H7 (2.61) → enh H4 and H5 (2.50-2.47)  
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13C-NMR (100 MHz, CDCl3): δ 173.1 (C6), 167.1 (C1), 157.8 (C3), 139.2 (2 x ar.), 136.7 (2 x 
ar.), 134.0 (ar.), 131.3 (ar.), 115.8 (C2), 51.0 (C8), 35.5 (C4), 31.9 (C5), 18.7 (C7) 
 
19F-NMR (376 MHz, CDCl3): δ -164.2 (dd, 3JF10,F11 = 3JF10’,F11’ = 17.5 Hz, 4JF10,F12 = 4JF10’,F12 
= 5.5 Hz, 2 F, A2B2, F10, F10’), -164.9 (≈dt, 3JF11,F12 = 3JF11’,F12 = 3JF11,F10’ = 3JF11’,F10’ = 21.8 Hz, 
4JF11,F11’ = 4JF11’,F11 = 4.3 Hz, 2 F, A2B2, F11, F11’), -169.8 (tt, 3JF12,F11 = 3JF12,F11’ = 22.0 Hz, 
4JF12,F10 = 4JF12,F10’ = 5.5 Hz, 2 F, A2B2, F13, F13’)  
 
Analytical Data for (Z)-245: 
 
 
1H-NMR (400 MHz, CDCl3): δ 5.71 (≈tq, 4JH2,H7 = 1.4 Hz, 4JH2,H4 = 0.6 Hz, 1 H, H2), 3.68 (s, 
3 H, H8), 2.91 (≈t, 3JH4,H5 = 7.6 Hz, 2 H, H4), 2.53-2.51 (m, 2 H, H5), 1.91 (d, 4JH7,H2 = 1.4 Hz, 
3 H, H7)  
 
1H, NOE diff: irrad H7 (1.91) → enh H2 (5.71), H4 (2.91) and H5 (2.53-2.51) 
 
13C-NMR (100 MHz, CDCl3): δ 173.5 (C6), 166.6 (C1), 158.4 (C3), 139.2 (2 x ar.), 136.7 (2 x 
ar.), 134.0 (ar.), 131.3 (ar.), 116.9 (C2), 51.8 (C8), 32.4 (C5), 28.7 (C4), 25.1 (C7) 
 
19F-NMR (376 MHz, CDCl3): δ -164.2 (dd, 3JF10,F11 = 3JF10’,F11’ = 17.5 Hz, 4JF10,F12 = 4JF10’,F12 
= 5.5 Hz, 2 F, A2B2, F10, F10’), -164.9 (≈dt, 3JF11,F12 = 3JF11’,F12 = 3JF11,F10’ = 3JF11’,F10’ = 21.8 Hz, 
4JF11,F11’ = 4JF11’,F11 = 4.3 Hz, 2 F, A2B2, F11, F11’), -169.8 (tt, 3JF12,F11 = 3JF12,F11’ = 22.0 Hz, 
4JF12,F10 = 4JF12,F10’ = 5.5 Hz, 2 F, A2B2, F13, F13’)  
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5.2.25. (E/Z)-Ethyl 3-ethyl-6-(4-(2-nitrophenyl)-2-oxo-2,5-dihydro-1H-
pyrrol-1-yl)-6-oxohex-2-enoate (246) 
 
 
To a solution of pyrrolinone 235 (50 mg, 0.25 mmol) in dry THF (3.0 mL) was added 
dropwise BuLi (2.0 M in cyclohexane, 0.13 mL, 0.25 mmol) at -55 °C and under argon. After 
10 min at -54 °C, a solution of activated ester 229 (98 mg, 0.27 mmol) in dry THF (2.0 mL) 
was added dropwise over 15 min. The mixture was allowed to stir for an additional 5 min. 
Over this 30 min period, the temperature had been allowed to reach -45 °C. The mixture was 
quenched with AcOH (0.1 mL) and evaporated with 5 mL of silica. The product was purified 
by column chromatography on silica gel (cyclohexane/EtOAc, 70:30 to 50:50) to afford 43 
mg (45%) of E/Z mixture (70:30) of 246 as an orange oil.  
 
Analytical Data for 246: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 50:50) = 0.45 
 
HPLC-MS (EI, 70 eV): tR = 6.94 min ((E)-57); 7.08 min ((Z)-57); m/z (%) = 425.1 (11, 
[M+K]+), 409.2 (100, [M+Na]+), 387.2 (14, [M+H]+) 
 
HR-MS (ESI): 409.13695 ([M+Na]+; C20H22N2O6Na+; calc. 409.13756) 
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IR (KBr, film): ν = 3079 (vw), 2979 (w), 2924 (w), 1744 (s), 1713 (vs), 1683 (s), 1646 (s), 
1601 (w), 1570 (w), 1531 (s), 1478 (w), 1446 (m), 1373 (m), 1349 (s), 1319 (s), 1259 (m), 
1239 (s), 1208 (s), 1190 (s), 1172 (s), 1152 (s), 1085 (w), 1048 (m), 984 (w), 897 (w), 882 
(w), 866 (m), 796 (w), 755 (m), 726 (w), 697 (w), 688 (w), 646 (vw), 629 (vw), 574 (vw), 533 
(vw) cm–1 
 
Analytical Data for (E)-246: 
 
1H-NMR (400 MHz, CDCl3): δ 8.11-8.08 (m, 1 H, H8), 7.73 (td, 3JH10,H11 = 3JH10,H9obs. = 7.3 
Hz, 4JH10,H8obs. = 2.4 Hz,  1 H, H10), 7.67-7.62 (m, 1 H, H9), 7.41 (dd, 3JH11,H10 = 7.2 Hz, 
4JH11,H9obs. = 2.3 Hz, 1 H, H11), 6.15 (t, 4JH3,H5 = 1.5 Hz, 1 H, H3), 5.71 (s, 1 H, H16), 4.64 (d, 
4JH5,H3 = 1.5 Hz, 2 H, H5), 4.15 (q, 3JH20,H21 = 7.1 Hz, 2 H, H20), 3.21-3.13 (m, 2 H, H13), 2.68 
(q, 3JH18,H19 = 7.5 Hz, 2 H, H18), 2.23 (td, 3JH14,H13 = 7.6 Hz, 4JH14,H16 = 0.8 Hz, 2 H, H14), 1.28 
(t, 3JH21,H20 = 7.1 Hz, 3 H, H21), 1.12 (t, 3JH19,H18 = 7.5 Hz, 3 H, H19)  
 
13C-NMR (100 MHz, CDCl3): δ 171.8 (C12), 168.7 (C2), 166.3 (C17), 163.5 (C15), 156.8 (C4), 
147.6 (C7), 133.6 (C10), 130.9 (C9), 130.1 (C11), 128.0 (C6), 125.1 (C8), 124.5 (C3), 115.5 
(C16), 59.6 (C20), 52.3 (C5), 34.7 (C13), 31.8 (C14), 25.5 (C18), 14.3 (C21), 13.0 (C19) 
 
Analytical Data for (Z)-246: 
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1H-NMR (400 MHz, CDCl3): δ 8.11-8.08 (m, 1 H, H8), 7.73 (td, 3JH10,H11 = 3JH10,H9obs. = 7.3 
Hz, 4JH10,H8obs. = 2.4 Hz,  1 H, H10), 7.67-7.62 (m, 1 H, H9), 7.41 (dd, 3JH11,H10 = 7.2 Hz, 
4JH11,H9obs. = 2.3 Hz, 1 H, H11), 6.13 (t, 4JH3,H5 = 1.5 Hz, 1 H, H3), 5.69 (s, 1 H, H16), 4.64 (d, 
4JH5,H3 = 1.5 Hz, 2 H, H5), 4.14 (q, 3JH20,H21 = 7.1 Hz, 2 H, H20), 3.21-3.13 (m, 2 H, H13), 2.97 
(≈t, 3JH14,H13 = 7.9 Hz, 2 H, H14), 2.26 (q, 3JH18,H19 = 7.3 Hz, 2 H, H18), 1.27 (t, 3JH21,H20 = 7.1 
Hz, 3 H, H21), 1.11 (t, 3JH19,H18 = 7.3 Hz, 3 H, H19) 
 
13C-NMR (100 MHz, CDCl3): δ 172.2 (C12), 168.7 (C2), 166.4 (C17), 163.5 (C15), 156.5 (C4), 
147.6 (C7), 133.5 (C10), 130.8 (C9), 130.1 (C11), 128.1 (C6), 125.0 (C8), 124.6 (C3), 115.6 
(C16), 59.6 (C20), 52.3 (C5), 35.4 (C13), 31.4 (C18), 26.9 (C14), 14.3 (C21), 11.9 (C19) 
 
5.2.26. (E/Z)- Ethyl 6-(2-((tert-butyldimethylsilyl)oxy)-4-(2-nitrophenyl)-
1H-pyrrol-1-yl)-3-ethyl-6-oxohex-2-enoate (257) 
 
2,6-Lutidine, TBSOTf
CH2Cl2, 15 min, r.t.
(69%)
257
C26H36N2O6Si
500.66
N O
NO2
O
O
O
Si
246
C20H22N2O6
386.40
N O
NO2
O
O
O
 
 
To a stirred solution of pyrrolinone 246 (40 mg, 0.11 mmol) in dry CH2Cl2 (1 mL) at room 
temperature and under argon was added 2,6-lutidine (0.04 g, 0.31 mmol) followed by 
TBSOTf (0.02 mL, 0.11 mmol). The reaction mixture was stirred at room temperature for 15 
min (reaction progress monitored by TLC) and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (cyclohexane/EtOAc, 90:10) to afford 36 mg 
(69%) of E/Z mixture (60:40) of 257 as a yellow oil.  
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Analytical Data for 257: 
 
TLC: Rf (Cyclohexane/EtOAc, 90:10) = 0.39 
 
MS-ESI: 539.4 (7, [M+K]+), 423.5 (100, [M+Na]+), 501.5 (8, [M+H]+) 
 
HR-MS (ESI): 523.22399 ([M+Na]+; C26H36N2O6SiNa+; calc. 523.22403) 
 
Analytical Data for (E)-257: 
 
H-NMR (400 MHz, CDCl3): δ 7.70 (ddd, 3JH8,H9 = 8.0 Hz, 4JH8,H10 = 4.2 Hz, 5JH8,H11 = 1.2 Hz, 
1 H, H8), 7.54 (ddd, 3JH11,H10 = 7.8 Hz, 4JH11,H9obs. = 2.7 Hz, 5JH11,H8 = 1.2 Hz, 1 H, H11), 7.51-
7.47 (m (partially solved), 3JH10,H11 = 7.8 Hz, 4JH10,H8 = 4.2 Hz,  1 H, H10), 7.40-7.35 (m 
(partially solved), 3JH9,H8 = 8.0 Hz, 1 H, H9), 7.17 (d, 4JH5,H3 = 2.3 Hz, 1 H, H5), 5.66 (s, 1 H, 
H16), 5.28 (d, 4JH3,H5 = 2.3 Hz, 1 H, H3), 4.15 (q, 3JH20,H21 = 7.2 Hz, 2 H, H20), 3.13-3.08 (m, 2 
H, H13), 2.66 (q, 3JH18,H19 = 7.5 Hz, 2 H, H18), 2.62 (dd, 3JH14,H13a = 7.7 Hz, 3JH14,H13b = 6.4 Hz, 
2 H, H14), 1.28 (t, 3JH21,H20 = 7.2 Hz, 3 H, H21), 1.11 (t, 3JH19,H18 = 7.5 Hz, 3 H, H19), 1.00 (s, 9 
H, H3’), 0.32 (s, 6 H, H1’) 
  
13C-NMR (100 MHz, CDCl3): δ 169.9 (C12), 166.1 (C17), 163.4 (C15), 149.0 (C7), 143.0 (C2), 
132.1 (C11), 130.8 (C10), 129.0 (C6), 127.7 (C9), 123.8 (C8), 120.4 (C4), 115.6 (C16), 109.7 
(C5), 91.8 (C3), 59.6 (C20), 35.3 (C13), 31.7 (C14), 25.7 (C3’), 25.6 (C18), 18.3 (C2’), 14.3 (C21), 
13.0 (C19) 
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Analytical Data for (Z)-257: 
 
 
1H-NMR (400 MHz, CDCl3): δ 7.70 (ddd, 3JH8,H9 = 8.0 Hz, 4JH8,H10 = 4.2 Hz, 5JH8,H11 = 1.2 
Hz, 1 H, H8), 7.54 (ddd, 3JH11,H10 = 7.8 Hz, 4JH11,H9obs. = 2.7 Hz, 5JH11,H8 = 1.2 Hz, 1 H, H11), 
7.51-7.47 (m (partially solved), 3JH10,H11 = 7.8 Hz, 4JH10,H8 = 4.2 Hz,  1 H, H10), 7.40-7.35 (m 
(partially solved), 3JH9,H8 = 8.0 Hz, 1 H, H9), 7.20 (d, 4JH5,H3 = 2.3 Hz, 1 H, H5), 5.71 (s, 1 H, 
H16), 5.25 (d, 4JH3,H5 = 2.3 Hz, 1 H, H3), 4.13 (q, 3JH20,H21 = 7.1 Hz, 2 H, H20), 3.13-3.08 (m, 2 
H, H13), 2.96 (dd, 3JH14,H13a = 9.0 Hz, 3JH14,H13b = 6.7 Hz, 2 H, H14), 2.23 (qd, 3JH18,H19 = 7.4 
Hz, 4JH18,H16 obs. = 1.3 Hz, 2 H, H18), 1.26 (t, 3JH21,H20 = 7.1 Hz, 3 H, H21), 1.10 (t, 3JH19,H18 = 7.4 
Hz, 3 H, H19), 0.95 (s, 9 H, H3’), 0.28 (s, 6 H, H1’) 
 
13C-NMR (100 MHz, CDCl3): δ 170.4 (C12), 166.2 (C17), 163.8 (C15), 149.1 (C7), 143.1 (C2), 
132.0 (C11), 130.8 (C10), 129.2 (C6), 127.5 (C9), 123.7 (C8), 120.1 (C4), 115.6 (C16), 109.7 
(C5), 91.5 (C3), 59.7 (C20), 36.4 (C13), 31.8 (C18), 27.1 (C14), 25.7 (C3’), 18.1 (C2’), 14.1 (C21), 
12.0 (C19) 
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5.2.27. 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-
(triisopropylsilyl)-1H-pyrrole (143)43 
A glass microwave tube was initially charged with PdCl2(CH3CN)2 (6 mg, 0.02 mmol, 3 mol 
%) and SPhos (28 mg, 0.07 mmol, 9 mol %). The vial was sealed with a Teflon-coated screw 
cap, a needle was inserted through the cap and the vial was then evacuated and backfilled with 
argon. 1.5 mL of dry and degased toluene were added at room temperature. To a resulting 
mixture were added dropwise 3-bromo-1-(triisopropyl-silanyl)-1H-pyrrole (141) (0.2 mL, 
0.75 mmol) followed by triethylamine (0.26 mL, 1.88 mmol) and pinacolborane (0.13 mL, 
0.90 mmol). The resulting mixture was heated at 90 °C for 3.5 h, and then allowed to cool to 
room temperature. The reaction solution was filtered through a thin pad of Al2O3 (eluting with 
35 mL of EtOAc), and the eluent was concentrated under reduced pressure. The crude 
material so obtained was purified by flash chromatography on silica gel (petroleum ether and 
then petroleum ether/EtOAc, 20:1) to afford 262 mg (100 %) of 143 as a yellow solid. 
Analytical Data for 143: 
TLC: Rf (Petroleum ether/EtOAc, 95:5) = 0.28 
1H-NMR (400 MHz, CDCl3): δ 7.23 (t, 4JH2,H4 = 4JH2,H5 = 1.4 Hz, 1 H, H2), 6.81 (t, 3JH5,H4 = 
2.4 Hz, 1 H, H5), 6.62 (dd, 3JH4,H5 = 2.5 Hz, 4JH4,H2 = 1.2 Hz, 1 H, H4), 1.46 (sept, 3JH1’,H2’ = 7.5 
Hz, 3 H, H1’), 1.32 (s, 12 H, H2’’’), 1.09 (d, 3JH2’,H1’ = 7.5 Hz, 18 H, H2’) 
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13C-NMR (100 MHz, CDCl3): δ 133.7 (C2), 125.0 (C5), 115.6 (C4), 82.7 (C3), 24.9 (C2’’), 
17.8 (C2’), 11.7 (C1’) 
 
MS-ESI: 350.3 (100, [M+Na]+) 
5.2.28. 3-(2-Nitrophenyl)-1-(triisopropylsilyl)-1H-pyrrole (44)37 
 
 
In an over-dried glass microwave flask, the solid starting materials were combined: N-
(TIPS)pyrrole pinacol boronate 143 (230 mg, 0.66 mmol), 2-bromo-nitrobenzene (238) (111 
mg, 0.55 mmol), palladium acetate (6 mg, 0.03 mmol), 2-dicyclohexyl-phosphino-2′,6′-
dimethoxybiphenyl (23 mg, 0.06 mmol), and K3PO4 (233 mg, 1.10 mmol). The vial was 
sealed with a Teflon-coated screw cap, a needle was inserted through the cap and the vial was 
then evacuated and backfilled with argon. The solvent system (1.10 mL, 2.0 mL/mmol 2-
bromo-nitrobenzene), consisting of degassed n-butanol (0.78 mL) and degassed deionized 
water (0.32 mL) in the ratio of 2.5:1 was added. The resulting mixture was heated at 35 °C for 
16 h. The crude reaction mixture was then filtered through a plug of silica gel (eluting with 30 
mL of EtOAc) and concentrated in vacuo. The crude material so obtained was purified by 
flash chromatography on silica gel (petroleum ether and then petroleum ether/EtOAc 
gradually to 20:1) to provide 189 mg (100%) of desired TIPS-protected phenylpyrrole 253 as 
a yellow oil. 
 
Analytical Data for 253: 
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TLC: Rf (Petroleum ether/EtOAc, 95:5) = 0.32 
 
1H-NMR (400 MHz, acetone-d6): δ 7.66 (dd, 3JH11,H10 = 7.8 Hz, 4JH11,H9 = 1.3 Hz, 1 H, H11), 
7.65 (dd, 3JH8,H9 = 8.1 Hz, 4JH8,H10 = 1.2 Hz, 1 H, H8), 7.58 (dt, 3JH10,H11 = 3JH10,H9 = 7.6 Hz, 
4JH10,H8 = 1.3 Hz, 1 H, H10), 7.40 (ddd, 3JH9,H8 = 8.0 Hz, 3JH9,H10 = 7.4 Hz, 4JH9,H11 = 1.3 Hz, 1 
H, H9), 7.05 (t, 4JH2,H4 = 4JH2,H5 = 1.7 Hz, 1 H, H2), 6.92 (≈t, 3JH5,H4 = 2.6 Hz, 1 H, H5), 6.41 
(dd, 3JH4,H5 = 2.8 Hz, 4JH4,H2 = 1.5 Hz, 1 H, H4), 1.55 (sept, 3JH1’,H2’ = 7.5 Hz, 3 H, H1’), 1.13 (d, 
3JH2’,H1’ = 7.5 Hz, 18 H, H2’) 
 
13C-NMR (100 MHz, acetone-d6): δ 150.3 (C7), 132.2 (C10), 131.3 (C11), 130.0 (C6), 127.3 
(C9), 126.2 (C5), 123.8 (C8), 123.7 (C2), 121.8 (C3), 111.0 (C4), 18.1 (C2’), 12.7 (C1’) 
 
HPLC-MS (EI, 70 eV): tR = 17.1 min; m/z (%) = 345.4 (100, [M+H]+) 
 
HR-MS (ESI): 367.18132 ([M+Na]+; C19H28N2O2SiNa+; calc. 367.18177) 
 
5.2.29. 3-(2-Nitrophenyl)-1H-pyrrole (45)37 
 
 
Tetrabutylammonium fluoride (1.0 M in THF, 1.03 mL, 1.03 mmol) was added dropwise to a 
solution of TIPS-protected phenylpyrrole 253 (177 mg, 0.51 mmol) in dry THF (1.0 mL) at 
room temperature and under argon. The reaction vessel was covered in aluminium foil to 
minimize light exposure; the mixture was stirred at room temperature for 1.5 h (reaction 
progress monitored by TLC). The reaction mixture was quenched with a saturated aqueous 
NH4Cl (10 mL) and the resulting biphasic mixture was transferred to a separatory funnel. The 
organic and aqueous layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 10 mL). Combined organic extracts were washed with brine (10 mL), dried over MgSO4, 
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filtered and evaporated. The residue was purified by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10 to 80:20) to afford 97 mg (100%) of deprotected 
phenylpyrrole 254 as a yellow oil.  
 
Analytical Data for 254: 
 
 
TLC: Rf (Petroleum ether/EtOAc, 80:20) = 0.22 
 
GC (method IZ): tR = 11.88 min 
 
1H-NMR (400 MHz, acetone-d6): δ 10.37 (br s, 1 H, NH), 7.64-7.62 (m, 2 H, H11, H8), 7.57 
(ddd, 3JH10,H11 obs. = 8.1 Hz, 3JH10,H9 obs. = 7.2 Hz, 4JH10,H8 = 1.2 Hz, 1 H, H10), 7.38 (ddd, 3JH9,H8 
= 7.9 Hz, 3JH9,H10 = 7.2 Hz, 4JH9,H11 = 1.6 Hz, 1 H, H9), 7.05 (td, 3JH2,H1 = 2.8 Hz, 4JH2,H4 = 
4JH2,H5 = 1.7 Hz, 1 H, H2), 6.87 (dt, 3JH5,H4 = 3JH5,H1 = 2.7 Hz, 4JH5,H2 = 2.0 Hz, 1 H, H5), 6.26 
(dt, 3JH4,H5 = 2.6 Hz, 4JH4,H2 = 4JH4,H1 = 1.7 Hz, 1 H, H4) 
 
13C-NMR (100 MHz, acetone-d6): δ 150.3 (C7), 132.2 (C10), 131.3 (C11), 130.4 (C6), 127.0 
(C9), 123.7 (C8), 120.0 (C5), 119.1 (C3), 117.8 (C2), 108.1 (C4) 
 
MS-ESI: 205.1 (100, [M-H+H2O]-), 287.2 (66, [M-H]-) 
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5.3. Experimental procedures and characterization data 
associated with compounds described in Chapter Three 
 
5.3.1. Preparation of 1-(2-nitrophenyl)ketones: General Procedure: 
 
 
 
To a solution of the 2-iodonitrobenzene (8.03 mmol, 1.0 equiv.) in dry THF (56 mL, 0.14 M) 
phenylmagnesium chloride (2.0 M in THF, 8.84 mmol, 1.1 equiv.) was added dropwise over a 
period of 10 min at −40 °C and under argon. The red solution was stirred for another 10 min, 
and then the corresponding aldehyde (9.64 mmol, 1.2 equiv.) was added dropwise over a 
period of 5 min. The reaction mixture was stirred for 0.5 h at −40 °C, and then quenched with 
a saturated aqueous NH4Cl (10 mL) and poured into water (100 mL). The aqueous layer was 
extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated. The crude alcohol was engaged in the next step without further 
purification. 
 
Preparation of Jones’ reagent 2.67 M CrO3 in 4.14 M H2SO4 (6.5 mL): Water (5.0 mL) was 
added dropwise to a solution of CrO3 (1.72 g, 17.18 mmol) in 1.5 mL of 98% H2SO4 at 0 °C. 
To a stirred solution of the corresponding alcohol (8.03 mmol, 1.0 equiv.) in acetone (13 mL, 
0.6 M) at 0 °C was added dropwise a freshly prepared Jones’ reagent (2.67 M, 6.5 mL, ca. 2.1 
equiv.). The resulting yellow-brown reaction mixture was stirred at 0 °C for 1 h (reaction 
progress monitored by TLC), before it was quenched with iPrOH (15 mL) and warmed to 
room temperature for 10 min. The crude reaction mixture was then filtered through a plug of 
Celite (eluting with 100 mL of Et2O) and concentrated in vacuo. The organic residue was 
taken up in Et2O (100 mL) and washed with brine (50 mL), dried over Na2SO4, filtered and 
concentrated. The crude ketone was purified by flash chromatography on silica gel.  
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5.3.2. 1-(2-Nitrophenyl)propan-1-one (261a) 
 
 
1-(2-Nitrophenyl)propan-1-ol (266a) was prepared from 2-iodonitrobenzene (75) (2.0 g, 8.03 
mmol), phenylmagnesium chloride (2.0 M in THF, 4.42 mL, 8.84 mmol) and propanal (S4) 
(0.75 mL, 9.64 mmol) in dry THF (56 mL). The crude alcohol was engaged in the next step 
without further purification. Rf (CH2Cl2, 100%) = 0.34. GC (method IZ): tR = 9.42 min. 
 
 
 
1-(2-Nitrophenyl)propan-1-one (261a) was prepared from the crude 1-(2-nitrophenyl)propan-
1-ol (266a) (2.0 g, 8.03 mmol) and Jone’s reagent (2.67 M in H2SO4, 6.5 mL) in acetone (13 
mL). Solvent system for chromatography: cyclohexane/CH2Cl2, 70:30. The product was 
isolated in 69% yield (0.99 g) over the two steps as a yellow oil.  
 
Analytical Data for 261a: 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.27 
 
GC (method IZ): tR = 9.32 min 
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1H-NMR (400 MHz, CDCl3): δ 8.13 (dd, 3JH3’,H4’ = 8.2 Hz, 4JH3’,H5’ = 1.2 Hz, 1 H, H3’), 7.72 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.2 Hz, 1 H, H5’), 7.60 (ddd, 3JH4’,H3’ = 8.2 Hz, 
3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 7.38 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.4 Hz, 
5JH6’,H3’ = 0.3 Hz, 1 H, H6’), 2.79 (q,  3JH2,H3 = 7.2 Hz, 2 H, H2), 1.26 (t,  3JH3,H2 = 7.2 Hz, 3 H, 
H3) 
 
13C-NMR (100 MHz, CDCl3): δ 203.3 (C1), 145.6 (C2’), 138.3 (C1’), 134.3 (C5’), 130.3 (C4’), 
127.3 (C6’), 124.4 (C3’), 36.4 (C2), 8.2 (C3) 
 
MS-EI (70 eV): 180.0 (100, [M+H]+), 150.0 (53, [M-CH3CH2]+), 120.1 (36), 92.1 (19), 51.1 
(31) 
 
5.3.3. 1-(2-Nitrophenyl)butan-1-one (261b) 
 
 
1-(2-Nitrophenyl)butan-1-ol (266b) was prepared from 2-iodonitrobenzene (75) (4.0 g, 16.06 
mmol), phenylmagnesium chloride (2.0 M in THF, 8.83 mL, 17.67 mmol) and butanal (S5) 
(1.76 mL, 19.28 mmol) in dry THF (110 mL). The crude alcohol was engaged in the next step 
without further purification. Rf (CH2Cl2, 100%) = 0.30. GC (method IZ): tR = 10.17 min. 
 
 
 
1-(2-nitrophenyl)butan-1-one (261b) was prepared from the crude 1-(2-nitrophenyl)butan-1-ol 
(266b) (2.0 g, 8.03 mmol) and Jone’s reagent (2.67 M in H2SO4, 13.0 mL) in acetone (26 
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mL). Solvent system for chromatography: cyclohexane/CH2Cl2, 70:30. The product was 
isolated in 68% yield (2.12 g) over the two steps as a yellow oil.  
 
Analytical Data for 266b: 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.27 
 
GC (method IZ): tR = 10.09 min 
 
1H-NMR (400 MHz, CDCl3): δ 8.10 (dd, 3JH3’,H4’ = 8.2 Hz, 4JH3’,H5’ = 1.2 Hz, 1 H, H3’), 7.71 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.2 Hz, 1 H, H5’), 7.58 (ddd, 3JH4’,H3’ = 8.2 Hz, 
3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 7.37 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.4 Hz, 1 
H, H6’), 2.75 (t, 3JH2,H3 = 7.4 Hz, 2 H, H2), 1.77 (sext, 3JH3,H4 = 3JH3,H2 = 7.4 Hz, 2 H, H3), 1.00 
(t, 3JH4,H3 = 7.4 Hz, 3 H, H4) 
 
13C-NMR (100 MHz, CDCl3): δ 202.5 (C1), 145.6 (C2’), 138.2 (C1’), 134.2 (C5’), 130.3 (C4’), 
127.3 (C6’), 124.3 (C3’), 44.8 (C2), 17.3 (C3), 13.5 (C4) 
 
HR-MS (ESI): 216.06290 ([M+Na]+; C10H11NO3Na+; calc. 216.06366) 
 
IR (KBr): ν = 3071 (vw), 2966 (s), 2936 (m), 2877 (m), 2378 (vw), 1708 (vs), 1604 (w), 
1575 (m), 1530 (vs), 1465 (m), 1442 (w), 1402 (m), 1348 (vs), 1309 (m), 1277 (w), 1211 (s), 
1166 (vw), 1147 (vw), 1112 (vw), 1087 (vw), 1051 (vw), 1004 (w), 991 (w), 962 (vw), 900 
(vw), 854 (m), 822 (vw), 789 (s), 752 (m), 729 (m), 702 (m), 641 (vw), 556 (vw), 409 (vw) 
cm–1 
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5.3.4. Preparation of α-bromoketones: General Procedure: 
 
To an ice-cooled solution of the ketone 213 (40 mmol, 1.0 equiv.) in CCl4 (100 mL) bromine 
(40 mmol, 1.0 equiv.) was added dropwise at such a rate as to obtain a continuous 
discoloration. The almost colourless solution was stirred for another 15 min at room 
temperature (reaction progress monitored by TLC), and then the reaction was quenched with a 
saturated aqueous NaHCO3 (100 mL). The aqueous layer was extracted with CH2Cl2 (2 x 40 
mL). The combined organic layers were washed with Na2S2O3 (0.1 M, 80 mL), dried over 
Na2SO4, filtered and concentrated. The α-bromoketone 272 was purified by flash 
chromatography (in some batches we observed 1-2% 2,2-dibromoketone). 
 
5.3.5. 2-Bromo-1-phenylbutan-1-one (272c) 
 
 
Prepared from butyrophenone 213c (6.0 g, 40.5 mmol) and bromine (2.08 mL, 40.5 mmol) in 
CCl4 (120 mL). Solvent system for chromatography: cyclohexane/CH2Cl2, 50:50. The product 
was isolated quantitatively (9.19 g) as a slightly yellow oil.  
 
Analytical Data for 272c: 
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TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.37 
 
1H-NMR (400 MHz, CDCl3): δ 8.02-8.00 (m (partially solved), 3JH2’,H3’obs. = 8.4 Hz, 4JH2’,H4’ 
= 2.0 Hz, 2 H, H2’), 7.60 (t, 3JH4’,H3’obs. = 7.4 Hz, 4JH4’,H2’ = 2.0 Hz, 1 H, H4’), 7.52-7.47 (m, 2 
H, H3’), 5.08 (dd, 3JH2,H3b = 7.8 Hz, 3JH2,H3a = 6.4 Hz, 1 H, H2), 2.25 (quint d, 3JH3a,H4 = 2JH3a,H3b 
= 7.3 Hz, 3JH3a,H2 = 6.4 Hz, 1 H, H3a), 2.14 (sext,  3JH3b,H4 = 3JH3b,H2 = 2JH3b,H3a = 7.3 Hz, 1 H, 
H3b), 1.09 (t, 3JH4,H3 = 7.3 Hz, 3 H, H4) 
 
13C-NMR (100 MHz, CDCl3): δ 193.2 (C1), 134.5 (C1’), 133.6 (C4’), 128.8 and 128.7 (C2’ 
and C3’), 49.0 (C2), 26.9 (C3), 12.2 (C4) 
 
MS-ESI: 248.8 (96, [M (79Br)+Na]+), 250.7 (100, [M (81Br)+Na]+) 
 
IR (KBr, film): ν = 3063 (w), 2973 (s), 2937 (m), 2877 (w), 1966 (vw), 1904 (vw), 1814 
(vw), 1686 (vs), 1597 (m), 1580 (m), 1449 (s), 1381 (m), 1365 (m), 1319 (m), 1295 (m), 1271 
(s), 1225 (vs), 1196 (w), 1160 (m), 1110 (w), 1084 (vw), 1028 (vw), 1003 (m), 930 (vw), 899 
(m), 835 (w), 819 (w), 801 (m), 777 (vw), 722 (m), 704 (s), 686 (s), 658 (m), 646 (w), 618 
(vw), 546 (vw), 485 (vw) cm–1 
 
5.3.6. 2-Bromo-3-methyl-1-phenylbutan-1-one (272d) 
 
 
Prepared from isovalerophenone (213d) (6.0 g, 36.98 mmol) and bromine (1.90 mL, 36.98 
mmol) in CCl4 (110 mL, 0.34 M). Solvent system for chromatography: cyclohexane/CH2Cl2, 
70:30 to 50:50. The product was isolated in 97% yield (8.66 g) as a slightly yellow oil which 
solidified on standing.  
 
Analytical Data for 272d: 
159 
 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 70:30) = 0.21 
 
1H-NMR (400 MHz, CDCl3): δ 8.00 (d, 3JH2’,H3’ = 7.4 Hz, 2 H, H2’), 7.60 (t, 3JH4’,H3’ = 7.4 Hz, 
1 H, H4’), 7.49 (t, 3JH3’,H2’ = 3JH3’,H4’ = 7.5 Hz, 2 H, H3’), 4.94 (d, 3JH2,H3obs. = 8.6 Hz, 1 H, H2), 
2.54-2.42 (m (partially solved), 3JH3,H4a = 3JH3,H4b = 6.6 Hz 1 H, H3), 1.21 (d,  3JH4a,H3 = 6.6 Hz, 
3 H, H4a), 1.03 (d,  3JH4b,H3 = 6.6 Hz, 3 H, H4b) 
 
13C-NMR (100 MHz, CDCl3): δ 193.6 (C1), 135.0 (C1’), 133.6 (C4’), 128.8 and 128.7 (C2’ 
and C3’), 55.9 (C2), 31.0 (C3), 20.7 (C4b), 20.4 (C4a) 
 
MS-ESI: 262.9 (99, [M (79Br)+Na]+), 265.0 (100, [M (81Br)+Na]+) 
 
IR (KBr): ν = 3089 (w), 3064 (w), 3042 (w), 2967 (vs), 2930 (s), 2873 (s), 2341 (w), 1967 
(w), 1908 (vw), 1813 (vw), 1776 (vw), 1678 (vs), 1596 (s), 1579 (s), 1465 (s), 1447 (vs), 
1385 (m), 1369 (vs), 1307 (s), 1289 (vs), 1236 (vs), 1171 (vs), 1124 (m), 1103 (m), 1076 (m), 
1028 (vw), 1011 (s), 1011 (m), 961 (w), 928 (vs), 847 (s), 811 (s), 796 (s), 718 (vs), 684 (vs), 
659 (vs), 606 (vs), 493 (m), 417 (vw) cm–1 
 
5.3.7. 2-Bromo-1-(2-nitrophenyl)propan-1-one (272h) 
O
Br
O
Br2, CCl4
0 °C to r.t., 0.5 h
(85%)
272h
C9H9NO3
179.17
C9H8BrNO3
258.07
NO2 NO2
261a
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Prepared from 1-(2-nitrophenyl)propan-1-one (261a) (187 mg, 1.04 mmol) and bromine (0.05 
mL, 1.04 mmol) in CCl4 (3.0 mL). Solvent system for chromatography: cyclohexane/CH2Cl2, 
50:50. The product was isolated in 85% yield (228 mg) as a slightly yellow oil which 
solidified on standing.  
 
Analytical Data for 272h: 
O
Br
4'
3'
NO2
5'
1
2
3
2'
1'
6'
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.33 
 
GC (method IZ): tR = 10.76 min 
 
1H-NMR (400 MHz, CDCl3): δ 8.23 (ddd, 3JH3’,H4’ = 8.2 Hz, 4JH3’,H5’ = 1.2 Hz, 5JH3’,H6’ = 0.3 
Hz, 1 H, H3’), 7.78 (td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.2 Hz, 1 H, H5’), 7.66 (ddd, 
3JH4’,H3’ = 8.2 Hz, 3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.5 Hz, 1 H, H4’), 7.63 (ddd, 3JH6’,H5’ = 7.5 Hz, 
4JH6’,H4’ = 1.5 Hz, 5JH6’,H3’ = 0.3 Hz, 1 H, H6’), 4.74 (q,  3JH2,H3 = 6.7 Hz, 1 H, H2), 2.01 (d,  
3JH3,H2 = 6.7 Hz, 3 H, H3) 
 
13C-NMR (100 MHz, CDCl3): δ 196.1 (C1), 145.0 (C2’), 135.5 (C1’), 134.7 (C5’), 131.0 (C4’), 
130.9 (C6’), 124.3 (C3’), 47.1 (C2), 20.1 (C3) 
 
MS-EI (70 eV): 259.9 (15, [M (81Br)]+), 257.9 (13, [M (79Br)]+), 178.0 (15, [M-Br]+), 162.0 
(28), 151.0 (43), 150.0 (50), 134.0 (100), 121.1 (58), 104.1 (55), 93.0 (25), 78.1 (28), 76.0 
(48), 65.1 (40), 51.0 (99), 50.0 (48)  
 
IR (KBr): ν = 3103 (vw), 3016 (vw), 3001 (w), 2936 (vw), 2862 (vw), 1703 (vs), 1614 (vw), 
1569 (w), 1531 (vs), 1473 (w), 1449 (m), 1439 (m), 1374 (w), 1342 (vs), 1272 (w), 1225 (s), 
1186 (m), 1145 (w), 1101 (w), 1068 (w), 1040 (vw), 996 (m), 963 (w), 951 (m), 857 (m), 788 
(m), 768 (w), 727 (s), 693 (m), 679 (w), 639 (w), 572 (w), 500 (w), 416 (vw) cm–1 
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5.3.8. 2-Bromo-1-(2-nitrophenyl)butan-1-one (272i) 
 
 
Prepared from 1-(2-nitrophenyl)butan-1-one (261b)( 1.80 g, 9.30 mmol) and bromine (0.48 
mL, 9.30 mmol) in CCl4 (27 mL). Solvent system for chromatography: cyclohexane/CH2Cl2, 
70:30. The product was isolated in 96% yield (2.44 g) as a slightly yellow oil which solidified 
on standing.  
 
Analytical Data for 272i: 
 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.28 
 
GC (method IZ): tR = 11.50 min 
 
1H-NMR (400 MHz, CDCl3): δ 8.21 (ddd, 3JH3’,H4’ = 8.5 Hz, 4JH3’,H5’ = 1.2 Hz, 5JH3’,H6’ = 0.6 
Hz, 1 H, H3’), 7.77 (ddd, 3JH5’,H6’ = 8.0 Hz, 3JH5’,H4’ = 7.4 Hz, 4JH5’,H3’ = 1.2 Hz, 1 H, H5’), 7.65 
(ddd, 3JH4’,H3’ = 8.5 Hz, 3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.5 Hz, 1 H, H4’), 7.64 (ddd, 3JH6’,H5’ = 8.0 
Hz, 4JH6’,H4’ = 1.5 Hz, 5JH6’,H3’ = 0.6 Hz, 1 H, H6’), 4.55 (dd, 3JH2,H3b = 9.2 Hz, 3JH2,H3a = 4.5 Hz, 
1 H, H2), 2.36 (dqd, 2JH3a,H3b = 14.6 Hz, 3JH3a,H4 = 7.3 Hz, 3JH3a,H2 = 4.5 Hz, 1 H, H3a), 2.36 
(ddq, 2JH3b,H3a = 14.6 Hz, 3JH3b,H2 = 9.2 Hz, 3JH3b,H4 = 7.3 Hz, 1 H, H3b), 1.16 (t, 3JH4,H3a = 
3JH4,H3b = 7.3 Hz, 3 H, H4) 
 
13C-NMR (100 MHz, CDCl3): δ 195.9 (C1), 145.0 (C2’), 135.6 (C1’), 134.6 (C5’), 131.1 (C4’), 
130.9 (C6’), 124.2 (C3’), 55.4 (C2), 26.4 (C3), 11.8 (C4) 
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MS-EI (70 eV): 273.8 (16, [M (81Br)]+), 271.8 (20, [M (79Br)]+), 192.0 (13, [M-Br]+), 176.0 
(42), 151.0 (64), 150.0 (68), 134.0 (78), 121.1 (100), 104.1 (28), 93.1 (27), 92.1 (16), 78.1 
(13), 76.1 (35), 65.1 (46), 51.0 (41) 
HR-MS (ESI): 293.97384 ([M (79Br)+Na]+; C10H1079BrNO3Na+; calc. 293.97418), 295.97136 
([M (81Br)+Na]+; C10H1081BrNO3Na+; calc. 295.97213) 
IR (KBr): ν = 3079 (vw), 2974 (w), 1705 (vs), 1572 (w), 1524 (vs), 1370 (m), 1346 (vs), 
1302 (m), 1212 (m), 1010 (w), 903 (w), 860 (w), 789 (w), 761 (w), 728 (w), 700 (m), 572 (w), 
502 (vw) cm–1 
5.3.9. Preparation of α-azidoketones: General Procedures: 
Method A: To a stirred solution of sodium azide (79.26 mmol, 3.0 equiv.) in DMSO (130 
mL) was added the corresponding α-bromoketone (26.42 mmol, 1.0 equiv.) at room 
temperature. After 20 min of vigorous stirring, the mixture was poured onto ice-water (200 
mL) and extracted with ether (3 x 100 mL). The combined organic phases were washed with 
water (4 x 300 mL), dried over Na2SO4, filtered and evaporated in vacuo. The α-azidoketone 
was obtained mostly quantitatively and engaged in the next step without further purification. 
In some cases, the DMSO was still present, and the product was purified by flash 
chromatography. 
Method B: To a stirred solution of sodium azide (6.51 mmol, 3.0 equiv.) in acetone (8 mL) 
was added the corresponding α-bromoketone (2.17 mmol, 1.0 equiv.) at room temperature. 
After 18 h of vigorous stirring, the mixture was filtered to remove inorganic salts and the 
filtrate was concentrated carefully under reduced pressure. The product was purified by flash 
chromatography. 
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5.3.10. 2-Azido-1-phenylpropan-1-one (214c) 
Prepared from 2-bromopropiophenone (272c) (1.81 g, 8.51 mmol) and sodium azide (2.02 g, 
31.07 mmol) in DMSO (50 mL) following method A. The product was isolated quantitatively 
(1.49 g) as a slightly yellow oil.  
Analytical Data for 214c: 
TLC: Rf (Cyclohexane/CH2Cl2, 70:30) = 0.27 
GC (method IZ): tR = 8.74 min 
1H-NMR (400 MHz, CDCl3): δ 7.96-7.93 (m (partially solved), 3JH2’,H3’obs. = 8.2 Hz, 2 H, 
H2’), 6.12(tt, 3JH4’,H3’obs. = 7.4 Hz, 4JH4’,H2’ = 1.2 Hz, 1 H, H4’), 7.52-7.48 (m, 2 H, H3’), 4.71 (q,
3JH2,H3 = 7.0 Hz, 1 H, H2), 1.57 (d, 3JH3,H2 = 7.0 Hz, 3 H, H3) 
13C-NMR (100 MHz, CDCl3): δ 196.7 (C1), 134.3 (C1’), 133.9 (C4’), 128.9 and 128.6 (C2’
and C3’), 58.4 (C2), 16.5 (C3) 
MS-EI (70 eV): 176.0 (17, [M+H]+), 148.0 (5, [M-N2+H]+), 147.0 (2, [M-N2]+), 105.0 (100, 
[M-CH3CHN3]+), 77.2 (44), 51.2 (13) 
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5.3.11. 2-Azido-1-phenylbutan-1-one (214d) 
Prepared from 2-bromo-1-phenylbutan-1-one (272d) (6.0 g, 26.42 mmol) and sodium azide 
(5.15 g, 79.26 mmol) in DMSO (130 mL) following method A. Solvent system for 
chromatography: CH2Cl2, 100%. The product was isolated in 92% yield (4.58 g) as a slightly 
yellow oil.  
Analytical Data for 214d: 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.43 
GC (method IZ): tR = 9.44 min 
1H-NMR (400 MHz, CDCl3): δ 7.93 (d, 3JH2’,H3. = 8.0 Hz, 2 H, H2’), 7.62 (t, 3JH4’,H3’ = 7.7 Hz, 
1 H, H4’), 7.50 (t, 3JH3’,H4’ = 3JH3’,H2’ = 7.7 Hz, 2 H, H3’), 4.53 (dd, 3JH2,H3b obs. = 8.2 Hz, 3JH2,H3a 
obs. = 5.1 Hz, 1 H, H2), 2.05-1.82 (m, 2 H, H3a and H3b), 1.08 (t, 3JH4,H3 = 7.4 Hz, 3 H, H4) 
13C-NMR (100 MHz, CDCl3): δ 196.7 (C1), 134.9 (C1’), 133.8 (C4’), 128.9 (C3’), 128.5 (C2’), 
64.6 (C2), 24.8 (C3), 10.6 (C4) 
MS-ESI: 212.0 (100, [M+Na]+) 
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HR-MS (ESI): 212.07942 ([M+Na]+; C10H11N3ONa+; calc. 212.07998) 
IR (KBr, film): ν = 3065 (vw), 2974 (m), 2937 (w), 2879 (w), 2503 (vw), 2104 (vs), 1690 
(vs), 1597 (m), 1460(m), 1449 (s), 1384 (w), 1364 (w), 1339 (w), 1266 (m), 1235 (s), 1214 
(vs), 1183 (w), 1160 (vw), 1116 (vw), 1002 (m), 989 (m), 940 (w), 893 (vw), 862 (w), 787 
(w), 761 (w), 694 (s), 637 (w), 557 (vw), 507 (vw) cm–1 
5.3.12. 2-Azido-3-methyl-1-phenylbutan-1-one (214e) 
Prepared from 2-bromo-3-methyl-1-phenylbutan-1-one (272e) (6.0 g, 24.88 mmol) and 
sodium azide (4.85 g, 74.65 mmol) in DMSO (125 mL) following method A. The product 
was isolated in 99% yield (5.02 g) as a slightly yellow oil.  
Analytical Data for 214e: 
TLC: Rf (Cyclohexane/CH2Cl2, 70:30) = 0.26 
GC (method IZ): tR = 9.83 min 
1H-NMR (400 MHz, CDCl3): δ 7.94 (d, 3JH2’,H3’ = 8.1 Hz, 2 H, H2’), 7.62 (t, 3JH4’,H3’ = 7.3 Hz, 
1 H, H4’), 7.52-7.48 (m, 2 H, H3’), 4.40 (d, 3JH2,H3obs. = 6.9 Hz, 1 H, H2), 2.34 (oct, 3JH3,H4a = 
3JH3,H4b = 3JH3,H2 = 7.0 Hz 1 H, H3), 1.03 (d,  3JH4a,H3 = 7.1 Hz, 3 H, H4a), 1.01 (d,  3JH4b,H3 = 7.1 
Hz, 3 H, H4b) 
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13C-NMR (100 MHz, CDCl3): δ 196.8 (C1), 135.6 (C1’), 133.8 (C4’), 128.9 (C3’), 128.5 (C2’), 
69.1 (C2), 30.9 (C3), 19.9 (C4b), 18.1 (C4a) 
MS-ESI: 226.1 (100, [M+Na]+) 
HR-MS (ESI): 226.09515 ([M+Na]+; C11H13N3ONa+; calc. 226.09563) 
IR (KBr, film): ν = 3065 (vw), 2969 (s), 2933 (w), 2876 (w), 2104 (vs), 1687 (vs), 1597 (w), 
1580 (w), 1466 (w), 1449 (m), 1389 (w), 1370 (w), 1327 (w), 1281 (m), 1246 (m), 1216 (vs), 
1183 (w), 1127 (vw), 1003 (w), 976 (vw), 949 (vw), 931 (vw), 911 (w), 892 (vw), 837 (w), 
785 (vw), 762 (w), 725 (w), 693 (s), 646 (w), 629 (w), 556 (vw) cm–1 
5.3.13. 2-Azido-2-methyl-1-phenylpropan-1-one (214f) 
Prepared from 2-bromoisobutyrophenone (272f) (2.11 g, 9.27 mmol) and sodium azide (1.81 
g, 27.82 mmol) in DMSO (50 mL) following method A. The product was isolated 
quantitatively (1.75 g) as a slightly yellow oil.  
Analytical Data for 214f: 
TLC: Rf (Cyclohexane/CH2Cl2, 70:30) = 0.31 
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1H-NMR (400 MHz, CDCl3): δ 8.12-8.09 (m (partially solved), 3JH2’,H3’obs. = 7.4 Hz, 2 H, 
H2’), 7.56 (tt, 3JH4’,H3’obs. = 7.4 Hz, 4JH4’,H2’obs. = 1.3 Hz, 1 H, H4’), 7.48-7.44 (m, 2 H, 3JH3’,H4’obs. 
= 7.4 Hz, H3’), 1.62 (s, 6 H, H3) 
13C-NMR (100 MHz, CDCl3): δ 199.4 (C1), 134.5 (C1’), 132.9 (C4’), 129.7 (C2’), 128.3 (C3’), 
67.6 (C2), 24.9 (C3) 
HR-MS (ESI): 212.07940 ([M+Na]+; C10H11N3ONa+; calc. 212.07998) 
IR (KBr, film): ν = 3065 (w), 2984 (w), 2938 (w), 2478 (vw), 2106 (vs), 1683 (vs), 1597 (w), 
1464 (m), 1447 (m), 1387 (w), 1370 (w), 1251 (vs), 1170 (s), 1149 (s), 1078 (vw), 1002 (w), 
981 (m), 954 (w), 935 (w), 908 (w), 794 (w), 714 (s), 690 (m), 666 (w), 560 (w), 445 (vw) 
cm–1 
5.3.14. 2-Azido-1-(4-nitrophenyl)ethanone (214g) 
Prepared from 2-bromo-1-(4-nitrophenyl)ethanone (272g) (1.0 g, 4.10 mmol, 1 equiv.) and 
sodium azide (0.29 g, 4.52 mmol, 1.1 equiv.) in DMSO (16 mL, 0.26 M) following modified 
method A. Solvent system for chromatography: CH2Cl2, 100%. The product was isolated in 
78% yield (0.66 g) as a yellow solid.  
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Analytical Data for 214g: 
TLC: Rf (CH2Cl2, 100%) = 0.46 
1H-NMR (400 MHz, CDCl3): δ 8.36 (dt, 3JH3’,H2’ = 9.2 Hz, 4JH3’,H3’’ = 2.1 Hz, 2 H, H3’ and 
H3’’), 8.09 (dt, 3JH2’,H3’ = 9.2 Hz, 4JH2’,H2’’ = 2.1 Hz, 2 H, H2’ and H2’’), 4.61 (s, 2 H, H2) 
13C-NMR (100 MHz, CDCl3): δ 191.9 (C1), 150.8 (C4’), 138.7 (C1’), 129.1 (C2’ and C2’’), 
124.2 (C3’ and C3’’), 55.2 (C2) 
MS-EI (70 eV): 207.1 (7, [M+H]+), 164.0 (85, [M-N3]+), 150.0 (100, [M-CH2N3]+), 134.1 
(34), 120.1 (57), 104.2 (21, [M-CH2N3-NO2]+), 92.1 (84), 76.1 (25), 50.0 (13) 
IR (KBr): ν = 2897 (w), 2152 (m), 2113 (vs), 1705 (s), 1602 (w), 1524 (vs), 1346 (vs), 1319 
(s), 1213 (vs), 1006 (w), 916 (m), 855 (s), 750 (w), 690 (w), 640 (w), 552 (w), 502 (vw) cm–1 
5.3.15. 2-Azido-1-(2-nitrophenyl)propan-1-one (214h) 
Prepared from 2-bromo-1-(2-nitrophenyl)propan-1-one (272h) (560 mg, 2.17 mmol) and 
sodium azide (423 mg, 6.51 mmol) in acetone (8 mL) following method B. Solvent system for 
169 
chromatography: cyclohexane/CH2Cl2, 50:50. The product was isolated in 85% yield (410 
mg) as an orange oil.  
Analytical Data for 214h: 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.31 
GC (method IZ): tR = 10.86 min 
1H-NMR (400 MHz, CDCl3): δ 8.22 (dd, 3JH3’,H4’ = 8.3 Hz, 4JH3’,H5’ = 1.1 Hz, 1 H, H3’), 7.78 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.1 Hz, 1 H, H5’), 7.67 (ddd, 3JH4’,H3’ = 8.3 Hz, 
3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 7.39 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.4 Hz, 1 
H, H6’), 4.37 (q,  3JH2,H3 = 7.0 Hz, 1 H, H2), 1.61 (d,  3JH3,H2 = 7.0 Hz, 3 H, H3) 
13C-NMR (100 MHz, CDCl3): δ 200.0 (C1), 145.7 (C2’), 135.5 (C1’), 134.7 (C5’), 131.0 (C4’), 
127.9 (C6’), 124.3 (C3’), 63.2 (C2), 16.1 (C3) 
MS-EI (70 eV): 221.1 (4, [M+H]+), 151.0 (67, [M-CH3CHN3+H]+), 121.0 (100), 107.1 (11), 
93.0 (66), 76.0 (43), 74.1 (21), 65.1 (89), 50.0 (54) 
IR (KBr, film): ν = 3107 (vw), 2990 (vw), 2938 (vw), 2871 (vw), 2105 (vs), 1717 (vs), 1613 
(vw), 1574 (w), 1530 (vs), 1476 (vw), 1450 (w), 1375 (vs), 1313 (w), 1258 (m), 1230 (m), 
1174 (vw), 1148 (vw), 1081 (vw), 1018 (vw), 969 (w), 911 (vw), 857 (w), 791 (w), 757 (w), 
717 (w), 699 (w), 649 (vw), 622 (vw), 555 (vw) cm–1 
170 
5.3.16. 2-Azido-1-(2-nitrophenyl)butan-1-one (214i) 
Prepared from 2-bromo-1-(2-nitrophenyl)butan-1-one (272i) (1.0 g, 3.68 mmol) and sodium 
azide (717 mg, 11.03 mmol) in acetone (14 mL) following method B. Solvent system for 
chromatography: cyclohexane/CH2Cl2, 70:30. The product was isolated in 79% yield (680 
mg) as an orange oil.  
Analytical Data for 214i: 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.27 
GC (method IZ): tR = 11.50 min 
1H-NMR (400 MHz, CDCl3): δ 8.22 (dd, 3JH3’,H4’ = 8.3 Hz, 4JH3’,H5’ = 1.1 Hz, 1 H, H3’), 7.78 
(td, 3JH5’,H6’ = 3JH5’,H4’ = 7.5 Hz, 4JH5’,H3’ = 1.1 Hz, 1 H, H5’), 7.67 (ddd, 3JH4’,H3’ = 8.3 Hz, 
3JH4’,H5’ = 7.5 Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 7.38 (dd, 3JH6’,H5’ = 7.5 Hz, 4JH6’,H4’ = 1.4 Hz, 1 
H, H6’), 4.21 (dd, 3JH2,H3b = 8.9 Hz, 3JH2,H3a = 4.3 Hz, 1 H, H2), 2.06 (dqd, 2JH3a,H3b = 14.4 Hz, 
3JH3a,H4 = 7.4 Hz, 3JH3a,H2 = 4.3 Hz, 1 H, H3a), 1.87 (ddq, 2JH3b,H3a = 14.4 Hz, 3JH3b,H2 = 8.9 Hz, 
3JH3b,H4 = 7.4 Hz, 1 H, H3b), 1.10 (t, 3JH4,H3a = 3JH4,H3b = 7.4 Hz, 3 H, H4) 
13C-NMR (100 MHz, CDCl3): δ 199.7 (C1), 145.7 (C2’), 135.8 (C1’), 134.67 (C5’), 131.0 
(C4’), 128.0 (C6’), 124.3 (C3’), 69.5 (C2), 24.6 (C3), 10.5 (C4) 
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MS-ESI: 257.3 (43, [M+Na]+), 229.3 (14, [M-N2+Na]+), 207.2 (100, [M-N2+H]+) 
IR (KBr, film): ν = 3106 (vw), 2976 (w), 2939 (w), 2880 (w), 2495 (vw), 2108 (vs), 1716 
(vs), 1574 (w), 1530 (vs), 1462 (w), 1442 (w), 1347 (vs), 1314 (m), 1239 (m), 1148 (vw), 
1085 (vw), 993 (w), 963 (vw), 941 (vw), 858 (w), 790 (m), 757 (m), 714 (m), 646 (vw), 555 
(vw) cm–1 
5.3.17. Preparation of azidoesters by Mukaiyama aldol reaction: General 
Procedures: 
O
N3
N3
OO
O
OTMS
(up to 98%)
+
TiCl4 (0.5 equiv.)
CH2Cl2
30 °C to 15 °C
40 min
(3 or 5 equiv.)
R1
R2 R2
R'
R'
OH
R1215
214 216
To a stirred solution of ((1-methoxyvinyl)oxy)trimethylsilane S4 (43.66 mmol, 3.0 or 5.0 
equiv.) in dry CH2Cl2 (60 mL, 0.26 M) was added the corresponding α-azidoketone (14.55 
mmol, 1.0 equiv.) at -30 °C and under argon. A solution of freshly distilled TiCl4 (7.28 mmol, 
0.5 equiv.) in dry CH2Cl2 (10 mL, 0.73 M) was added dropwise over 15 min. The resulting 
mixture was stirred at -30 °C for 15 min and then allowed to reach -15 °C over a period of 30 
min. The dark red solution was quenched with NaOH (2.0 M, 15 mL) and extracted with 
CHCl3 (4 x 20 mL). The combined organic phases were washed with brine (30 mL), dried 
over MgSO4, filtered and concentrated. The product was purified by flash chromatography 
and in the some cases crystallised from the appropriate solvent. 
172 
5.3.18. Methyl 4-azido-3-hydroxy-3-phenylpentanoate (216c) 
Prepared from 2-azido-1-phenylpropan-1-one (214c) (0.94 g, 5.39 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (4.25 g, 29.06 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.32 mL, 2.90 mmol) in dry CH2Cl2 (33 mL). Solvent system for 
chromatography: cyclohexane/EtOAc, 95:5. The product was isolated in 92% yield (1.23 g) as 
a slightly yellow oil and as a mixture of two pairs of diastereomers in 90:10 ratio. The oil 
could be crystallised from EtOAc/petroleum ether to give the product as white solid and as a 
major diastereomer. 
Analytical Data for 216c: 
TLC: Rf (Cyclohexane/EtOAc, 95:5) = 0.28 
MP: 64-65 °C 
GC (method IZ): tR = 11.17 min (minor isomer, 10%), tR = 11.28 min (major isomer, 90%) 
GC-MS (EI, 70 eV): tR = 14.75 min (minor isomer, 10%), tR = 14.88 min (major isomer, 
90%); m/z (%) = 249.9 (1, [M]+), 179.0 (27), 105.0 (100), 77.1 (41), 51.0 (10) 
MS-ESI: 272.3 (100, [M+Na]+) 
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HR-MS (ESI): 272.10062 ([M+Na]+; C12H15N3O3Na+; calc. 272.10111) 
IR (KBr): ν = 3463 (s), 3088 (w), 2985 (w), 2955 (m), 2487 (vw), 2100 (vs), 2067 (vs), 1709 
(vs), 1489 (w), 1443 (s), 1421 (m), 1374 (vs), 1364 (vs), 1309 (m), 1247 (vs), 1207 (vs), 1174 
(vs), 1114 (s), 1078 (m), 1054 (m), 1028 (m), 1005 (m), 996 (m), 960 (vs), 869 (w), 833 (vw), 
773 (m), 753 (s), 731 (w), 702 (s), 642 (w), 615 (m), 579 (m), 501 (m), 459 (vw) cm–1 
CHN: calc.: C: 57.82; H: 6.07; N: 16.86; found: C: 58.11; H: 6.07; N: 16.47 
Major diastereomer (R/S, S/R, 90 %): 
1H-NMR (400 MHz, CDCl3): δ 7.40-7.33 (m, 4 H, H2’ and H3’), 7.29-7.25 (m, 1 H, H4’), 4.66 
(br s, 1 H, OH), 3.54 (s, 3 H, H1’’), 3.38 (q, 3JH4,H5 = 6.7 Hz, 1 H, H4), 3.17 and 2.94 (2 x d AB 
system, 2JH2a,H2b = 16.0 Hz, 2 H, H2a and H2b), 1.12 (d, 3JH5,H4 = 6.7 Hz, 3 H, H5) 
13C-NMR (100 MHz, CDCl3): δ 173.4 (C1), 142.6 (C1’), 128.4 (C3’), 127.5 (C4’), 125.2 (C2’), 
76.7 (C3), 64.1 (C4), 51.9 (C1’’), 42.3 (C2), 12.6 (C5) 
5.3.18. Methyl 4-azido-3-hydroxy-3-phenylhexanoate (216d) 
Prepared from 2-azido-1-phenylbutan-1-one (214d) (1.0 g, 5.29 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (3.92 g, 26.77 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.29 mL, 2.64 mmol) in dry CH2Cl2 (33 mL). Solvent system for 
chromatography: cyclohexane/CH2Cl2, 50:50 to CH2Cl2, 100%. The product was isolated in 
98% yield (1.37 g) as a slightly yellow oil and as a mixture of two pairs of diastereomers in 
90:10 ratio.  
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Analytical Data for 216d: 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 50:50) = 0.23 
 
GC (method IZ): tR = 11.68 min (minor isomer, 10%), tR = 11.71 min (major isomer, 90%) 
 
MS-ESI: 286.5 (100, [M+Na]+) 
 
HR-MS (ESI): 286.11607 ([M+Na]+; C13H17N3O3Na+; calc. 286.11676) 
 
IR (KBr, film): ν = 3480 (w), 3061 (vw), 3029 (vw), 2971 (m), 2880 (w), 2105 (vs), 1715 
(s), 1602 (vw), 1495 (w), 1439 (m), 1359 (s), 1299 (m), 1267 (m), 1233 (s), 1210 (s), 1168 
(s), 1068 (w), 1029 (w), 1005 (w), 937 (w), 903 (vw), 883 (w), 849 (vw), 808 (vw), 768 (w), 
703 (s), 645 (vw), 573 (w), 560 (w), 503 (vw) cm–1 
 
Major diastereomer (R/S, S/R, 90 %): 
 
1H-NMR (400 MHz, CDCl3): δ 7.40-7.33 (m, 4 H, H2’ and H3’), 7.29-7.25 (m, 1 H, H4’), 4.67 
(br s, 1 H, OH), 3.55 (s, 3 H, H1’’), 3.16 and 2.97 (2 x d AB system, 2JH2a,H2b = 15.9 Hz, 2 H, 
H2a and H2b), 3.03 (dd, 3JH4,H5b = 2.5 Hz, 3JH4,H5a = 11.2 Hz, 1 H, H4), 1.65 (ddq, 2JH5a,H5b = 
14.7 Hz, 3JH5a,H4 = 11.2 Hz, 3JH5a,H6 = 7.4 Hz, 1 H, H5a), 1.33 (dqd, 2JH5b,H5a = 14.7 Hz, 3JHb5,H6 
= 7.4 Hz, 3JH5b,H4 = 2.5 Hz, 1 H, H5b), 0.92 (t, 3JH6,H5a = 3JH6,H5b = 7.4 Hz, 3 H, H6) 
 
13C-NMR (100 MHz, CDCl3): δ 173.4 (C1), 142.9 (C1’), 128.4 (C3’), 127.5 (C4’), 125.2 (C2’), 
78.4 (C3), 71.5 (C4), 51.9 (C1’’), 42.5 (C2), 20.6 (C5), 11.5 (C6) 
 
Some distinct signals of the minor diastereomer (R/R, S/S, 10 %) were observed. 
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1H-NMR (400 MHz, CDCl3): δ 7.46-7.44 (m, 2 H, H2’), 3.63 (s, 3 H, H1’’), 3.34 (dd, 3JH4,H5b 
= 2.4 Hz, 3JH4,H5a = 11.1 Hz, 1 H, H4), 3.15 and 2.97 (2 x d AB system, 2JH2a,H2b = 16.5 Hz, 2 
H, H2a and H2b), 1.49 (dqd, 2JH5b,H5a = 14.8 Hz, 3JHb5,H6 = 7.4 Hz, 3JH5b,H4 = 2.4 Hz, 1 H, H5b), 
1.12-0.99 (m, 1 H, H5a) 
 
13C-NMR (100 MHz, CDCl3): δ 173.5 (C1), 142.2 (C1’), 128.3 (C3’), 127.7 (C4’), 125.9 (C2’), 
77.9 (C3), 72.8 (C4), 52.0 (C1’’), 39.6 (C2), 22.1 (C5), 11.7 (C6) 
 
5.3.19. Methyl 4-azido-3-hydroxy-5-methyl-3-phenylhexanoate (216e) 
 
 
Prepared from 2-azido-3-methyl-1-phenylbutan-1-one (214e) (1.0 g, 4.92 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (3.6 g, 24.60 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.27 mL, 2.46 mmol) in dry CH2Cl2 (30 mL). Solvent system for 
chromatography: cyclohexane/EtOAc, 95:5. The product was isolated in 64% yield (0.87 g) as 
a slightly yellow oil and as a pair of enantiomers.  
 
Analytical Data for 216e: 
N3
OO
OH
4'
3'
2'
1'
1
2
1''
4
35
6a
6b
 
 
TLC: Rf (cyclohexane/EtOAc, 95:5) = 0.27 
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GC (method IZ): tR = 12.06 min  
 
1H-NMR (400 MHz, CDCl3): δ 7.43-7.40 (m, 2 H, H2’), 7.38-7.33 (m, 2 H, H3’), 7.29-7.25 
(m, 1 H, H4’), 4.51 (d, 4JOH,H4 = 1.0 Hz, 1 H, OH), 3.55 (s, 3 H, H1’’), 3.27 (dd, 3JH4,H5 = 3.0 
Hz, 4JH4,OH = 1.0 Hz, 1 H, H4), 3.13 and 2.96 (2 x d AB system, 2JH2a,H2b = 15.5 Hz, 2 H, H2a 
and H2b), 1.80 (sept d, 3JH5,H6 = 6.8 Hz, 3JH5,H4 = 3.0 Hz, 1 H, H5), 1.00 (d, 3JH6a,H5 = 6.8 Hz, 3 
H, H6a), 0.88 (d, 3JH6b,H5 = 6.8 Hz, 3 H, H6b) 
 
13C-NMR (100 MHz, CDCl3): δ 173.0 (C1), 143.1 (C1’), 128.5 (C3’), 127.5 (C4’), 125.2 (C2’), 
78.7 (C3), 75.4 (C4), 51.9 (C1’’), 43.8 (C2), 29.8 (C5), 23.1 (C6b), 17.6 (C6a) 
 
MS-ESI: 300.3 (100, [M+Na]+) 
 
HR-MS (ESI): 300.13144 ([M+Na]+; C14H19N3O3Na+; calc. 300.13241) 
 
IR (KBr, film): ν = 3480 (w), 3062 (vw), 2962 (m), 2875 (w), 2103 (vs), 1716 (s), 1496 
(vw), 1439 (m), 1346 (m), 1265 (m), 1210 (s), 1169 (m), 1104 (vw), 1071 (w), 1003 (w), 965 
(vw), 909 (vw), 890 (vw), 821 (vw), 768 (vw), 703 (m), 644 (vw), 559 (vw) cm–1 
 
5.3.20. Methyl 4-azido-3-hydroxy-4-methyl-3-phenylpentanoate (216f) 
 
 
Prepared from 2-azido-2-methyl-1-phenylpropan-1-one (214f) (0.40 g, 2.11 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (1.55 g, 10.57 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.12 g, 1.06 mmol) in dry CH2Cl2 (18 mL). Solvent system for chromatography: 
cyclohexane/EtOAc, 95:5. The product was isolated in 70% yield (0.39 g) as a slightly yellow 
oil and as a a pair of enantiomers.  
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Analytical Data for 216f: 
 
TLC: Rf (cyclohexane/EtOAc, 95:5) = 0.31 
 
GC (method IZ): tR = 11.54 min  
 
1H-NMR (400 MHz, CDCl3): δ 7.49 (d, 3JH2’,H3’obs. = 7.3 Hz, 2 H, H2’), 7.34-7.30 (m, 2 H, 
H3’), 7.27 (tt, 3JH4’,H3’obs. = 7.3 Hz, 4JH4’,H2’obs. = 1.4 Hz, 1 H, H4’), 4.67 (br s, 1 H, OH), 3.53 (s, 
3 H, H1’’), 3.30 and 3.03 (2 x d AB system, 2JH2a,H2b = 16.1 Hz, 2 H, H2a and H2b), 1.33 (s, 3 
H, H5a), 1.12 (s, 3 H, H5b) 
 
13C-NMR (100 MHz, CDCl3): δ 173.9 (C1), 141.8 (C1’), 127.7 (C3’), 127.5 (C4’), 127.1 (C2’), 
79.5 (C3), 66.2 (C4), 51.9 (C1’’), 39.4 (C2), 22.4 (C5b), 21.4 (C5a) 
 
MS-EI (70 eV): 263.9 (12, [M]+), 221.0 (5, [M-N3]+), 203.0 (10), 179.0 (40), 158.1 (15), 
119.1 (51), 105.1 (100), 91.2 (7), 77.1 (20), 58.1 (8) 
 
HR-MS (ESI): 286.11697 ([M+Na]+; C13H17N3O3Na+; calc. 286.11676) 
 
IR (KBr, film): ν = 3479 (m), 3060 (vw), 2982 (w), 2954 (w), 2504 (vw), 2111 (vs), 2066 
(m), 1716 (vs), 1602 (vw), 1494 (w), 1439 (s), 1388 (m), 1369 (s), 1344 (s), 1267 (s), 1216 
(s), 1153 (vs), 1108 (w), 1071 (w), 1045 (w), 1025 (m), 1005 (m), 916 (vw), 899 (vw), 857 
(vw), 799 (vw), 764 (m), 705 (s), 661 (w), 630 (vw), 578 (w), 559 (w) cm–1 
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5.3.21. Methyl 4-azido-3-hydroxy-3-(4-nitrophenyl)butanoate (216g) 
 
 
Prepared from 2-azido-1-(4-nitrophenyl)ethanone (214g) (500 mg, 2.43 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (1.77 g, 12.13 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.14 mL, 1.21 mmol) in dry CH2Cl2 (18 mL). Solvent system for 
chromatography: CH2Cl2, 100%. The product was isolated in 96% yield (656 mg) as a slightly 
yellow oil and as a pair of enantiomers.  
 
Analytical Data for 216g: 
 
 
TLC: Rf (CH2Cl2, 100%) = 0.36 
 
1H-NMR (400 MHz, CDCl3): δ 8.23 (dt, 3JH3’,H2’ = 9.4 Hz, 4JH3’,H3’’ = 5JH3’,H2’’ = 2.3 Hz, 2 H, 
H3’), 7.65 (dt, 3JH2’,H3’ = 9.4 Hz, 4JH2’,H2’’ = 5JH2’,H3’’ = 2.3 Hz, 2 H, H2’), 4.81 (d, 4JOH,H4b = 1.0 
Hz, 1 H, OH), 3.63 (s, 3 H, H1’’), 3.50 (d AB system, 2JH4a,H4b = 12.7 Hz, 1 H, H4a), 3.32 (dd 
AB system, 2JH4b,H4a = 12.7 Hz, 4JH4b,OH = 1.0 Hz, 1 H, H4b), 3.11 and 3.00 (2 x d AB system, 
2JH2a,H2b = 16.5 Hz, 2 H, H2a and H2b) 
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13C-NMR (100 MHz, CDCl3): δ 172.6 (C1), 150.0 (C1’), 147.6 (C4’), 126.3 (C2’), 123.8 (C3’), 
75.7 (C3), 60.1 (C4), 52.3 (C1’’), 41.1 (C2) 
 
MS-ESI: 303.2 (100, [M+Na]+) 
 
HR-MS (ESI): 303.06908 ([M+Na]+; C11H12N4O5Na+; calc. 303.07054) 
 
IR (KBr, film): ν = 3479 (m), 3113 (vw), 3080 (vw), 2956 (w), 2459 (vw), 2108 (vs), 1717 
(vs), 1606 (m), 1522 (vs), 1494 (w), 1439 (s), 1414 (m), 1351 (vs), 1288 (s), 1209 (vs), 1111 
(m), 1059 (m), 1012 (m), 949 (w), 915 (w), 855 (s), 756 (m), 702 (m), 642 (vw), 557 (w) cm–1 
 
5.3.22. Methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)pentanoate (216h) 
 
 
Prepared from 2-azido-1-(2-nitrophenyl)propan-1-one (214h) (375 mg, 1.70 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (1.25 g, 8.52 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.10 mL, 0.85 mmol) in dry CH2Cl2 (11 mL). Solvent system for 
chromatography: CH2Cl2, 100%. The product was isolated in 90% yield (453 mg) as a yellow 
oil and as a pair of enantiomers.  
 
Analytical Data for 216h: 
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TLC: Rf (CH2Cl2, 100%) = 0.40 
 
GC (method IZ): tR = 13.18 min 
 
1H-NMR (400 MHz, CDCl3): δ 7.53-7.49 (m, 2 H, H6’ and H5’), 7.44-7.39 (m, 2 H, H3’ and 
H4’), 4.86 (br s, 1 H, OH), 3.88 (q, 3JH4,H5 = 6.7 Hz, 1 H, H4), 3.61 (s, 3 H, H1’’), 3.09 and 3.04 
(2 x d AB system, 2JH2a,H2b = 16.4 Hz, 2 H, H2a and H2b), 1.26 (d, 3JH5,H4 = 6.7 Hz, 3 H, H4) 
 
13C-NMR (100 MHz, CDCl3): δ 173.0 (C1), 150.1 (C2’), 134.6 (C1’), 130.6 (C5’), 129.0 (C4’), 
128.6 (C6’), 124.1 (C3’), 77.9 (C3), 62.8 (C4), 52.3 (C1’’), 40.3 (C2), 13.2 (C5) 
MS-EI (70 eV): 294.9 (4, [M]+), 224.0 (11), 192.0 (73), 150.0 (100), 135.1 (20), 104.1 (17), 
77.1 (24), 51.0 (42) 
 
HR-MS (ESI): 317.08597 ([M+Na]+; C12H14N4O5Na+; calc. 317.08619) 
 
IR (KBr, film): ν = 3457 (m), 2990 (w), 2956 (w), 2488 (vw), 2120 (vs), 1713 (vs), 1604 
(vw), 1539 (vs), 1486 (w), 1440 (s), 1379 (vs), 1250 (s), 1213 (vs), 1175 (s), 1116 (m), 1092 
(w), 1036 (m), 997 (m), 968 (w), 911 (vw), 872 (w), 855 (m), 774 (s), 736 (m), 673 (w), 649 
(vw), 584 (w), 562 (w), 508 (vw) cm–1 
 
5.3.23. Methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)hexanoate (216i) 
 
 
Prepared from 2-azido-1-(2-nitrophenyl)butan-1-one (214i) (500 mg, 2.14 mmol), ((1-
methoxyvinyl)oxy)trimethylsilane 215 (1.56 g, 10.67 mmol, 5.0 equiv.) and titanium 
tetrachloride (0.12 mL, 1.07 mmol) in dry CH2Cl2 (14 mL). Solvent system for 
chromatography: CH2Cl2, 100%. The product was isolated in 96% yield (632 mg) as a slightly 
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yellow oil and as a pair of enantiomers. The oil could be crystallised from THF/cyclohexane 
to give the product as white solid. 
 
Analytical Data for 216i: 
 
TLC: Rf (CH2Cl2, 100%) = 0.50 
 
1H-NMR (400 MHz, CDCl3): δ 7.52 (dd, 3JH6’,H5’ = 8.0 Hz, 4JH6’,H4’obs. = 2.2 Hz, 1 H, H6’), 
7.50 (td, 3JH5’,H6’ = 3JH5’,H4’obs. = 8.0 Hz, 4JH5’,H3’obs. = 2.3 Hz, 1 H, H5’), 7.44-7.38 (m, 2 H, H3’ 
and H4’), 4.89 (br s, 1 H, OH), 3.61 (s, 3 H, H1’’), 3.53 (dd, 3JH4,H5a = 10.5 Hz, 3JH4,H5b = 3.0 
Hz, 1 H, H4), 3.11 and 3.03 (2 x d AB system, 2JH2a,H2b = 16.3 Hz, 2 H, H2a and H2b), 1.64 
(ddq, 2JH5a,H5b = 14.6 Hz, 3JH5a,H4 = 10.5 Hz, 3JH5a,H6 = 7.4 Hz, 1 H, H5a), 1.57 (dqd, 2JH5b,H5a = 
14.6 Hz, 3JH5b,H6 = 7.4 Hz, 3JH5b,H4 = 3.0 Hz, 1 H, H5b), 1.01 (t, 3JH6,H5a = 3JH6,H5b = 7.4 Hz, 3 
H, H6) 
 
13C-NMR (100 MHz, CDCl3): δ 173.0 (C1), 150.1 (C2’), 134.9 (C1’), 130.7 (C5’), 129.0 (C4’), 
128.4 (C6’), 124.1 (C3’), 78.6 (C3), 70.2 (C4), 52.3 (C1’’), 40.6 (C2), 21.5 (C5), 11.5 (C6) 
 
MS-ESI: 331.2 (100, [M+Na]+) 
 
HR-MS (ESI): 331.10166 ([M+Na]+; C13H16N4O5Na+; calc. 331.10184) 
 
IR (KBr, film): ν = 3457 (m), 2972 (s), 2881 (w), 2497 (vw), 2107 (vs), 1713 (vs), 1604 
(vw), 1537 (vs), 1486 (m), 1440 (vs), 1378 (vs), 1302 (s), 1211 (vs), 1172 (vs), 1112 (m), 
1046 (m), 1004 (m), 936 (w), 905 (w), 888 (w), 850 (s), 775 (s), 742 (w), 703 (w), 673 (w), 
646 (w), 585 (w), 559 (w) cm–1 
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5.3.24. Preparation of pyrrolidinones by Staudinger cyclisation: General 
Procedures:  
 
 
 
To a stirred solution of the corresponding azidoester 216 (30.05 mmol, 1 equiv.) in THF (126 
mL, 0.24 M) was added triphenylphosphine or tributylphosphine (45.07 mmol, 1.5 equiv.) at 
room temperature. After 30 min, deionized water (1%, 1.26 mL) was added. The resulting 
mixture was stirred at room temperature for at least 3 days. The solvents were removed in 
vacuo and the crude product 217 was purified by crystallisation from the appropriate solvent 
and/or by flash chromatography in the some cases. 
 
5.3.25. 4-Hydroxy-5-methyl-4-phenylpyrrolidin-2-one (217c) 
 
 
 
Prepared from methyl 4-azido-3-hydroxy-3-phenylpentanoate (216c) (1.23 g, 4.94 mmol) and 
tributylphosphine (1.85 mL, 7.41 mmol) in THF (18 mL)/water (0.18 mL). Solvent system for 
chromatography: CH2Cl2/MeOH, 96:4. The product was crystallised from EtOAc to give 474 
mg (56%) of pure pyrrolidinone as a white solid. 
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Analytical Data for 217c: 
 
TLC: Rf (CH2Cl2/MeOH, 96:4) = 0.25 
 
MP: 186 °C 
 
1H-NMR (400 MHz, DMSO-d6): δ 7.70 (br s, 1 H, H1), 7.55 (ddd, 3JH2’,H3’ = 8.4 Hz, 
4JH2’,H2’’obs. = 2.7 Hz, 4JH2’,H4’ = 1.2 Hz, 2 H, H2’), 7.36-7.31 (m (partially solved), 3JH3’,H2’ = 8.4 
Hz, 3JH3’,H4’ = 7.2 Hz, 4JH3’,H3’’obs. = 2.0 Hz, 5JH3’,H2’’obs. = 1.5 Hz, 2 H, H3’), 7.24 (tt, 3JH4’,H3’ = 
7.2 Hz, 4JH4’,H2’ = 1.2 Hz, 1 H, H4’), 5.44 (br s, 1 H, OH), 3.71 (q, 3JH5,H6 = 6.5 Hz, 1 H, H5), 
2.88 and 2.30 (2 x d AB system, 2JH3a,H3b = 16.4 Hz, 2 H, H3a and H3b), 0.95 (d, 3JH6,H5 = 6.5 
Hz, 3 H, H6) 
 
13C-NMR (400 MHz, DMSO-d6): δ 173.8 (C2), 144.3 (C1’), 127.9 (C3’), 127.7 (C4’), 125.6 
(C2’), 77.8 (C4), 60.2 (C5), 47.7 (C3), 12.6 (C6) 
 
MS-ESI: 214.1 (100, [M+Na]+) 
 
HR-MS (ESI): 214.08360 ([M+Na]+; C11H13NO2Na+; calc. 214.08440) 
 
IR (KBr): ν = 3195 (vs), 3080 (s), 2991 (m), 2931 (m), 2876 (m), 1958 (vw), 1705 (vs), 1669 
(vs), 1495 (m), 1444 (s), 1400 (s), 1376 (s), 1333 (m), 1311 (m), 1291 (w), 1266 (m), 1221 
(s), 1186 (w), 1140 (vw), 1095 (m), 1072 (w), 1032 (vw), 1006 (m), 999 (m), 956 (w), 918 
(w), 900 (w), 876 (w), 769 (s), 741 (s), 699 (vs), 659 (m), 601 (w), 565 (vw), 529 (w), 518 
(w), 492 (m), 409 (vw) cm–1 
 
CHN: calc.: C: 69.09; H: 6.85; N: 7.32; found: C: 68.94; H: 6.85; N: 7.29 
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5.3.26. 5-Ethyl-4-hydroxy-4-phenylpyrrolidin-2-one (217d) 
 
Prepared from methyl 4-azido-3-hydroxy-3-phenylhexanoate (216d) (1.01 g, 3.84 mmol) and 
tributylphosphine (1.44 mL, 5.75 mmol) in THF (15 mL)/water (0.15 mL). The product was 
crystallised from EtOAc/pentane to give 364 mg (45%) of pure pyrrolidinone. The filtrate was 
evaporated and the residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 98:2) to afford 260 mg of yellow solid which was crystallised from 
MeOH/pentane to give 84 mg (11%) of pure pyrrolidinone. The product was isolated in 57% 
total yield (448 mg) as a white solid. 
 
Analytical Data for 217d: 
 
TLC: Rf (CH2Cl2/MeOH, 98:2) = 0.20 
 
MP: 225 °C 
 
GC (method IZ): tR = 12.77 min  
 
1H-NMR (400 MHz, DMSO-d6): δ 7.90 (br s, 1 H, H1), 7.57-7.55 (m (partially solved), 
3JH2’,H3’obs. = 8.5 Hz, , 4JH2’,H4’obs. = 1.2 Hz, 2 H, H2’), 7.36-7.31 (m (partially solved), 3JH3’,H4’ = 
7.3 Hz, 2 H, H3’), 7.23 (t, 3JH4’,H3’ = 7.3 Hz, 1 H, H4’), 5.46 (br s, 1 H, OH), 3.52 (t, 3JH5,H6 = 
6.6 Hz, 1 H, H5), 2.83 and 2.31 (2 x d AB system, 2JH3a,H3b = 16.5 Hz, 2 H, H3a and H3b), 1.45-
1.38 (m (partially solved), 3JH6,H7 = 7.5 Hz, 2 H, H6), 0.72 (t, 3JH7,H6 = 7.5 Hz, 3 H, H7) 
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13C-NMR (400 MHz, DMSO-d6): δ 174.0 (C2), 145.0 (C1’), 127.8 (C3’), 126.6 (C4’), 125.5 
(C2’), 77.7 (C4), 66.9 (C5), 48.6 (C3), 21.2 (C6), 11.2 (C7) 
 
MS-EI (70 eV): 205.1 (12, [M]+), 187.1 (9, [M-H2O]+), 158.1 (9, [M-H2O-CH3CH2]+), 120.1 
(12), 105.0 (56), 91.1 (12), 78.1 (21), 77.1 (35), 58.1 (100) 
 
HR-MS (ESI): 228.09953 ([M+Na]+; C12H15NO2Na+; calc. 228.10005) 
 
IR (KBr): ν = 3285 (s), 3199 (vs), 3081 (m), 3029 (m), 2963 (m), 2923 (w), 2875 (m), 1954 
(vw), 1693 (vs), 1669 (vs), 1494 (w), 1462 (w), 1447 (m), 1405 (s), 1389 (s), 1357 (w), 1317 
(s), 1293 (m), 1257 (w), 1222 (s), 1186 (w), 1138 (vw), 1097 (w), 1074 (m), 1048 (w), 1001 
(vw), 976 (w), 939 (vw), 912 (vw), 902 (vw), 860 (vw), 827 (w), 788 (w), 758 (s), 697 (vs), 
660 (m), 498 (m), 472 (vw), 425 (w) cm–1 
 
CHN: calc.: C: 70.22; H: 7.37; N: 6.82; found: C: 69.95; H: 7.38; N: 6.67 
 
5.3.27. 4-Hydroxy-5-isopropyl-4-phenylpyrrolidin-2-one (217e) 
 
 
Prepared from methyl 4-azido-3-hydroxy-5-methyl-3-phenylhexanoate (216e) (680 mg, 2.45 
mmol) and tributylphosphine (0.92 mL, 3.68 mmol) in THF (9 mL)/water (0.09 mL). The 
product was crystallised from MeOH to give 279 mg (52%) of pure pyrrolidinone. The filtrate 
was evaporated and the residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 96:4) to afford 143 mg of yellow solid which was crystallised from MeOH to 
give 10 mg (2%) of pure pyrrolidinone. The product was isolated in 54% total yield (289 mg) 
as a white solid. 
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Analytical Data for 217e: 
 
 
TLC: Rf (CH2Cl2/MeOH, 96:4) = 0.28 
 
MP: 252 °C 
 
GC (method IZ): tR = 13.07 min  
 
1H-NMR (400 MHz, DMSO-d6): δ 7.87 (br s, 1 H, H1), 7.56 (d, 3JH2’,H3’= 7.3 Hz, 2 H, H2’), 
7.32 (t, 3JH3’,H4’ = 3JH3’,H2’ = 7.3 Hz, 2 H, H3’), 7.20 (t, 3JH4’,H3’ = 7.3 Hz, 1 H, H4’), 5.58 (br s, 1 
H, OH), 3.45 (t, 3JH5,H6obs. = 8.1 Hz, 1 H, H5), 2.68 and 2.34 (2 x d AB system, 2JH3a,H3b = 16.6 
Hz, 2 H, H3a and H3b), 1.96-1.88 (m (partially solved), 3JH6,H7a = 3JH6,H7b = 6.7 Hz, 1 H, H6), 
0.91 (d, 3JH7a,H6 = 6.7 Hz, 3 H, H7a), 0.48 (d, 3JH7b,H6 = 6.7 Hz, 3 H, H7b) 
 
13C-NMR (400 MHz, DMSO-d6): δ 174.4 (C2), 147.2 (C1’), 128.3 (C3’), 126.8 (C4’), 125.8 
(C2’), 78.3 (C4), 71.3 (C5), 50.8 (C3), 28.7 (C6), 20.9 and 20.8 (C7a and C7b) 
 
MS-ESI: 242.1 (100, [M+Na]+), 239.1 (67), 183.0 (67), 143.0 (83) 
 
HR-MS (ESI): 242.11509 ([M+Na]+; C13H17NO2Na+; calc. 242.11570) 
 
IR (KBr): ν = 3292 (vs), 3215 (vs), 3086 (s), 3034 (m), 2984 (m), 2954 (m), 2871 (s), 1950 
(vw), 1697 (vs), 1671 (vs), 1601 (w), 1494 (w), 1446 (s), 1409 (s), 1393 (s), 1353 (m), 1323 
(w), 1302 (s), 1277 (m), 1260 (m), 1221 (s), 1180 (m), 1145 (w), 1087 (w), 1064 (s), 1031 
(w), 980 (w), 961 (w), 917 (w), 906 (w), 852 (vw), 808 (w), 760 (vs), 699 (vs), 660 (m), 499 
(m), 439 (w) cm–1 
 
CHN: calc.: C: 71.21; H: 7.81; N: 6.39; found: C: 71.06; H: 7.80; N: 6.36 
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5.3.28. 4-Hydroxy-5,5-dimethyl-4-phenylpyrrolidin-2-one (217f) 
 
Prepared from methyl 4-azido-3-hydroxy-4-methyl-3-phenylpentanoate (216f) (205 mg, 0.78 
mmol) and tributylphosphine (0.29 mL, 1.17 mmol) in THF (3 mL)/water (0.03 mL). The 
product was crystallised from MeOH to give 83 mg (62%) of pure pyrrolidinone as a white 
solid. 
 
Analytical Data for 217f: 
 
MP: 234-235 °C 
 
1H-NMR (400 MHz, DMSO-d6): δ 7.67 (br s, 1 H, H1), 7.54-7.51 (m, 2 H, H2’), 7.36-7.31 
(m (partially solved), 3JH3’,H4’ = 7.3 Hz, 2 H, H3’), 7.27 (tt, 3JH4’,H3’ = 7.3 Hz, 4JH4’,H2’obs. = 1.2 
Hz, 1 H, H4’), 5.45 (br s, 1 H, OH), 3.30 and 2.22 (2 x d AB system, 2JH3a,H3b = 16.3 Hz, 2 H, 
H3a and H3b), 1.18 (s, 3 H, H6a), 0.67 (s, 3 H, H7b) 
 
13C-NMR (400 MHz, DMSO-d6): δ 173.2 (C2), 142.6 (C1’), 127.7 (C3’), 127.0 (C4’), 126.5 
(C2’), 79.9 (C4), 62.3 (C5), 43.5 (C3), 27.1 (C6b), 20.9 (C6a) 
 
MS-EI (70 eV): 207.1 (7, [M+2H]+), 205.1 (8, [M]+), 187.1 (4, [M-H2O]+), 172.1 (19, [M-
H2O-CH3]+), 144.1 (15), 105.0 (31), 91.1 (8), 78.1 (15), 77.1 (20), 58.1 (100) 
HR-MS (ESI): 228.09947 ([M+Na]+; C12H15NO2Na+; calc. 228.10005) 
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IR (KBr): ν = 3298 (vs), 3184 (vs), 3061 (vs), 3003 (s), 2975 (s), 2934 (s), 1958 (vw), 1683 
(vs), 1495 (m), 1446 (s), 1432 (s), 1386 (vs), 1288 (w), 1227 (m), 1190 (vs), 1159 (s), 1099 
(w), 1068 (s), 1046 (s), 1033 (m), 997 (w), 953 (m), 917 (w), 895 (m), 862 (w), 765 (vs), 703 
(vs), 661 (m), 619 (w), 604 (w), 570 (w), 534 (m), 506 (s), 453 (vw), 423 (w) cm–1 
 
CHN: calc.: C: 70.22; H: 7.37; N: 6.82; found: C: 69.93; H: 7.36; N: 6.77 
 
5.3.29. 4-Hydroxy-4-(4-nitrophenyl)pyrrolidin-2-one (217g) 
 
 
 
Prepared from methyl 4-azido-3-hydroxy-3-(4-nitrophenyl)butanoate (216g) (407 mg, 1.45 
mmol) and triphenylphosphine (571 mg, 2.18 mmol) in THF (6 mL)/water (0.06 mL). The 
product was crystallised from MeOH to give 255 mg (79%) of pure pyrrolidinone as a white 
solid. 
 
Analytical Data for 217g: 
 
MP: 203-204 °C 
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1H-NMR (400 MHz, DMSO-d6): δ 8.21 (dt, 3JH3’,H2’ = 9.5 Hz, 4JH3’,H3’’ = 5JH3’,H2’’ = 2.3 Hz, 
2 H, H3’), 7.84 (br s, 1 H, H1), 7.81 (dt, 3JH2’,H3’ = 9.5 Hz, 4JH2’,H2’’ = 5JH2’,H3’’ = 2.3 Hz, 2 H, 
H2’), 6.00 (br s, 1 H, OH), 3.56 and 3.38 (2 x d AB system, 2JH5a,H5b = 10.4 Hz, 2 H, H5a and 
H5b), 2.79 and 2.36 (2 x d AB system, 2JH3a,H3b = 16.4 Hz, 2 H, H3a and H3b) 
 
13C-NMR (400 MHz, DMSO-d6): δ 174.3 (C2), 152.8 (C1’), 146.5 (C4’), 126.8 (C2’), 123.2 
(C3’), 76.7 (C4), 56.1 (C5), 46.5 (C3) 
 
MS-ESI: 245.2 (100, [M+Na]+) 
 
HR-MS (ESI): 245.05299 ([M+Na]+; C10H10N2O4Na+; calc. 245.05383) 
 
IR (KBr): ν = 3372 (vs), 2951 (w), 1696 (vs), 1600 (m), 1512 (vs), 1474 (s), 1406 (m), 1343 
(vs), 1288 (s), 1235 (s), 1105 (m), 1069 (m), 1049 (m), 1012 (w), 978 (w), 929 (w), 907 (vw), 
876 (w), 855 (s), 797 (vw), 753 (w), 717 (w), 700 (m), 681 (m), 560 (w), 483 (w), 420 (w) 
cm–1 
 
CHN: calc.: C: 54.05; H: 4.54; N: 12.61; found: C: 53.78; H: 4.69; N: 12.62 
 
5.3.30. 4-Hydroxy-5-methyl-4-(2-nitrophenyl)pyrrolidin-2-one (217h) 
 
 
Prepared from methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)pentanoate (216h) (396 mg, 1.35 
mmol) and triphenylphosphine (530 mg, 2.02 mmol) in THF (6 mL)/water (0.06 mL). Solvent 
system for chromatography: CH2Cl2/MeOH, 90:10. The product was isolated in 54% yield 
(172 mg) as a white powder.  
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Analytical Data for 217h: 
 
 
TLC: Rf (CH2Cl2/MeOH, 90:10) = 0.46 
 
MP: 215-216 °C 
 
1H-NMR (400 MHz, DMSO-d6): δ 7.84 (br s, 1 H, H1), 7.61 (dd, 3JH3’,H4’ = 7.7 Hz, 4JH3’,H5’ = 
1.3 Hz, 1 H, H3’), 7.58 (ddd, 3JH5’,H6’ = 8.0 Hz, 3JH5’,H4’ = 7.1 Hz, 4JH5’,H3’ = 1.3 Hz, 1 H, H5’), 
7.54 (dd, 3JH6’,H5’ = 8.0 Hz, 4JH6’,H4’ = 1.5 Hz, 1 H, H6’), 7.48 (ddd, 3JH4’,H3’ = 7.7 Hz, 3JH4’,H5’ = 
7.1 Hz, 4JH4’,H6’ = 1.5 Hz, 1 H, H4’), 5.97 (br s, 1 H, OH), 3.95 (q, 3JH5,H6 = 6.4 Hz, 1 H, H5), 
2.73 and 2.62 (2 x d AB system, 2JH3a,H3b = 16.8 Hz, 2 H, H3a and H3b), 1.06 (d, 3JH6,H5 = 64 
Hz, 3 H, H6) 
 
13C-NMR (400 MHz, DMSO-d6): δ 172.7 (C2), 150.0 (C2’), 137.3 (C1’), 130.9 (C5’), 128.5 
(C4’), 127.2 (C6’), 123.9 (C3’), 76.9 (C4), 58.9 (C5), 46.1 (C3), 14.7 (C6) 
 
MS-ESI: 259.3 (100, [M+Na]+), 237.2 (3, [M+H]+) 
 
HR-MS (ESI): 259.06859 ([M+Na]+; C11H12N2O4Na+; calc. 259.06948) 
 
IR (KBr): ν = 3427 (s), 3311 (vs), 3045 (w), 2987 (w), 2943 (w), 1689 (vs), 1528 (vs), 1375 
(vs), 1258 (m), 1211 (m), 1128 (w), 1084 (m), 1057 (m), 1036 (m), 1009 (m), 961 (w), 902 
(vw), 851 (vw), 777 (m), 708 (m), 642 (m), 606 (s), 523 (m), 496 (m) cm–1 
 
CHN: calc.: C: 55.93; H: 5.12; N: 11.86; found: C: 55.66; H: 5.23; N: 11.64 
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5.3.31. 5-Ethyl-4-hydroxy-4-(2-nitrophenyl)pyrrolidin-2-one (217i) 
 
 
Prepared from methyl 4-azido-3-hydroxy-3-(2-nitrophenyl)hexanoate (216i) (482 mg, 1.56 
mmol) and triphenylphosphine (615 mg, 2.35 mmol) in THF (7 mL)/water (0.07 mL). Solvent 
system for chromatography: CH2Cl2/MeOH, 98:2. The product was isolated in 49% yield 
(190 mg) as a white powder.  
 
Analytical Data for 217i 
 
 
TLC: Rf (CH2Cl2/MeOH, 98:2) = 0.17 
 
GC (method IZ): tR = 16.10 min  
 
1H-NMR (400 MHz, CDCl3): δ 7.60 (d, 3JH3’,H4’ = 8.1 Hz, 1 H, H3’), 7.58-7.52 (m, 2 H, H5’ 
and H6’), 7.47-7.43 (m (partially solved), 3JH4’,H3’ = 8.1 Hz, 1 H, H4’), 6.36 (br s, 1 H, H1), 3.99 
(dd, 3JH5,H6b = 9.5 Hz, 3JH5,H6a = 4.2 Hz, 1 H, H5), 3.00 and 2.87 (2 x d AB system, 2JH3a,H3b = 
17.4 Hz, 2 H, H3a and H3b), 2.75 (br s, 1 H, OH), 1.83 (dqd, 2JH6a,H6b = 14.5 Hz, 3JH6a,H7 = 7.4 
Hz, 3JH6a,H5 = 4.2 Hz, 1 H, H6a), 1.62 (ddq, 2JH6b,H6a = 14.5 Hz, 3JH6b,H5 = 9.5 Hz, 3JH6b,H7 = 7.4 
Hz, 1 H, H6b), 0.97 (t, 3JH7,H6a = 3JH7,H6b = 7.4 Hz, 3 H, H6) 
 
MS-ESI: 249.1 (100, [M-H]-) 
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HR-MS (ESI): 273.08450 ([M+Na]+; C12H14N2O4Na+; calc. 273.08513) 
 
IR (KBr): ν = 3456 (m), 3402 (m), 3046 (w), 2958 (m), 2873 (w), 1739 (vs), 1573 (vw), 
1526 (vs), 1482 (w), 1458 (w), 1434 (s), 1365 (s), 1315 (w), 1242 (m), 1206 (s), 1167 (s), 
1134 (m), 1116 (m), 1093 (m), 1080 (m), 1051 (m), 1025 (m), 996 (w), 908 (w), 851 (w), 784 
(w), 739 (s), 720 (s), 699 (vs), 668 (m), 639 (w), 624 (w), 607 (m), 551 (s), 533 (s), 452 (m) 
cm–1 
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5.3.32. Preparation of intermediate (290) 
 
5.3.33. 3-Ethyloxepan-2-one (286) 
 
 
To a stirred solution of ε-caprolactone (285) (5.0 g, 43.81 mmol, 1 equiv.) in dry THF (40 
mL) was added dropwise a solution of LDA (2.0 M in THF, 26.3 mL, 52.57 mmol, 1.2 
equiv.) at −78 °C and under argon. After 30 min at −78 °C, ethyl iodide (7.0 mL, 87.61 mmol, 
2 equiv.) dissolved in anhydrous HMPA (16.86 mL, 96.37 mmol, 2.2 equiv.) was added 
dropwise over 10 min. The mixture was allowed to stir at −78 °C for 1 h, and then was 
warmed to –25 ºC over a period of 1 h. Quenching of the reaction with saturated aqueous 
NH4Cl solution (50 mL) at -–25 ºC followed by warm-up and extraction of the mixture with 
CHCl3 (3 x 150 mL), washing of the combined organic phase with water (200 mL), saturated 
aqueous NaHCO3 solution (200 mL), and brine (100 mL), drying (MgSO4), filtration, and 
concentration gave an oily residue. The product was purified by flash chromatography on 
silica gel (cyclohexane/Et2O, 50:50) to afford 1.25 g (20%) of 2-ethyl-ε-caprolactone (286) as 
a clear, slightly yellowish oil. 
 
Analytical Data for 286: 
 
 
TLC: Rf (cyclohexane/Et2O, 50:50) = 0.37 
 
GC (method IZ): tR = 7.19 min  
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1H-NMR (400 MHz, CDCl3): δ 4.30-4.20 (m, 2 H, H6), 2.47-2.41 (m, 1 H, H2), 2.00-1.89 (m, 
2 H, H5a and H1’a), 1.87-1.76 (m, 2 H, H3a and H5b), 1.74-1.54 (m, 2 H, H4a and H4b), 1.49-
1.36 (m, 2 H, H3b and H1’b), 0.95 (t, 3JH2’,H1’ = 7.4 Hz, 3 H, H2’) 
 
13C-NMR (400 MHz, CDCl3): δ 177.5 (C1), 68.2 (C6), 44.5 (C2), 29.7 (C3), 28.8 (C5), 28.3 
(C4), 25.6 (C1’), 11.9 (C2’) 
 
MS-ESI: 307.3 (16, [2M+Na]+), 165.2 (100, [M+Na]+) 
 
HR-MS (ESI): 165.08876 ([M+Na]+; C8H14O2Na+; calc. 165.08915) 
 
IR (KBr): ν = 2935 (vs), 2878 (m), 2252 (vw), 1734 (vs), 1457 (m), 1394 (m), 1374 (w), 
1306 (w), 1289 (m), 1264 (w), 1248 (m), 1228 (w), 1178 (vs), 1119 (m), 1104 (s), 1094 (s), 
1078 (m), 1055 (s), 1008 (w), 989 (w), 939 (w), 921 (w), 873 (w), 842 (vw), 797 (vw), 733 
(m), 647 (vw), 576 (vw), 548 (vw) cm–1 
 
5.3.34. 2-Ethyl-6-hydroxyhexanal (287) 
 
 
To a stirred solution of 2-ethyl-ε-caprolactone (286) (957 mg, 6.73 mmol, 1 equiv.) in dry 
CH2Cl2 (14 mL) was added dropwise a solution of DIBAL (1.0 M in hexane, 7.07 mL, 7.07 
mmol, 1.05 equiv.) at -78 °C and under argon. After 1.5 h at -78 °C, the reaction mixture was 
quenched by the addition of CH3OH (0.29 mL, 7.07 mmol, 1.05 equiv.) and then allowed to 
reach 25 °C. The resulting solution was diluted with EtOAc (100 mL), and then poured into a 
saturated solution of sodium potassium tartrate (50 mL). The layers were separated, and the 
aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were 
washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give 
287 as an oily residue (971 mg, 100% yield) pure enough for the next step. 
 
195 
 
Analytical Data for 287: 
 
 
TLC: Rf (cyclohexane/Et2O, 50:50) = 0.26 
 
GC (method IZ): tR = 6.88 min  
 
1H-NMR (400 MHz, CDCl3): δ 9.57 (d, 3JH1,H2 = 2.9 Hz, 1 H, H1), 3.64 (t, 3JH6,H5 = 6.5 Hz, 2 
H, H6), 2.23-2.15 (m (partially solved), 3JH2,H1 = 2.9 Hz, 1 H, H2), 1.72-1.43 (m, 6 H, H3, H5 
and H7), 1.40-1.32 (m, 2 H, H4), 0.91 (t, 3JH8,H7 = 7.5 Hz, 3 H, H8) 
 
MS-ESI: 199.3 (70, [M+Na+MeOH]+), 183.3 (21, [M+K]+), 167.3 (100, [M+Na]+) 
 
IR (KBr): ν = 3392 (br m), 2936 (vs), 2865 (s), 2714 (vw), 1724 (vs), 1460 (m), 1383 (w), 
1247 (w), 1054 (m), 917 (w), 770 (vw), 734 (m), 647 (vw) cm–1 
 
5.3.35. 6-((tert-Butyldiphenylsilyl)oxy)-2-ethylhexanal (288) 
 
 
To a stirred solution of the crude aldehyde 287  (971 mg, 6.73 mmol, 1 equiv.) in dry DMF (9 
mL) was added imidazole (688 mg, 10.10 mmol, 1.5 equiv.) followed by tert-
butyldiphenylsilyl chloride (1.9 mL, 7.41 mmol, 1.1 equiv.) at 0 °C and under argon. After 30 
min stirring at 0 °C, the reaction mixture was allowed to reach room temperature and stirred 
for additional 30 min. The resulting solution was diluted with Et2O (100 mL), washed with 
water (2 x 100 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo to 
give an oily residue. The product was purified by flash chromatography on silica gel 
(cyclohexane/Et2O, 95:5) to afford 2.00 g (78%) of aldehyde 288 as a clear, colourless oil. 
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Analytical Data for 288: 
 
 
TLC: Rf (cyclohexane/Et2O, 95:5) = 0.38 
 
GC (method IZ): tR = 16.47 min  
 
1H-NMR (400 MHz, CDCl3): δ 9.55 (d, 3JH1,H2 = 2.9 Hz, 1 H, H1), 7.68-7.67 (m, 4 H, H2’), 
7.45-7.36 (m, 6 H, H3’ and H4’), 3.65 (t, 3JH6,H5 = 6.4 Hz, 2 H, H6), 2.16 (ttd, 3JH2,H1 = 2.9 Hz, 
3JH2,H7obs. = 5.3 Hz, 3JH2,H3obs. = 10.5 Hz, 1 H, H2), 1.70-1.52 (m, 5 H, H3a, H5 and H7), 1.51-
1.42 (m, 1 H, H3b), 1.40-1.33 (m, 2 H, H4), 1.05 (s, 9 H, H2’’), 0.91 (t, 3JH8,H7 = 7.5 Hz, 3 H, 
H8) 
 
13C-NMR (400 MHz, CDCl3): δ 205.5 (C1), 135.6 (C2’), 134.0 (C1’), 129.5 (C4’), 127.6 (C3’), 
63.5 (C6), 53.3 (C2), 32.5 (C5), 28.2 (C3), 26.9 (C2’’), 23.3 (C4), 21.8 (C7), 19.2 (C1’’), 11.4 
(C8) 
 
HR-MS (ESI): 405.22191 ([M+Na]+; C24H34O2SiNa+; calc. 405.22258) 
 
IR (KBr): ν = 3071 (m), 3050 (w), 2999 (w), 2933 (vs), 2859 (vs), 2707 (w), 1960 (vw), 
1890 (vw), 1824 (vw), 1727 (vs), 1589 (vw), 1473 (m), 1462 (m), 1428 (m), 1389 (m), 1362 
(w), 1306 (vw), 1245 (vw), 1188 (w), 1111 (vs), 1008 (w), 939 (w), 823 (m), 741 (s), 703 
(vs), 688 (m), 614 (m), 505 (vs), 428 (vw) cm–1 
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5.3.36. 6-((tert-Butyldiphenylsilyl)oxy)-2-ethyl-1-(2-nitrophenyl)hexan-1-
one (289) 
 
 
 
6-((tert-Butyldiphenylsilyl)oxy)-2-ethyl-1-(2-nitrophenyl)hexan-1-ol (S6) was prepared 
following the general procedure from 2-iodonitrobenzene (75) (1.0 g, 4.02 mmol), 
phenylmagnesium chloride (2.0 M in THF, 2.2 mL, 4.42 mmol) and aldehyde 288 (1.84 g, 
4.82 mmol) in dry THF (28 mL). The crude alcohol was engaged in the next step without 
further purification. Rf (cyclohexane/Et2O, 75:25= 0.44. GC (method AG): tR = 22.77 min 
(minor diastereomer, 45 %), tR = 22.98 min (major diastereomer, 55 %). 
 
 
 
6-((tert-Butyldiphenylsilyl)oxy)-2-ethyl-1-(2-nitrophenyl)hexan-1-one (289) was prepared 
from the crude 6-((tert-butyldiphenylsilyl)oxy)-2-ethyl-1-(2-nitrophenyl)hexan-1-ol (S6) 
(2.03 g, 4.02 mmol) and Jone’s reagent (2.67 M in H2SO4, 3.25 mL) in acetone (7 mL). 
Solvent system for chromatography: cyclohexane/Et2O, 95:5. The product was isolated in 
75% yield (1.51 g) over the two steps as an orange oil.  
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Analytical Data for 289: 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 75:25) = 0.42 
 
GC (method AG): tR = 23.07 min 
 
1H-NMR (400 MHz, CDCl3): δ 8.06 (dd, 3JH3’,H4’ = 8.1 Hz, 4JH3’,H5’obs. = 1.1 Hz, 1 H, H3’), 
7.68-7.64 (m, 5 H, H2’’ and H5’), 7.58 (ddd, 3JH4’,H3’ = 8.1 Hz, 3JH4’,H5’obs. = 7.5 Hz, 4JH4’,H6’obs. 
= 1.5 Hz, 1 H, H4’), 7.44-7.35 (m, 7 H, H3’’, H4’’ and H6’), 3.64 (t, 3JH6,H5 = 6.4 Hz, 2 H, H6), 
2.79 (quint, 3JH2,H7obs. = 3JH2,H3obs. = 6.1 Hz, 1 H, H2), 1.84-1.70 (m, 2 H, H7a and H3a), 1.61-
1.47 (m, 4 H, H7b, H5 and H3b), 1.45-1.37 (m, 2 H, H4), 1.04 (s, 9 H, H6’’), 0.93 (t, 3JH8,H7 = 7.5 
Hz, 3 H, H8) 
 
13C-NMR (100 MHz, CDCl3): δ 204.6 (C1), 146.5 (C2’), 137.5 (C1’), 135.5 (C2’’), 134.0 
(C1’’), 133.7 (C5’), 130.6 (C4’), 129.5 (C4’’), 128.4 (C6’), 127.6 (C3’’), 124.4 (C3’), 63.6 (C6), 
52.1 (C2), 32.7 (C5), 29.4 (C3), 26.8 (C6’’), 23.0 and 22.9 (C4 and C7), 19.2 (C5’’), 11.0 (C8) 
 
MS-ESI: 526.7 (100, [M+Na]+) 
 
HR-MS (ESI): 526.23872 ([M+Na]+; C30H37NO4SiNa+; calc. 526.23895) 
 
IR (KBr): ν = 3071 (w), 2932 (vs), 2859 (s), 1830 (vw), 1701 (s), 1574 (w), 1531 (vs), 1473 
(m), 1428 (m), 1347 (s), 1309 (w), 1264 (w), 1216 (m), 1111 (vs), 998 (m), 855 (w), 823 (m), 
759 (s), 742 (s), 706 (vs), 614 (w), 505 (s) cm–1 
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5.3.37. 2-Bromo-6-((tert-butyldiphenylsilyl)oxy)-2-ethyl-1-(2-
nitrophenyl)hexan-1-one (290) 
 
 
Prepared from 6-((tert-butyldiphenylsilyl)oxy)-2-ethyl-1-(2-nitrophenyl)hexan-1-one (289) 
(1.48 g, 2.93 mmol) and bromine (0.15 mL, 2.93 mmol) in CCl4 (9 mL) following the general 
procedure. Solvent system for chromatography: cyclohexane/Et2O, 95:5. The product was 
isolated in 53% yield (901 mg) as a viscous yellow oil.  
 
Analytical Data for 290: 
 
 
TLC: Rf (Cyclohexane/CH2Cl2, 75:25) = 0.52 
 
1H-NMR (400 MHz, CDCl3): δ 8.20 (dd, 3JH3’,H4’ = 8.2 Hz, 4JH3’,H5’obs. = 1.0 Hz, 1 H, H3’), 
7.76 (dd, 3JH6’,H5’obs. = 7.6 Hz, 4JH6’,H4’ = 1.4 Hz, 1 H, H6’), 7.73-7.69 (m, 1 H, H5’), 7.69-7.66 
(m, 4 H, H2’’), 7.60 (ddd, 3JH4’,H3’ = 8.2 Hz, 3JH4’,H5’obs. = 7.4 Hz, 4JH4’,H6’ = 1.4 Hz, 1 H, H4’), 
7.44-7.36 (m, 6 H, H3’’ and H4’’), 3.68 (t, 3JH6,H5 = 5.7 Hz, 2 H, H6), 2.40-2.31 (m, 1 H, H3a), 
2.35 (dq, 2JH7a,H7b = 14.5 Hz, 3JH7a,H8 = 7.4 Hz, 1 H, H7a), 2.13-2.04 (m, 1 H, H3b), 2.11 (dq, 
2JH7b,H7a = 14.5 Hz, 3JH7b,H8 = 7.4 Hz, 1 H, H7b), 1.64-1.55 (m, 4 H, H4 and H5), 1.07 (t, 3JH8,H7a 
= 3JH8,H7b = 7.4 Hz, 3 H, H8), 1.04 (s, 9 H, H6’’) 
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13C-NMR (100 MHz, CDCl3): δ 198.5 (C1), 146.0 (C2’), 135.7 (C1’), 135.6 (C2’’), 134.1 (C5’), 
134.0 (C1’’), 130.1 (C4’), 129.7 (C4’’), 129.6 (C6’), 127.6 (C3’’), 124.4 (C3’), 75.7 (C2), 63.4 
(C6), 37.2 (C3), 32.5 (C5), 30.8 (C7), 26.8 (C6’’), 21.5 (C4), 19.2 (C5’’), 9.7 (C8) 
 
MS-ESI: 605.2 (100, [M (79Br)+Na]+), 206.4 (99, [M (81Br)+Na]+) 
 
HR-MS (ESI): 604.14845 ([M (79Br)+Na]+; C30H3679BrNO4SiNa+; calc. 604.14947), 
606.14653 ([M (81Br)+Na]+; C30H3681BrNO4SiNa+; calc. 606.14742) 
 
IR (KBr): ν = 3071 (w), 3050 (w), 2931 (vs), 2858 (s), 1959 (vw), 1890 (vw), 1829 (vw), 
1703 (vs), 1589 (w), 1574 (w), 1532 (vs), 1472 (m), 1461 (m), 1428 (m), 1389 (w), 1348 (vs), 
1308 (w), 1228 (m), 1191 (w), 1111 (vs), 1008 (m), 939 (vw), 856 (m), 823 (m), 788 (m), 758 
(vs), 743 (s), 703 (vs), 614 (m), 505 (s), 430 (vw) cm–1 
 
5.3.38. Dehydration of hydroxy lactam 217i  
5.3.39. tert-Butyl 3-(tert-butoxycarbonyloxy)-2-ethyl-3-(2-nitrophenyl)-5-
oxopyrrolidine-1-carboxylate (295) 
 
 
To a stirred suspension of hydroxyl pyrrolidinone 217i (128 mg, 0.51 mmol) in dry THF (10 
mL) at room temperature and under argon was added DMAP (25 mg, 0.21 mmol) followed by 
Boc2O (234 mg, 1.07 mmol). The resulting solution was stirred at room temperature for 3 
days, and then was concentrated in vacuo. The residue was purified by flash chromatography 
on silica gel (CH2Cl2/MeOH, 99:1) to afford two fractions. The first fraction contained di-
boc-protected compound 295 (123 mg, 0.27 mmol, 53%). The second fraction showed to be a 
complex mixture (83 mg, 295/218i, 90:10) which corresponded to 295 (74.7 mg, 0.17 mmol, 
33%) and 218i (8.3 mg, 0.03 mmol, 5%).  
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Analytical Data for 295: 
 
TLC: Rf (CH2Cl2/MeOH, 90:10) = 0.18 
 
1H-NMR (400 MHz, CDCl3): δ 7.56-7.45 (m, (partially solved), 3JH5’,H6’ = 7.8 Hz, 3 H, H3’, 
H5’ and H6’), 7.32 (d, 3JH6’,H5’ = 7.8 Hz, 1 H, H6’), 4.87 (br s, 1 H, H5), 3.58 and 3.14 (2 x d AB 
system, 2JH3a,H3b = 17.9 Hz, 2 H, H3a and H3b), 2.05 (br s, 1 H, H6a), 1.62 (quint, 3JH6b,H5 = 
3JH6b,H7 = 7.3 Hz, 1 H, H6b), 1.50 (s, 9 H, H3’’’), 1.38 (s, 9 H, H3’’), 1.06 (t, 3JH7,H6a = 3JH7,H6b = 
7.4 Hz, 3 H, H6) 
 
13C-NMR (100 MHz, CDCl3): δ 151.3 (C1’’’), 149.4 (C1’’), 148.6 (C2’), 134.7 (C1’), 131.7 
(C5’), 129.4 (C4’), 126.0 (C6’), 124.6 (C3’), 83.9 and 83.8 (C2’’’ and C2’’), 79.6 (C4), 66.8 (C5), 
44.7 (C3), 27.9 (C3’’’), 27.4 (C3’’), 23.5 (C6), 10.2 (C7) 
 
MS-ESI: 473.5 (100, [M +Na]+) 
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Crystallographic studies 
1. X-Ray crystallographic analysis of compounds 216c. 
 
Anisotropic displacement ellipsoid plot of compound 216c. 
  
A view of the molecular structure and crystallographic numbering scheme of the title 
molecule, with displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 216c. 
 
 
A partial view of the crystal packing of the title compound 216c, viewed along the c-axis, 
showing the formation of the O−H…O hydrogen bonded chain propagating in the direction of 
the a-axis. H-atoms not involved in this interaction have been omitted for clarity; hydrogen 
bonds shown as dashed lines. 
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2. X-Ray crystallographic analysis of compounds 216g 
 
Anisotropic displacement ellipsoid plot of compound 216g. 
 
A view of the molecular structure and crystallographic numbering scheme of the title 
compound 216g, with displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 216g. 
 
The crystal packing of the title compound 216g, viewed along the b-axis. The O−H…O and N-
-H…O hydrogen bonds are shown as dashed cyan lines. H-atoms not involved in these 
interactions have been omitted for clarity. 
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3. X-Ray crystallographic analysis of compounds 217c. 
 
Anisotropic displacement ellipsoid plot of compound 217c. 
 
 
The molecular structure of the two independent molecules (A involving atoms N1,O1 and O2 
and B involving atoms N21,O21 and O22) of compound 217c, showing the numbering 
scheme and the displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 217c. 
 
 
A view along the b-axis of the crystal packing of compound 217c, showing the intermolecular 
N−H…O and O−H…N hydrogen bonds (dashed lines) leading to the formation of the two-
dimenssional networks of the individual molecules (A black; B red) lying parallel to plane. 
The H-atoms not involved in the hydrogen bonding have been removed for clarity. 
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The compound crystallized with two independent molecules (A and B) per asymmetric unit. 
They differ only in the orientation of the phenyl ring with respect to the rest of the molecule. 
 
A view of the automatic overalp of the two independent molecules (A black; B red) of 
compound 217c. 
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4. X-Ray crystallographic analysis of compounds 217d. 
 
Anisotropic displacement ellipsoid plot of compound 217d. 
 
A view of the molecular structure and crystallographic numbering scheme of the title 
compound 217d, with displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 217d. 
 
The crystal packing of the title compound 217d, viewed along the b-axis. The O−H…O and N-
-H…O hydrogen bonds are shown as dashed cyan lines. H-atoms not involved in these 
interactions have been omitted for clarity. 
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5. X-Ray crystallographic analysis of compounds 217e. 
 
 
Anisotropic displacement ellipsoid plot of compound 217e. 
A view of the molecular structure and crystallographic numbering scheme of the title 
compound 217e, with displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 217e. 
 
The crystal packing of the title compound 217e, viewed along the b-axis. The O−H…O and N--
H…O hydrogen bonds are shown as dashed cyan lines. H-atoms not involved in these 
interactions have been omitted for clarity. 
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6. X-Ray crystallographic analysis of compounds 217f. 
 
Anisotropic displacement ellipsoid plot of compound 217f. 
 
A view of the molecular structure and crystallographic numbering scheme of the title 
compound 217f, with displacement ellipsoids drawn at the 50% probability level. 
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ORTEP unit-cell plot of compound 217f. 
 
 
 
A view of the automatic overalp of the two independent molecules (A black; B red) of 
compound 217f. 
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7. X-Ray crystallographic analysis of compounds 217g. 
 
Anisotropic displacement ellipsoid plot of compound 217g. 
 
A view of the molecular structure and crystallographic numbering scheme of the two 
independent molecules of the title compound 217g, with displacement ellipsoids drawn at the 
50% probability level. Only the major component of the disordered atoms is shown. 
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ORTEP unit-cell plot of compound 217g. 
The crystal packing of the title compound 217g, with the O−H…O and N−H…O hydrogen 
bonds shown as dashed lines. H-atoms not involved in these short contacts have been omitted 
for clarity. Only the major component of the disordered atoms is shown. 
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8. X-Ray crystallographic analysis of compounds 217h. 
 
Anisotropic displacement ellipsoid plot of compound 217h. 
 
A view of the molecular structure and crystallographic numbering scheme of the title 
compound 217h, with displacement ellipsoids drawn at the 50% probability level. 
 
ORTEP unit-cell plot of compound 217h. 
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9. X-Ray crystallographic analysis of compounds 295. 
 
Anisotropic displacement ellipsoid plot of compound 295. 
A view of the molecular structure and crystallographic numbering scheme of the two 
independent molecules of the title compound 295, with displacement ellipsoids drawn at the 
50% probability level. 
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ORTEP unit-cell plot of compound 295. 
 
The crystal packing of the title compound 295, viewed along the a-axis [H-atoms have been 
omitted for clarity. 
